



L4 ANSWER 8 OF 29 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1988:183063 CAPLUS
 DOCUMENT NUMBER: 108:183063
 TITLE: Fast atom bombardment and tandem mass spectrometry for structure determination: remote site fragmentation of steroid conjugates and bile salts
 AUTHOR(S): Tomer, K. B.; Gross, M. L.
 CORPORATE SOURCE: Midwest Cent. Mass Spectrom., Univ. Nebraska, Lincoln, NE, 68588-0362, USA
 SOURCE: 89-98
 CODEN: BEHSEN; ISSN: 0887-6134
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of 35 steroid conjugates (sulfates and glucuronides) and bile salts were investigated by using fast atom bombardment and tandem mass spectrometry. Collisional activation of the [M-H]⁻ anions of sulfate conjugates and bile salts predominantly yields fragment ions arising by reactions occurring remote from the charge site. These reactions are sometimes sensitive to differences in stereochem. at positions remote from the charge site and are useful for positional isomer differentiation. On the other hand, collisional activation of the [M-H]⁻ anions of the glucuronide conjugates leads primarily to charge-driven fragmentations.
 IT 56162-42-6
 RL: PRP (Properties) (structure of, detn. of, by fast-atom-bombardment and tandem mass spectrometry)
 RN 56162-42-6 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnan-21-yl- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1986:443183 CAPLUS
 DOCUMENT NUMBER: 105:43183
 TITLE: Chemical conversion of corticosteroids to 3.alpha.,5.alpha.-tetrahydro derivatives.
 Synthesis of allottetrahydro-11-deoxycortisol glucuronides
 Hosoda, Hiroshi; Takasaki, Wataru; Miura, Hiroya; Tokhin, Masahiro; Maruyama, Yukio; Nambara, Toshio
 CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
 SOURCE: Chem. Pharm. Bull. (1985), 33(10), 4281-7
 CODEN: CPBTAU; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:43183
 AB A method for the conversion of 11-deoxycortisol into 3.alpha.-hydroxy-5.alpha.-pregnanones is described. The allottetrahydro-11-deoxycortisol monoacetates I (R = H, R1 = Ac; R = Ac, R1 = H), which are key intermediates in the prepn. of the 3- or 21-glucuronide of allottetrahydro-11-deoxycortisol, were the target compds. 5.alpha.-Dihydro-11-deoxycortisol 21-acetate was prepd. by hydrogenation of the 3-ethoxy-3,5-diene II, followed by acid hydrolysis. When the pregnanones III (R1 = tetrahydropyranyl, MeSCSI Me2) were treated with potassium tri-sec-butylborohydride in THF under mild conditions, selective reductn. of the carbonyl group at C-3 took place, yielding the 3.alpha.-alcs. IV. Allottetrahydro-11-deoxycortisol 3-glucuronide V (R1 = H) and allottetrahydro-11-deoxycortisol 21-glucuronide VI were then prepd. via Koenigs-Knorr glycosidations.
 IT 103292-99-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and acetylation of)
 RN 103292-99-5 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




not
 R₉ = H
 R₁₀ = H

L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 IT 103293-04-5P 103293-07-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and hydrolysis of)
 RN 103293-04-5 CAPLUS
 CN Pregnan-20-one, 3-(acetyloxy)-17-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 103293-07-8 CAPLUS
 CN Pregnan-20-one, 3-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-17-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



IT 103293-12-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and sapon. of)
 RN 103293-12-5 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.)-3-(acetyloxy)-17-

R = 1
 R₁ = H
 R₂ = H
 R₃ = C₁₇-O-D
 R₄ = C₁₇
 R₅ = H
 R₆ = H
 R₇ = H
 R₈ = H

USPT

US-PAT-NO: 3969345

DOCUMENT-IDENTIFIER: US 3969345 A

TITLE: 20.beta.,21-Epoxy-3.alpha.-hydroxy-5.alpha.-pregnanes and derivatives thereof

DATE-ISSUED: July 13, 1976

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE
COUNTRY			
Phillipps; Gordon	Wembley	N/A	N/A
EN			
Hanley	London	N/A	N/A
EN			
Newall; Christopher			
Earle			

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE
COUNTRY TYPE CODE			
Glaxo Laboratories	Greenford	N/A	N/A
EN 03			
Limited			

APPL-NO: 5/ 551315

DATE FILED: February 20, 1975

PARENT-CASE:

This application is a division of application Ser. No. 208,961, filed Dec.

16, 1971, and now U.S. Pat. No. 3,882,151.

FOREIGN-APPL-PRIORITY-DATA:

FOREIGN-PRIORITY:

FOREIGN-PRIORITY-APPL-NO: UK 60065/70

FOREIGN-PRIORITY-APPL-DATE: December 17, 1970

INT-CL: [2] C07J005/00

US-CL-ISSUED: 260/239.55R,260/397.45 ,260/397.47 ,424/243 ,260/239.5

US-CL-CURRENT: 540/94,514/816 ,540/112 ,552/523 ,552/560 ,552/582 ,552/587

,552/589 ,552/591 ,552/600 ,552/603 ,552/604 ,552/609

FIELD-OF-SEARCH: 260/239.55R

REF-CITED:

PAT-NO	ISSUE-DATE	U.S. PATENT DOCUMENTS	PATENTEE-NAME	US-CL
3822298	July 1974		Clayton et al.	260/397.4
ART-UNIT:	124			
PRIMARY-EXAMINER:	Roberts; Elbert L.			
ATTY-AGENT-FIRM:	Bacon & Thomas			
ABSTRACT:				

The invention provides 3.alpha.-oxygenated pregnane 21-ethers possessing a

hydroxy group in the 3.alpha.-position; a hydrogen atom or a methyl group at the 10-position; a hydrogen atom in the 17.alpha.-position; a keto group in the 20-position; and an etherified hydroxyl group in the 21-position.

4 Claims, 0 Drawing figures

USPT

US-PAT-NO: 3822298

DOCUMENT-IDENTIFIER: US 3822298 A

TITLE: TEXT NOT AVAILABLE

DATE-ISSUED: July 2, 1974

US-CL-ISSUED: 552/609,540/94

US-CL-CURRENT: 552/609,540/100 ,540/111 ,540/94 ,552/529 ,552/560
,552/582

,552/586 ,552/587 ,552/589 ,552/590 ,552/591 ,552/599 ,552/600

,552/603

,552/604

Claims, 0 Drawing figures

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1973:30134 CAPLUS

DOCUMENT NUMBER: 78:30134

TITLE: Glucosiduronates of 3.alpha.,21-dihydroxy-5.beta.-pregnane-11,20-dione. Synthesis of C-3, C-21, and C-3, 21 derivatives

AUTHOR(S): Mattox, Vernon R.; Vrieze, Wiley D.
CORPORATE SOURCE: Mayo Clin. and Mayo Found., Rochester, Minn., USA
SOURCE: J. Org. Chem. (1972), 37(25), 3990-6
CODEN: JOCHAH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB C-3, C-21, and C-3, 21 glucosiduronates of

3.alpha.,21-dihydroxy-5.beta.-

pregnane-11,20-dione were prepd.

IT 36707-52-5P 36707-53-6P 36707-54-7P

36707-55-8P 36707-56-9P 36707-58-1P

36707-59-2P 36707-60-5P 36707-61-6P

36707-63-8P 36763-75-4P

RL: SPN (Synthetic preparation); PREP (Preparation)


RN 36707-52-5 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-3-hydroxy-11,20-

dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX

NAME)



RN 36707-53-6 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,


(3.alpha.,5.beta.)-3-(acetyloxy)-11,20-

dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX

NAME)

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

dioxopregnan-21-yl (9CI) (CA INDEX NAME)




RN 36707-56-9 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-3-hydroxy-11,20-

dioxopregnan-21-yl, monoammonium salt (9CI) (CA INDEX NAME)



RN 36707-58-1 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,


(3.alpha.,5.beta.)-11,20-dioxopregnan-

3,21-diyl bis-, dimethyl ester, hexaacetate (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS

(Continued)




RN 36707-54-7 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-3-hydroxy-11,20-

dioxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)




RN 36707-55-8 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-3-hydroxy-11,20-

dioxopregnan-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 36707-59-2 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-11,20-dioxopregnan-

3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 36707-60-5 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-11,20-dioxopregnan-

3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1976:478264 CAPLUS

DOCUMENT NUMBER: 85:78264

TITLE: 21-Substituted pregnanes

INVENTOR(S): Philipps, Gordon H.; Lawrence, Robin; Newall, Christopher E.; Wright, Michael

PATENT ASSIGNEE(S): Glaxo Laboratories Ltd., Engl.

SOURCE: Brit., 21 pp.

CODEN: BROKAA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1432135	A	19760414	GB 1972-21145	19730504
BE 799103	A1	19731105	BE 1973-130750	19730504
NL 7306233	A	19731107	NL 1973-6233	19730504
DE 2322560	A1	19731115	DE 1973-2322560	19730504
FR 2183794	A1	19731221	FR 1973-16111	19730504
ZA 7303036	A	19740424	ZA 1973-3036	19730504
JP 49047361	A2	19740508	JP 1973-50184	19730504
AU 7355285	A1	19741107	AU 1973-55285	19730504
US 3959260	A	19760525	US 1974-488989	19740716
			GB 1972-21145	19720505
			US 1973-356097	19730501

AB Forty title compds. I (R = H, Me, alkoxy; R1, R2 = H, Me; R3 = O, R3 = H)

R4 = acylthio, heterocycle-substituted acylthio, alkylthio, heterocycle-substituted alkylthio, EtSO2, EtSO, NCS, HS, BuS2CS, morpholinocarbonylthio, morpholinoethoxythiocarbonylthio and 2 related compds., useful as anesthetics, were prepd. from 21-bromo-steroids by condensation reactions. Thus, refluxing 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione with BzSNa in Me2CO 40 min gave 1 (R =

R1 = H, R2 = Me, R3 = O, R4 = BzS). Solns. of I in aq. nonionic surfactants are suitable for parenteral administration, as is a similar soln. of 21-acetylthio-3.alpha.-hydroxy-5.beta.-pregnane-11,20-dione.

IT 51087-29-7P 51087-32-2P

RI: SPN (Synthetic preparation); PREP (Preparation)

(anesthetic, prepn. of)


RN 51087-29-7 CAPLUS

CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,

(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 51087-32-2 CAPLUS
CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1976:443170 CAPLUS

DOCUMENT NUMBER: 85:43170

TITLE: Liquid ion exchangers in reversed-phase systems for

AUTHOR(S): chromatography of steroidal glucosiduronic acids
Mattok, Vernon R.; Litwiller, Robert D.; Goodrich,
June E.; Tan, W. C.CORPORATE SOURCE: Mayo Clin. and Mayo Grad. Sch., Rochester, Minn.,
USA

SOURCE: J. Chromatogr. (1976), 120(2), 435-47

CODEN: JOCRAM

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Steroidal glucosiduronic acids were chromatographed on paper by the reversed-phase technique using 5 different liq. ion-exchangers as stationary phase and aq. KCl as mobile phase. The relation of mobility of the acids (RM) to both the amt. of exchanger on the paper and the concn. of KCl in the mobile phase is discussed: the relation may be expressed as

$RM = n \cdot \text{cndtd} \cdot \log [\text{exchanger}] + \text{const.}$ and $RM = -n \cdot \text{cndtd} \cdot \log [KCl] + \text{const.}$, resp. Migration of the acids in the presence of different exchangers is correlated by use of the equation $RM (\text{exchanger } Y) = a$

times $RM (\text{exchanger } X) + b$. The lack of appreciable correlation between migration of the acids in a reversed-phase system and a corresponding straight-phase system is discussed and expressed by means of regression equations. The correlation coeffs. and std. errors of est. from these equations provide useful indices for selecting 2 solvent systems that

are to be used sequentially to obtain max. resolu. of a group of compds. DELTA.RM values obtained for various functional groups with reversed-phase and straight-phase techniques are compared.

IT 36707-55-8 36707-60-5 56162-37-9
56162-38-0 56162-41-5 56162-42-6
56162-45-9 56316-33-7 56316-34-8

RI: ANT (Analyte); ANST (Analytical study)
(chromatog. of, by ion-exchange paper)

RN 36707-55-8 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)

IT 36707-55-8 36707-60-5 56162-37-9
56162-38-0 56162-41-5 56162-42-6
56162-45-9 56316-33-7 56316-34-8

RI: ANT (Analyte); ANST (Analytical study)


(chromatog. of, by ion-exchange paper)

RN 36707-55-8 CAPLUS


CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-

dioxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnan-3,21-diyl bis- (9CI) (CA INDEX NAME)




RN 56162-37-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1999:450892 CAPLUS
 DOCUMENT NUMBER: 131:102428
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk
 PATENT ASSIGNEE(S): J.; Lan, Nancy C.
 SOURCE: Cogenics, Inc., USA
 U.S., 28 pp.
 CODEN: USXOAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606
			US 1995-467404	19950606

PRIORITY APPL. INFO.: MARPAT 131:102428
 OTHER SOURCE(S):
 AB Neuroactive steroids of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R2 = H, alkoxy, keto, Me2N; R3 = alkoxy, alkenyloxy, alkynyloxy; R4 = H, Me; R5 = H, absent; R6 = H, alkanoyl, etc.; R7 = H, halo, OH, alkoxy, etc.; R8 = H, halo; R9 = H, halo, alkyl, alkoxy, arylalkoxy, amino; R10 = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These derivs. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.β-methoxy-5.β-androstan-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.
 IT 186264-24-4P 186264-34-6P 186264-35-7P
 186264-63-1P 186264-79-9P 186264-86-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neuroactive steroids of androstane and pregnane series)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)
 RN 186264-24-4 CAPLUS
 CN Pregnane-20-one, 3-hydroxy-3-(4-hydroxy-1-butenyl)-21-(4-pyridinylthio)-, (3.α.,5.β.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



Absolute stereochemistry.



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1998:112239 CAPLUS
 DOCUMENT NUMBER: 128:186632
 TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache
 INVENTOR(S): Lan, Nancy C.
 PATENT ASSIGNEE(S): Cocensys, Inc., USA; Lan, Nancy C.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731

DE, W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG


AU 9739672 A1 19980225 AU 1997-39672 19970731
 US 1996-22937 19960801
 WO 1997-US13430 19970731

PRIORITY APPL. INFO.:
 AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.
 IT 186264-24-4 186264-34-6 186264-35-7
 186264-63-1 186264-79-9 186264-86-8
 203785-83-5
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GABA agonists and NMDA receptor antagonists for migraine headache treatment)
 RN 186264-24-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 186264-34-6 CAPLUS
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 186264-35-7 CAPLUS
 CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 186264-63-1 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(5-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 186264-79-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 186264-86-8 CAPLUS
 CN Quinolinium, 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-ylidene]-1-methyl-, iodide (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 203785-83-5 CAPLUS
 CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS


ACCESSION NUMBER: 1997:113460 CAPLUS
 DOCUMENT NUMBER: 126:131695
 TITLE: Preparation of neuroactive steroids of the and pregnane series
 INVENTOR(S): Upasani, Ravindra B.; Pick, David B.; Hogenkamp, Derk
 PATENT ASSIGNEE(S): J.; Lan, Nancy C.
 SOURCE: Cocansys, Inc., USA
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, CA 2223996 AA 19961219 CA 1996-2223996 19960606 AU 9661725 A1 19961230 AU 1996-61725 19960606 EP 837874 A2 19980429 EP 1996-919372 19960606 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CN 1190404 A 19980812 CN 1996-195360 19960606 BR 9608592 A 19990629 BR 1996-8592 19960606 JP 11507643 T2 19990706 JP 1996-502210 19960606 NO 9705608 A 19980206 NO 1997-5608 19971204 FI 9704448 A 19971205 FI 1997-4448 19971205 US 1995-467404 19950606 WO 1996-US10115 19960606				

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 126:131695
 AB Comps. of formula I (R = H, NH2, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxy-carbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy,

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)
 amino; R10 = H, halogen, OH, alkyl, etc.] are prepd. as neuroactive prodrugs, due to their ability to modulate the GABA_A receptor-chloride ionophore complex. These derivs. are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.β-methoxy-5.β-androstan-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.
 IT 186264-24-4P 186264-34-6P 186264-35-7P
 186264-63-1P 186264-79-9P 186264-86-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neuroactive androstanes and pregnanes)
 RN 186264-24-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.α.,5.β.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


Absolute stereochemistry.



RN 186264-34-6 CAPLUS
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.α.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-35-7 CAPLUS
 CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.β.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


Absolute stereochemistry.



RN 186264-63-1 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.α.,5.α.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-86-8 CAPLUS
 CN Quinolium,
 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



● 1 -

=> d his

(FILE 'HOME' ENTERED AT 12:20:12 ON 18 NOV 1999)

FILE 'REGISTRY' ENTERED AT 12:20:24 ON 18 NOV 1999
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 7 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:21:23 ON 18 NOV 1999
L4 3 S L3

FILE 'BEILSTEIN' ENTERED AT 12:22:28 ON 18 NOV 1999
L5 0 S L1 FULL

FILE 'MARPAT' ENTERED AT 12:23:18 ON 18 NOV 1999
L6 0 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.30	132.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.61

STN INTERNATIONAL LOGOFF AT 12:24:03 ON 18 NOV 1999



=> d ibib ab hitstr 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1999:450892 CAPLUS
 DOCUMENT NUMBER: 131:102428
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk
 PATENT ASSIGNEE(S): J.; Lan, Nancy C.
 SOURCE: Cogensys, Inc., USA
 U.S., 28 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606
			US 1995-467404	19950606

PRIORITY APPLN. INFO.: MARPAT 131:102428
 AB Neuroactive steroids of formula I [R = H, NH₂, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R₁ = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R₂ = H, alkoxy, keto, Me₂N; R₃ = alkoxy, alkenyloxy, alkynyloxy; R₄ = H, Me; R₅ = H, absent; R₆ = H, alkanoyl, etc.; R₇ = H, halo, OH, alkoxy, etc.; R₈ = H, halo; R₉ = H, halo, alkyl, alkoxy, arylalkoxy, amino; R₁₀ = H, halo, alkyl, OH, alkoxy, CN, etc.] are prepd. These deriva. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.β-methoxy-5.β-androstan-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.
 IT 186264-24-4P 186264-34-6P 186264-35-7P
 186264-63-1P 186264-79-9P 186264-86-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepa. of neuroactive steroids of androstane and pregnane series)



L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)
 RN 186264-24-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butenyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1998:112239 CAPLUS
 DOCUMENT NUMBER: 128:188632
 TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache
 INVENTOR(S): Lan, Nancy C.
 PATENT ASSIGNEE(S): Cogensys, Inc., USA; Lan, Nancy C.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9739672	A1	19980225	AU 1997-39672	19970731
US 1996-22937 19960801				
WO 1997-US13430 19970731				
PRIORITY APPLN. INFO.:				
AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.				
IT 186264-24-4 186264-34-6 186264-35-7 186264-63-1 186264-79-9 186264-86-8 203785-83-5				
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (GABA agonists and NMDA receptor antagonists for migraine headache treatment)				
RN 186264-24-4 CAPLUS				
CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)				
Absolute stereochemistry.				

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 186264-34-6 CAPLUS
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 186264-35-7 CAPLUS
 CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-63-1 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-79-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-86-8 CAPLUS
 CN Quinolinium, 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203785-83-5 CAPLUS
 CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:113460 CAPLUS
 DOCUMENT NUMBER: 126:131695
 TITLE: Preparation of neuroactive steroids of the androsterane and pregnane series
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, J.; Lan, Nancy C.
 PATENT ASSIGNEE(S): Cocensys, Inc., USA
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: FIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
V: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, CA 2223996 AA 19961219 CA 1996-2223996 19960606 AU 9661725 A1 19961230 AU 1996-61725 19960606 EP 837874 A2 19980429 EP 1996-919372 19960606 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CN 1190404 A 19980812 CN 1996-195360 19960606 BR 9608592 A 19990629 BR 1996-8592 19960606 JP 11507643 T2 19990706 JP 1996-502210 19960606 NO 9705608 A 19980206 NO 1997-5608 19971204 FI 9704448 A 19971205 FI 1997-4448 19971205 US 1995-467404 19950606 WO 1996-US10115 19960606				


PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 126:131695
 AB Comps. of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxy-carbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy,

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)
 amino; R10 = H, halogen, OH, alkyl, etc.) are prepd. as neuroactive prodrugs, due to their ability to modulate the GABA_A receptor-chloride ionophore complex. These derivs. are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.β-methoxy-5.β-androstan-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.
 IT 186264-24-4P 186264-34-6P 186264-35-7P
 186264-63-1P 186264-79-9P 186264-86-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neuroactive androstanes and pregnanes)
 RN 186264-24-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.α.,5.β.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 186264-34-6 CAPLUS
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.α.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 186264-35-7 CAPLUS
 CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.β.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 186264-63-1 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.α.,5.α.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-86-8 CAPLUS
 CN Quinolinium,
 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 1999 ACS (Continued)



● I -

=> d ibib ab fqhit


L6 ANSWER 1 OF 1 MARPAT COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 122:291311 MARPAT
 TITLE: Preparation and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics
 INVENTOR(S): Gee, Kelvin W.; Lan, Nancy Tsai-Yun
 PATENT ASSIGNEE(S): Cocensys, Inc., USA
 SOURCE: PCT Int. Appl., 152 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427608	A1	19941208	WO 1994-US5820	19940524
V: AU, CA, JP, KR, NO				
R2: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2163748	AA	19941208	CA 1994-2163748	19940523
JP 08511771	T2	19961210	JP 1994-500892	19940523
AU 9469883	A1	19941220	AU 1994-69883	19940524
EP 701444	A1	19960320	EP 1994-918659	19940524
R: DE, FR, GB				
US 5939545	A	19990817	US 1997-887229	19970702
PRIORITY APPLN. INFO.:				
US 1993-68378 19930524				
US 1994-196919 19940214				
US 1994-196972 19940214				
US 1994-246275 19940519				
WO 1994-US5820 19940523				
US 1994-346927 19941123				
US 1995-389820 19950214				

AB Title compds. [e.g. I; R = H, (halo)alkyl, alkenyl, alkynyl, aryl(alkyl), etc.; R1 = H or Me; R2 = cyano, CH2OH, COMe, C.tplbond.CH, etc.; R3 = H; R2R3 = CH2, CHOMe, CHMe, CHEt], for interaction with the GABAA receptor complex to induce sleep in humans, were prep'd. Thus, 5.alpha.-pregnane-3,20-dione 20-ketal was converted in 2 steps to title compd. II (R = C.tplbond.CH) which was condensed with 4-IC6H4COMe to give II (R = 4-(MeCO)C6H4C.tplbond.C) which had IC50 of 5nM against TBPS binding at rat cerebral cortex prepn. in vitro.

MFSTR 1


L6 ANSWER 1 OF 1 MARPAT COPYRIGHT 1999 ACS (Continued)



G1 = cycloalkyl<(3-8)> (50 (1-) G7)
 G4 = 25


BC
 25

G6 = 56



DER: and pharmaceutically acceptable esters
 MPL: claim 1


L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




● 1-

RN 186264-87-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 4 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:858705 CAPLUS
 DOCUMENT NUMBER: 123:266118
 TITLE: Codrugs as a method of controlled drug delivery
 INVENTOR(S): Ashton, Paul; Crooks, Peter Anthony; Riggs, Robert
 Mack; Cynkowski, Tadeusz; Cynkowska, Grazyna
 PATENT ASSIGNEE(S): University of Kentucky Research Foundation, USA
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9520567	A1	19950803	WO 1994-US1659	19940217
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2182228	AA	19950805	CA 1994-218228	19940217
AU 9462545	A1	19950815	AU 1994-62545	19940217
AU 705226	B2	19950520		
EP 740650	A1	19961106	EP 1994-909643	19940217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509151	T2	19970916	JP 1994-520023	19940217
PRIORITY APPLN. INFO.:			US 1994-187462	19940128
			WO 1994-US1659	19940217
AB	A codrug compns of at least two drug compds. covalently linked to one another via a labile bond to form a single codrug compn., and methods of use of the codrug for the treatment of various medical conditions are disclosed. The codrug may be administered by itself or as a bioerodible or nonbioerodible dosage form, such as injection, liposome, suspension, microsphere, nanoparticle, ointment, transdermal patch, etc.			
IT 169046-79-1P	Rf: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (codrug compns. for controlled drug delivery)			
RN 169046-79-1	CAPLUS			
CN 2,4-(1H,3H)-Pyrimidinedione, 1-[[[(3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnan-21-yl]oxy]-5-fluoro- (9CI) (CA INDEX NAME)				
Absolute stereochemistry.				

L4 ANSWER 5 OF 29 CAPLUS COPYRIGHT 1999 ACS


ACCESSION NUMBER: 1995:538364 CAPLUS
 DOCUMENT NUMBER: 122:291311
 TITLE: Preparation and formulation of 3.alpha.-hydroxypregnan-20-one and analogs as sedatives and hypnotics
 INVENTOR(S): Gee, Kelvin W.; Lan, Nancy Tsai-Yun
 PATENT ASSIGNEE(S): Cogensys, Inc., USA
 SOURCE: PCT Int. Appl., 152 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427608	A1	19941208	WO 1994-US5820	19940524
W: AU, CA, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2163748	AA	19941208	CA 1994-2163748	19940523
JP 08511771	T2	19961210	JP 1994-500892	19940523
AU 9469883	A1	19941220	AU 1994-69883	19940524
EP 701444	A1	19960320	EP 1994-918659	19940524
R: DE, FR, GB				
US 5939545	A	19990817	US 1997-887229	19970702
PRIORITY APPLN. INFO.:			US 1993-68378	19930524
			US 1994-196919	19940214
			US 1994-196972	19940214
			US 1994-246275	19940519
			WO 1994-US5820	19940523
			US 1994-346927	19941123
			US 1995-389820	19950214

OTHER SOURCE(S): MARPAT 122:291311
 AB Title compds. [e.g., R = H, (halo)alkyl, alkenyl, alkynyl, aryl(alkyl), etc.; R1 = H or Me; R2 = cyano, CH2OH, COMe, C.tplbond.CH, etc.; R3 = H; R2R3 = CH2, CHOMe, CHMe, CHEt], for interaction with the GABA_A receptor complex to induce sleep in humans, were prepd. Thus, 5.alpha.-pregnane-3,20-dione 20-ketal was converted in 2 steps to title compd. II (R = C.tplbond.CH) which was condensed with 4-ICGH4COMe to give II (R = 4-(MeCO)C6H4C.tplbond.C) which had IC50 of 5nM against TBPS binding at rat cerebral cortex prepn. in vitro.
 IT 162883-05-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and formulation of 3.alpha.-hydroxypregnan-20-one and analogs as sedatives and hypnotics)
 RN 162883-05-8 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI)

L4 ANSWER 5 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



provisional

L4 ANSWER 6 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1995:274566 CAPLUS

DOCUMENT NUMBER: 122:101622

TITLE: Glycosides of 19-formylthetvetogenin and 5.alpha.-thetvetogenin from Thetvetia nerifolia

AUTHOR(S): Abe, Fumiko; Yamauchi, Tatsuo; Yahara, Shoji;

Nohara,

Toshihiro
CORPORATE SOURCE: Fac. Pharmaceutical Sci., Fukuoka Univ., Fukuoka, 814-01, Japan

SOURCE: Phytochemistry (1994), 37(5), 1429-32

CODEN: PHYCAS; ISSN: 0031-9422

DOCUMENT TYPE: Journal

LANGUAGE: English

AB C-nor-D-homo-homologs of canogenin and uzarigenin glycosides were isolated along with known cardenolide glycosides from the frozen fresh leaves of Thetvetia nerifolia. A bisdesmosidic tetraoside of 3.beta.,14,21-trihydroxy-5.beta.,14.beta.-pregnan-20-one was also obtained from the polar fraction and the structure established.


IT 160625-67-2P

RL: BOC (Biological occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation) (glycosides of 19-formylthetvetogenin and 5.alpha.-thetvetogenin from Thetvetia nerifolia)

RN 160625-67-2 CAPLUS

CN Pregnan-20-one, 3-[(10-.beta.-D-glucopyranosyl-(1.fwdarv.6)-O-.beta.-D-glucopyranosyl-(1.fwdarv.4)-6-deoxy-3-O-methyl-.alpha.-L-mannopyranosyl)oxy]-21-(1.beta.-D-glucopyranosyloxy)-14-hydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 6 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1991:24305 CAPLUS

DOCUMENT NUMBER: 114:24305

TITLE: Studies of steroids. Part CCL. Chemical conversion

of corticosteroids to 3.alpha.,5.alpha.-tetrahydro derivatives. Synthesis of allotetrahydrocortisol glucuronides and allotetrahydrocortisone

glucuronides

AUTHOR(S):

Na-boc,

Na-boc,

Toshio
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan

SOURCE: Chem. Pharm. Bull. (Tokyo), 39(7), 1549-52

CODEN: CPBULJ; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:24305

AB The synthesis of the 3- and 21-glucuronides of allotetrahydrocortisol (allo-THF) and allotetrahydrocortisone (allo-THE) is described.

5.alpha.-Dihydrocortisol was prepd. by selective hydrogenation of 21-acetoxy-3,11.beta.,17.alpha.-trihydroxy-3,5-pregnadien-20-one 3-Et ether, followed by acid hydrolysis and sapon. When 5.alpha.-dihydrocortisol 21-tetrahydropyran ether was treated with potassium tri-sec-butylborohydride in THF under mild conditions, regioselective

and stereoselective redn. at C-3 took place to give allo-THF 21-tetrahydropyran ether. This compd. was converted into the 3- and 21-monoacetates of allo-THF and allo-THE, key intermediates.

Introduction of the glucuronyl residue at C-3 or C-21 was carried out by means of

the Koenigs-Knorr reaction. Prior to sapon. yielding the 3-glucuronides,

the alkali-sensitive ketol side chain at C-17 was protected as

20-semicarbazones.

IT 131061-52-4P 131061-53-5P 131061-60-4P

131061-61-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and hydrolysis of)

RN 131061-52-4 CAPLUS

CN Pregnane-11,20-dione, 3-(acetyloxy)-17-hydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

ClO₂CH₂-O-D


09/321,882

Page 12

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



Absolute stereochemistry.




Absolute stereochemistry.

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)


(prepn. and oxidn. or deprotection of)
RN 131061-51-3 CAPLUS
CN Pregnan-20-one,
3-(acetyloxy)-11,17-dihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 131061-50-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and O-acetylation of)
RN 131061-50-2 CAPLUS
CN Pregnan-20-one,
3,11,17-trihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




IT 131061-51-3P
RL: SPN (Synthetic preparation); PREP (Preparation)




IT 131061-63-7P
RL: SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 7 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
hydroxy-20-oxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)



IT 103293-00-1P 103293-13-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 103293-00-1 CAPLUS
CN Pregnan-20-one, 3,17-dihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 103293-13-6 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.)-3,17-dihydroxy-20-


L4 ANSWER 10 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1986:200334 CAPLUS
DOCUMENT NUMBER: 104:200334
TITLE: Steroid glucuronide conjugates: analysis by thermospray liquid chromatography negative ion mass spectrometry
AUTHOR(S): Watson, D.; Taylor, G. W.; Murray, S.
CORPORATE SOURCE: Dep. Clin. Pharmacol., R. Postgrad. Med. Sch., London, W12 0HS, UK
SOURCE: Biomed. Environ. Mass Spectrom. (1986), 13(2), 65-9
CODEN: BEMSEN

DOCUMENT TYPE: Journal
LANGUAGE: English
AB Thermospray neg. ion mass spectra of 18 steroid monoglucuronide conjugates were recorded. The salt-free aq. solvent system used gave mass spectra for glucuronides which contained mol. anions only. Selected ion monitoring indicated that as little as 100 pg of these compds. was detected. A gradient elution HPLC system was developed and applied to sepn. of the individual components of a mixt. of 12 steroid monoglucuronides and detection by thermospray liq. chromatog. neg. ion mass spectrometry.

IT 56162-41-5
RL: AMT (Analyte); ANST (Analytical study)
(detn. of, by thermospray liq. chromatog.-mass spectrometry)
RN 56162-41-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
oxopregnan-21-yl (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1985:7010 CAPLUS
DOCUMENT NUMBER: 102:7010
TITLE: Synthesis of mono- and diglucosiduronates of metabolites of deoxycorticosterone and corticosterone and analysis by a new mass spectrometric technique
AUTHOR(S): Mattox, V. R.; Nelson, A. N.; Vrieze, W. D.; Jardine, I.
CORPORATE SOURCE: Dep. Biochem., Mayo Found., Rochester, MN, 55901, USA
SOURCE: Steroids (1983), 42(4), 349-64
CODEN: STEDAM; ISSN: 0039-128X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB By condensing 3.alpha.,21-dihydroxy-5.beta.-pregnan-20-one, or its monoacetate, with Me 2,3,4-tri-O-acetyl-1-bromo-1-deoxy-.alpha.-D-glucuronate in the Koenigs-Knorr reaction .beta.-D-glucosiduronates, e.g., I (R = Me, R1 = Ac, R2 = H), were obtained as polyacetate Me esters. Alk. hydrolysis cleaved the ester groups and gave the corresponding steroidal glucosiduronic acids, e.g., II (R = R1 = R2 = H). Upon treatment with diazomethane, these acids produced the equiv. Me esters. The C-3, the C-21 and the C-3,21 glucosiduronates of 3.alpha.,21-dihydroxy-5.beta.-pregnane-11,20-dione were prepd. by previously reported methods and converted into the corresponding C-20 semicarbazones. With C-20 stabilized by the semicarbazone group against redn., it was possible to reduce the 11-oxo function in these substances to an 11.beta.-hydroxyl group; after removal of the semicarbazone moiety from these products at pH 2.0, glucosiduronic acids were obtained, e.g., II gave I (R = R1 = R2 = OH). The mass spectra of a representative group of the mono- and diglucosiduronic acids and esters were detd. by utilizing fast atom bombardment and monitoring ions in both pos. and neg. modes of operation.


IT 56162-37-9P 56162-41-5P 56316-34-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and esterification of, with diazomethane)
RN 56162-37-9 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

102

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 56162-41-5 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)




RN 56316-34-8 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,5,11-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 (prepn. and hydrolysis of)
 RN 93524-33-5 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11-hydroxy-20-oxopregnan-3,21-diyl bis-, dimethyl ester, 2,2',3,3',4,4'-hexaacetate (9CI) (CA INDEX NAME)




RN 93564-46-6 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-(acetyloxy)-20-oxopregnan-21-yl, methyl ester, triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 93524-34-6 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.beta.,5.alpha.,11.beta.)-11-hydroxy-20-oxopregnan-3,21-diyl bis- (9CI) (CA INDEX NAME)




IT 93524-33-5P 93564-46-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




IT 93524-27-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and sapon. of)
 RN 93524-27-7 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnan-3,21-diyl bis-, dimethyl ester, hexaacetate (9CI) (CA INDEX NAME)




IT 36707-58-1P 73847-70-8P 73847-72-0P
 73847-77-5P 73856-90-3P 93524-28-8P

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 93549-78-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (pregn. of)
 RN 36707-58-1 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-11,20-dioxopregnane-
 3,21-diyl bis-, dimethyl ester, hexaacetate (9CI) (CA INDEX NAME)




RN 73847-70-8 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 73847-72-0 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-dihydroxy-20-oxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)




RN 73847-77-5 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11-hydroxy-20-oxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 73856-90-3 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 93524-28-8 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-20-oxopregnane-3,21-

L4 ANSWER 11 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 diyl bis-, diammonium salt (9CI) (CA INDEX NAME)




RN 93549-78-1 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3-(acetyloxy)-11-hydroxy-20-oxopregnane-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1984:451073 CAPLUS
 DOCUMENT NUMBER: 101:51073
 TITLE: Analysis of steroid and vitamin D glucuronides and sulfates by fast atom bombardment mass spectrometry
 AUTHOR(S): Jardine, Ian; Scanlan, Gale F.; Mattox, Vernon R.; Kumar, Rajiv
 CORPORATE SOURCE: Dep. Pharmacol. Cell Biol. Endocrinol., Mayo Found., Rochester, MN, 55905, USA
 SOURCE: Biomed. Mass Spectrom. (1984), 11(1), 4-9
 CODEN: BMSVAL; ISSN: 0306-042X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The direct anal. of underivatized steroid and vitamin D glucuronide and sulfate conjugates by pos.- and neg.-ion fast-atom-bombardment mass spectrometry was demonstrated. A sample of each compd. was prepd. in a glycerol soln. and deposited on a Cu-tipped direct insertion probe. The sample and mass spectrometer source were held at ambient temp. Mass spectrometer was operated at 6 kV accelerating potential and the mass scale was calibrated by the data system with PEG of av. mol. wt. 600. A primary atom beam of Xe was produced by a saddle field ion source. This method allows unambiguous mol. wt. detn. and provides useful fragmentation information. Anal. of low microgram quantities of such conjugates purified from biol. sources was done, e.g., the monoglucuronide of 1,25-dihydroxyvitamin D3 and the .beta.-D-glucosiduronic acid of fluorescein. Thus, this method is an extremely useful complementary technique to electron-impact mass spectrometry.
 IT 36707-59-2 36707-60-5 56162-42-6
 RL: FRP (Properties)
 (mass spectrum of, pos.-ion fast-atom-bombardment)
 RN 36707-59-2 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 36707-60-5 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 56162-42-6 CAPLUS


L4 ANSWER 12 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnane-21-yl (9CI) (CA INDEX NAME)



102


L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1984:115104 CAPLUS
 DOCUMENT NUMBER: 100:115104
 TITLE: Studies on steroids. CLOXXIX. Preparation of haptens for use in immunoassays of tetrahydro-11-deoxycortisol and its glucuronides
 AUTHOR(S): Hosoda, Hiroshi; Yokohama, Hiromitsu; Ishii, Kazuo
 CORPORATE SOURCE: Ito, Yuko; Nambara, Toshio
 Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
 SOURCE: Chem. Pharm. Bull. (1983), 31(11), 4001-7
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Tetrahydro-11-deoxycortisol haptens including the 3-hemisuccinate [79489-05-7], 21-hemisuccinate [89155-00-0], 3-hemiglutarate [79489-08-0], 21-hemiglutarate [89155-01-1], 3-glucuronide [56162-40-4], 21-glucuronide [56162-38-0], and 3,21-diglucuronide (I) [89155-02-2] were synthesized for the purpose of developing immunoassays for tetrahydro-11-deoxycortisol or its glucuronides. Antisera were elicited in 2 rabbits by immunization with the bovine serum albumin conjugate of I. The antisera had binding affinities to enzyme-labeled antigens prepd. from the 3-hemisuccinate, 3-hemiglutarate, and I.
 IT 89154-99-4P
 RL: FRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (prepn. and conjugation of, with bovine serum albumin)
 RN 89154-99-4 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-21-[(2,5-dioxo-1-pyrrolidinyl)oxy]-17-hydroxy-20-oxopregnane-3-yl (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




IT 89154-97-2P 89154-98-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and sapon. of)
 RN 89154-97-2 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-3-(acetyloxy)-17-
 hydroxy-20-oxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI) (CA
 INDEX NAME)

L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 89154-98-3 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-17-hydroxy-20-
 oxopregnan-3,21-diyl di-, dimethyl ester, 2,2',3,3',4,4'-hexaacetate
 (9CI) (CA INDEX NAME)




IT 56162-38-0P 89155-02-2P


L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as hapten)

RN 56162-38-0 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-3,17-dihydroxy-20-
 oxopregnan-21-yl (9CI) (CA INDEX NAME)



RN 89155-02-2 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-17-hydroxy-20-
 oxopregnan-3,21-diyl di- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1982:563317 CAPLUS

DOCUMENT NUMBER: 97:163317

TITLE: Studies on steroids. Part CLXXVI. Synthesis of haptens for use in immunoassays of

tetrahydrocortisol,

tetrahydrocortisone and their glucuronides

Hosoda, Hiroshi; Saito, Keiko; Ito, Yuko;

Yokohama,

Hironitsu; Ishii, Kazuo; Nambara, Toshio

Pharm. Inst., Tohoku Univ., Sendai, 980, Japan

Chem. Pharm. Bull. (1982), 30(6), 2110-18

CODEN: CPBTAL; ISSN: 0009-2363

JOURNAL

LANGUAGE: English

AB In order to develop specific and sensitive immunoassays, carboxylated

derivs. of tetrahydrocortisol and tetrahydrocortisone were

synthesized.

The prepn. of the 3-hemisuccinates, 21-hemisuccinates,

3-hemiglutarates, and 21-hemiglutarates of these corticosteroids was carried out

starting

from cortisol 21-acetate. Tetrahydrocortisol monoglucuronides and

tetrahydrocortisone monoglucuronides were also prepd.

56162-42-6P 56162-45-9P 83274-86-6P

83274-87-7P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 56162-42-6 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-

11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

RN 56162-45-9 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.,11.beta.)-3,11,17-

trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)




RN 83274-86-6 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3-

(acetyloxy)-11,17-dihydroxy-20-oxopregnan-21-yl, methyl ester,

2,3,4-triacetate (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 83274-87-7 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-3-(acetyloxy)-17-

hydroxy-11,20-dioxopregnan-21-yl, methyl ester, 2,3,4-triacetate (9CI)

(CA INDEX NAME)



L4 ANSWER 15 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1981:12421 CAPLUS

DOCUMENT NUMBER: 94:12421

TITLE: Some experiences on radioimmunoassays of synthetic glucocorticoids

AUTHOR(S): Haack, D.; Vecsei, P.; Lichtwald, K.; Klee, H. R.;

Gless, K. H.; Weber, M.

CORPORATE SOURCE: Pharmakol. Inst., Univ. Heidelberg, Heidelberg,

D-6900, Fed. Rep. Ger.

SOURCE: Allergologie (1980), 3(5), 259-67

CODEN: ALLRDI; ISSN: 0344-5062

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Antibodies to betamethasone, dexamethasone, beclomethasone,

prednisolone,

6-methylprednisolone, and triamcinolone were raised, characterized,

and

used in radioimmunoassays (RIAs). While antibodies to betamethasone,

dexamethasone, and, to a lesser extent, triamcinolone were specific,

specific antibodies to prednisolone and 6-methylprednisolone have not

been

raised. One of the main problems of synthetic glucocorticoid RIA is

the

interference by endogenous steroids, e.g., cortisol. The

interference of

endogenous steroids in RIAs of triamcinolone, prednisolone, and

6-methylprednisolone could be decreased by forming derivs. of the

endogenous steroids by using the Girard reagent. Improvement of the

RIAs,

esp. in the case of dexamethasone and betamethasone, could also be

achieved by the presence of corticosteroid-binding globulins in simple

direct assays performed in unprocessed plasma samples. Practical

experiences with betamethasone and dexamethasone RIAs are presented.

IT 56162-45-9

RL: ANST (Analytical study)

(glucocorticoid radioimmunoassay cross reaction with)


RN 56162-45-9 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.,11.beta.)-3,11,17-

trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



102

L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1980:618513 CAPLUS

DOCUMENT NUMBER: 93:218513

TITLE: Corticosteroids in human blood. VII. Isolation, characterization, and quantitation of glucuronide-conjugated metabolites of cortisol in human plasma

AUTHOR(S): Kornel, Ludwig; Saito, Zenzo; Yuan, Larry C.
CORPORATE SOURCE: Steroid Unit, Rush-Presbyt.-St. Luke's Med. Cent., Chicago, IL, 60612, USASOURCE: J. Steroid Biochem. (1980), 13(7), 751-71
CODEN: JSTBBK; ISSN: 0022-4731

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Six steroid sulfoglucuronides, 7 steroid diglucuronides, and 22 steroid

monoglucuronide conjugated metabolites of cortisol were isolated from human plasma 2.25-2.5 h after i.v. administration of cortisol-4-14C,

and

their structure and quant. relation detd. Of all plasma metabolites

of

cortisol, total free and conjugated metabolites constituted 47.5 and 52.5%, resp. Of the latter, monoglucuronides, diglucuronides, and sulfoglucuronides constituted 86.0, 1.8, and 1.3%, resp. The relative plasma concns. of individual conjugates were similar to those of the urinary steroids. The quant. relations between concns. of various individual conjugates suggest certain substrate predilections of

steroid glucuronyltransferases and sulfotransferases.

IT 56162-45-9 75544-00-2 75544-01-3

75544-02-4

RL: BIOL (Biological study)


(as cortisol metabolite, of blood plasma)

RN 56162-45-9 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnane-21-yl (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 75544-00-2 CAPLUS


CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11,17-dihydroxy-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 75544-02-4 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-17-hydroxy-11,20-dioxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 75544-01-3 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.alpha.,11.beta.)-11,17-dihydroxy-20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1980:460554 CAPLUS

DOCUMENT NUMBER: 93:60554

TITLE: Liquid ion exchangers in paper chromatography of steroidal glucosiduronic esters

AUTHOR(S): Mattox, Vernon R.; Litwiler, Robert D.

CORPORATE SOURCE: Mayo Found. Mayo Grad. Sch., Rochester, MN,

55901, USA

SOURCE: J. Chromatogr. (1980), 189(1), 33-42

CODEN: JOCRAM; ISSN: 0021-9673

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Twenty-five steroidal glucosiduronic esters were chromatographed on paper

in each of 5 straight-phase systems and 5 reversed-phase systems. The resolving characteristics of these systems were compared by expressing the retention values in terms of R_M and correlating the data by use of linear regression equations. The resolving characteristics of the straight-phase

systems as a group are very similar, and those of the reversed-phase systems are somewhat less similar; the various systems differ considerably in polarity. The resolving properties of a straight-phase system and a

reversed-phase system which contain the same liq. ion exchanger are markedly different, a circumstance which increases the probability that a

pair of comds. which was not sep'd. in a straight-phase system will be resolved in the reversed-phase system which contains the same liq. ion exchanger. The migration of the esters in the foregoing systems was compared with the migration of the corresponding glucosiduronic acids

(a previous study) in the same solvent systems. If a particular pair of conjugates is not separable as carboxylic acids in a specific straight-phase system, there is a relatively good chance that they will be

separable as Me esters in the same system.

IT 36707-59-2 73847-70-8 73847-72-0

73847-73-1 73847-76-4 73847-77-5

73856-88-9 73856-90-3

RL: ANST (Analytical study)


(paper chromatog. of, liq. ion exchangers in reversed-phase and straight-phase)

RN 36707-59-2 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,


(3.alpha.,5.beta.)-11,20-dioxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73847-70-8 CAPLUS


CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-oxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)



RN 73847-72-0 CAPLUS


CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
dihydroxy-20-oxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)



RN 73847-73-1 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-11,20-dioxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)




RN 73847-76-4 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid,


(3.alpha.,5.beta.,11.beta.)-3,11,17-trihydroxy-20-oxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 73847-77-5 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11-hydroxy-20-oxopregnane-3,21-diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 73856-88-9 CAPLUS


CN .beta.-D-Glucopyranosiduronic acid,

(3.alpha.,5.beta.)-3,17-dihydroxy-20-oxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 73856-90-3 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-20-oxopregnane-3,21-
 diyl bis-, dimethyl ester (9CI) (CA INDEX NAME)



IT 36707-54-7P
 RL: ANST (Analytical study); PREP (Preparation)

L4 ANSWER 17 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

(prepn. of)
 RN 36707-54-7 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-3-hydroxy-11,20-
 dioxopregnane-21-yl, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1977:596703 CAPLUS
 DOCUMENT NUMBER: 87:196703
 TITLE: Radioimmunoassays of tetrahydrocortisone and
 tetrahydrocortisol in human urine
 AUTHOR(S): Will, H.; Aderjan, R.; Winkler, T.; Penke, B.;
 Vecsei,
 P.
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Heidelberg, Heidelberg,
 Ger.
 SOURCE: Acta Endocrinol. (Copenhagen) (1977), 86(2),
 369-79
 CODEN: ACENA7
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A simple radioimmunoassay for the detn. of tetrahydrocortisone (THE),
 tetrahydrocortisol (THF), and their 21-glucosiduronate conjugates is
 described. White New Zealand rabbits were immunized with THF- and
 THE-20-oxime-bovine serum albumin conjugates. The resulting

antisera were very specific. Both allo-THE and allo-THF gave min.
 crossreactions;

however, THE- and THF-21-glucosiduronate bind with the corresponding
 antibodies at a level of 100%. The following types of estns. were
 introduced: estn. of the sum of unconjugated THF and THF-21-
 glucosiduronate in highly dild. unprocessed human urine; a similar


estn. of THE and THF-21-glucosiduronate; and estn. of THF or THE after
 .beta.-glucuronidase treatment and dildn. without further procedures.

THF and THE values correlated significantly with known parameters that
 characterize cortisol prodn., such as cortisol secretion rate and the
 urinary corticoid (C21-.alpha.-ketosteroid) levels.


IT 56162-42-6 56162-45-9
 RL: ANT (Analyte); ANST (Analytical study)
 (detn. of, in urine by radioimmunoassay)

RN 56162-42-6 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-
 11,20-dioxopregnane-21-yl (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 56162-45-9 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.,11.beta.)-3,11,17-
 trihydroxy-20-oxopregnane-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 56162-38-0 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-3,17-dihydroxy-20-
 oxopregnan-21-yl (9CI) (CA INDEX NAME)




RN 56162-41-5 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11-
 dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 56162-42-6 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-
 11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)





RN 56162-45-9 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-
 trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56316-33-7 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.,11.beta.)-11-hydroxy-
 20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56316-34-8 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-3,17-dihydroxy-
 20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1975:590726 CAPLUS

DOCUMENT NUMBER: 83:190726

TITLE: Steroid conjugates. VIII. Isolation and characterization of glucuronide-conjugated

metabolites

of cortisol in human urine
 AUTHOR(S): Kornel, Ludwig; Saito, Zenzo
 CORPORATE SOURCE: Steroid Unit, Rush-Presbyt.-St. Luke's Med. Cent., Chicago, Ill., USA
 SOURCE: J. Steroid Biochem. (1975), 6(8), 1267-84

CODEN: JSTBKK

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A total spectrum of glucuronide-conjugated metabolites of cortisol (22 steroid monoglucuronides and 7 steroid diglucuronides) was isolated from

human urine and characterized. Following i.v. administration of a tracer dose of ¹⁴C-labeled cortisol to 10 normal subjects, urine was collected

for 2 consecutive 24-hr periods. Free steroids were removed and all conjugated metabolites were extd. by Amberlite XAD-2 chromatog. and were

further purified by chromatog. on a polyethyleneimine-impregnated cellulose column. Groups of mono- and diglucuronide conjugated

steroids were sepd. from each other and from other groups of steroid conjugates by

high-voltage paper electrophoresis. Individual monoglucuronide-conjugated

metabolites were sepd. from each other by consecutive paper chromatographies and their homogeneity ascertained. Each steroid conjugate was then characterized. The following monoglucuronide-conjugated (-G) metabolites of cortisol were isolated: cortisol-21-G, cortisone-21-G, 20.β.-dihydrocortisol-21-G, tetrahydrocortisol-3-G, tetrahydrocortisol-21-G, 5.α.-tetrahydrocortisol-3-G, tetrahydrocortisone-3-G, 5.α.-tetrahydrocortisone-3-G, cortol-20.α.-3-G, 5.α.-cortol-20.α.-3-G, cortol-20.β.-3-G, 5.α.-cortol-20.β.-3-G, cortolone-20.α.-3-G, 5.α.-cortolone-20.α.-3-G, cortolone-20.β.-3-G, 5.α.-cortolone-20.β.-3-G, 11-hydroxyastiocholanolone-3-G, 11-hydroxyandrosterone-3-G, 11-oxoastiocholanolone-3-G, 11-oxoandrosterone-3-G. In addn., 6.β.-hydroxy-20.β.-dihydrocortisol and 6.β.-hydroxy-20.β.-cortol were isolated as monoglucuronides, but their site of conjugation was not detd. The steroids identified as diglucuronide conjugates were:

cortol-20.α. and -20.β., cortolone-20.α. and -20.β., tetrahydrocortisol, 5.α.-tetrahydrocortisol and tetrahydrocortisone. Three of the isolated metabolites were not known to exist as glucuronide conjugates.

L4 ANSWER 21 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

The quantitation of individual steroid conjugates revealed interesting relations between various metabolites.


IT 56162-45-9

RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)

(of urine)

RN 56162-45-9 CAPLUS

CN .β.-D-Glucopyranosiduronic acid, (3.α., 5.β., 11.β.)-3, 11, 17-trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1975:455414 CAPLUS

DOCUMENT NUMBER: 83:55414

TITLE: Liquid ion exchangers in paper chromatography of steroidal glucosiduronic acids, glucosiduronic

esters,

and free steroids. Influence of concentration of exchanger and counterion

AUTHOR(S): Robert D. Mattox, V. R. Goodrich, June E. Litwiller,

CORPORATE SOURCE: Mayo Clin. and Mayo Found., Rochester, Minn., USA

SOURCE: J. Chromatogr. (1975), 108(1), 23-35

CODEN: JOCRAM

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The chromatog. mobility of steroidal glucosiduronic acids on paper in CHCl₃-formamide increases as the concn. of ion exchanger in the CHCl₃ phase increases; mobility decreases as the concn. of counterion in formamide increases. Mobility of glucosiduronic esters and of hydroxylated free steroids increases with an increase in concn. of exchanger; small changes in concn. of counterion in the stationary

phase do not alter the migration of these nonionizable compds. Data are presented that suggest that partition of the glucosiduronic acids between

the 2 phases occurs predominantly by an ion-exchange process and that

H bonding plays a secondary role. Partition of the glucosiduronic

esters and hydroxylated free steroids appears to occur primarily by a H

bonding

process.


IT 36707-59-2 36707-60-5

RL: ANT (Analyte); ANST (Analytical study) (chromatog. of, paper, liq. ion exchangers in)

RN 36707-59-2 CAPLUS


CN .β.-D-Glucopyranosiduronic acid, (3.α., 5.β., 11.β.)-11, 20-dioxopregnan-3, 21-diyl bis- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS

CN .β.-D-Glucopyranosiduronic acid, (3.α., 5.β., 11.β.)-11, 20-dioxopregnan-3, 21-diyl bis- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1975:439624 CAPLUS

DOCUMENT NUMBER: 83:39624

TITLE: Liquid ion exchangers in paper chromatography of steroidal glucosiduronic acids. Influence of different exchangers on the mobility in chloroform-formamide and correlation of chromatographic data

AUTHOR(S): Mattox, Vernon R.; Litviller, Robert D.; Goodrich, June E.

CORPORATE SOURCE: Mayo Clin. and Mayo Found., Rochester, Minn., USA

SOURCE: J. Chromatogr. (1975), 109(1), 129-47

CODEN: JOCRAM

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A group of 25 steroidal glucosiduronic acids was chromatog. on paper in

in CHCl₃-formamide in the presence of several different liq. ion exchangers.

Chromatograms were run also in 3 Bush-type systems. The R_f values

were converted into R_m values, and the data were correlated by use of a

series of regression equations of the type R_m(Y) = a(R_m(X) + b, in which X

designated a std. system to which each other system (Y) was compared.

The ratio of the slope a to the correlation coeff. r was a measure of the

resolving power of system Y relative to the std. system; intercept b,

in assocn. with slope a, was an indication of the polarity of system Y

relative to X. The correlation coeff. r. and the std. error of est.

were indications of whether solvent systems Y and X had very similar or

relatively different resolving properties for a group of solutes. The

regression equations were useful for correlating chromatog. data

obtained from a group of compds. in several solvent systems. Properties of the

chromatog. systems were discussed, and the relative importance of ion

exchange and H-bonding with the various solvent systems was pointed

out. The .DELTA.R_mr and .DELTA.R_mr values were given for functional groups

at several locations in the conjugates for 10 of the chromatog. systems.

IT 36707-55-8 36707-60-5 56162-37-9

56162-38-0 56162-41-5 56162-42-8

56162-45-9 56316-33-7 56316-34-8

RL: ANT (Analyte); ANST (Analytical study)


(chromatog. of, paper, liq. ion-exchangers for)

RN 36707-55-8 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-11,20-

dioxopregnan-21-yl (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 36707-60-5 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-11,20-dioxopregnan-

3,21-diyl bis- (9CI) (CA INDEX NAME)




RN 56162-37-9 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3-hydroxy-20-

oxopregnan-21-yl (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-38-0 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-20-

oxopregnan-21-yl (9CI) (CA INDEX NAME)




RN 56162-41-5 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-

dihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56162-42-6 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.)-3,17-dihydroxy-

11,20-dioxopregnan-21-yl (9CI) (CA INDEX NAME)




RN 56162-45-9 CAPLUS


CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-3,11,17-

trihydroxy-20-oxopregnan-21-yl (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56316-33-7 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.,11.beta.)-11-hydroxy-
 20-oxopregnane-3,21-diyl bis- (9CI) (CA INDEX NAME)



RN 56316-34-8 CAPLUS
 CN .beta.-D-Glucopyranosiduronic acid,
 (3.alpha.,5.beta.)-20-oxopregnane-3,21-

L4 ANSWER 23 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
diyl bis- (9CI) (CA INDEX NAME)


L4 ANSWER 24 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1974:37397 CAPLUS
 DOCUMENT NUMBER: 80:37397
 TITLE: Pregnane derivatives
 INVENTOR(S): Phillips, Gordon Hanley; Lawrence, Robin; Newall,
 Christopher E.; Wright, Michael
 PATENT ASSIGNEE(S): Glaxo Laboratories Ltd.
 SOURCE: Ger. Offen., 58 pp.
 CODEN: GWXEXX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2322560	A1	19731115	DE 1973-2322560	19730504
GB 1432135	A	19760414	GB 1972-21145	19730504
			GB 1972-21145	19720505

PRIORITY APPLN. INFO.:
 AB Pregnanediones I-VIII (R = alkyl, aryl, morpholinoalkyl, piperidinoalkyl) (45 compds.), possessing anesthetic activity, were prepd. from 21-bromo-3.alpha.-hydroxy-5.alpha.-pregnane-11,20-dione (II). Thus, II was treated with EtSH to give VII (R = Et). I-VI and VIII were prepd. similarly.
 IT 51087-29-7# 51087-32-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 51087-29-7 CAPLUS
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-32-2 CAPLUS
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L4 ANSWER 24 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




Handwritten signature/initials

L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
3,21-diyl bis- (9CI) (CA INDEX NAME)




L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 25 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
CN .alpha.-D-Glucopyranuronic acid,
1,2-O-[1-[(3.alpha.,5.beta.)-11,20-dioxo-

21-[(2,3,4-tri-O-acetyl-6-methyl-.beta.-D-glucopyranuronosyl)oxy]pregnan-3-yl]oxy]ethylidene]-, methyl ester, diacetate, (S)- (9CI) (CA INDEX NAME)



RN 36763-75-4 CAPLUS
CN .alpha.-D-Glucopyranuronic acid, 1,2-O-[1-[(3.alpha.,5.beta.)-3-(acetyloxy)-11,20-dioxopregnane-21-yl]oxy]ethylidene]-, methyl ester, diacetate (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1971:498741 CAPLUS
DOCUMENT NUMBER: 75:98741
TITLE: 3.beta.,5.beta.,14.beta.,21-Tetrahydroxypregnan-20-one
INVENTOR(S): Stache, Ulrich; Haede, Werner; Fritsch, Werner;
Radsch, Kurt
PATENT ASSIGNEE(S): Farbwerke Hoechst A.-G.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2003653	A	19710805	DE 1970-2003653	19700128
GB 1345041	A	19740130	GB 1971-2248	19710118
GB 1345042	A	19740130	GB 1973-30724	19710118
NL 7100872	A	19710730	NL 1971-872	19710122
CH 559756	A	19750314	CH 1971-1070	19710125
BE 762055	A1	19710726	BE 1971-98981	19710126
US 3732210	A	19730508	US 1971-109932	19710126
FR 2077028	A5	19711015	FR 1971-2630	19710127
DK 125792	B	19730507	DK 1971-357	19710127
CA 942295	A1	19740219	CA 1971-103755	19710127
AT 320871	B	19750310	AT 1971-660	19710127
PRIORITY APPLN. INFO.:		DE 1970-2003653 19700128		
AB The title compd. (I), an important intermediate in the prepn. of periplogenin, was prepd. from 21-hydroxypregna-4,14-diene-3,20-dione (II).				
Thus, II was treated with ethylene glycol in the presence of p-MeC6H4SO3H to give 3,3,20,20-bis(ethylenedioxy)-21-hydroxypregna-5,14-diene (III).				
III acetate was partially deketalized to yield 20,20-(ethylenedioxy)-21-acetoxypregna-4,14-dien-3-one, reduced with LiAlH4 in THF and acylated with Ac2O in pyridine to give 20,20-(ethylenedioxy)-3.beta.,21-diacetoxypregna-4,14-diene. Reaction of this with PhSO2NBr2 in aq. HOAc-dioxane gave 5.alpha.,15.alpha.-dibromo-20,20-(ethylenedioxy)-3.beta.,21-diacetoxypregna-4,14-diene. Treatment of the product with aq. KOH in MeOH and redn. of the product with LiAlH4 in THF yielded 20,20-(ethylenedioxy)-3.beta.,5.beta.,14.beta.,21-tetrahydroxypregnan-20-one, which was deketalized to give I.				
IT 33439-97-3P				
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN 33439-97-3 CAPLUS				
CN 5.beta.,14.beta.-Pregnan-20-one, 5,14-dihydroxy-3.beta.,21-bis[(tetrahydro-2H-pyran-2-yl)oxy]- (8CI) (CA INDEX NAME)				

Absolute stereochemistry.

=> d ibib ab hitstr 1-3


L5 ANSWER 1 OF 3 USPATFULL
 ACCESSION NUMBER: 1999:96496 USPATFULL
 TITLE: Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
 PATENT ASSIGNEE(S): Xia, Haiji, Foothill Ranch, CA, United States
 Hogenkamp, Derk, Carlsbad, CA, United States
 CoCensys, Inc., Irvine, CA, United States (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5939545 19990817
 APPLICATION INFO.: US 1997-887229 19970702 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-389820, filed on Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-346927, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-196919, filed on 14 Feb 1994, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Dees, Jose G.
 ASSISTANT EXAMINER: Badio, Barbara
 LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
 NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
 LINE COUNT: 3557
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
 IT 162883-05-8P (prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)
 RN 162883-05-8 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
 (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 1 OF 3 USPATFULL (Continued)




L5 ANSWER 2 OF 3 USPATFULL
 ACCESSION NUMBER: 1999:81822 USPATFULL
 TITLE: Neuroactive steroids of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
 PATENT ASSIGNEE(S): Fick, David B., Mission Viejo, CA, United States
 Hogenkamp, Derk J., Carlsbad, CA, United States
 Lan, Nancy C., South Pasadena, CA, United States
 CoCensys, Inc., Irvine, CA, United States (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5925630 19990720
 APPLICATION INFO.: US 1996-659192 19960606 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-467404, filed on 6 Jun 1995
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Dees, Jose G.
 ASSISTANT EXAMINER: Badio, Barbara
 LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 3047
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural formula:
 ##STR1##
 wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein
 and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).
 IT 16264-74-4P (prepn. of neuroactive steroids of androstane and pregnane series)
 RN 16264-74-4 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.beta.,3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)




IT 162883-05-8P 16264-24-4P 16264-27-7P
 16264-34-6P 16264-35-7P 16264-36-8P
 16264-37-9P 16264-38-0P 16264-54-0P
 16264-61-9P 16264-63-1P 16264-79-9P
 16264-84-6P 16264-85-7P 16264-86-8P
 16264-87-9P 203719-57-7P 230958-75-5P
 RN 162883-05-8 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI)
 (CA INDEX NAME)
 Absolute stereochemistry.




RN 16264-24-4 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-27-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-34-6 USPATFULL
CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-35-7 USPATFULL
CN Pregnan-20-one, 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-36-8 USPATFULL
CN Pyridinium, 4-[[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)

● I⁻

RN 186264-37-9 USPATFULL
CN Pyridinium, 4-[[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● I⁻

RN 186264-38-0 USPATFULL
CN Pyridinium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)

● I⁻

RN 186264-54-0 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-61-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-63-1 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-79-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-84-6 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-,
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-85-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-,
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 186264-86-8 USPATFULL
CN Quinolinium,
6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● I⁻

RN 186264-87-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-,
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



RN 203719-57-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 230958-75-5 USPATFULL
CN Pyridinium, 4-[[[(2.beta.,3.beta.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 USPATFULL (Continued)



● 1-

L5 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER: 76:29138 USPATFULL
 TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England
 Lawrence, Robin, Stoke Poges, England
 Newall, Christopher Earle, London, England
 Wright, Michael, Stoke Poges, England
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England (non-U.S. corporation)

NUMBER	DATE
US 3959260	19760525
US 1974-488989	19740716 (5)

PATENT INFORMATION:
 APPLICATION INFO.: Continuation of Ser. No. US 1973-356097, filed on 1 May 1973, now Defensive Publication No.

NUMBER	DATE
GB 1972-21145	19720505

PRIORITY INFORMATION:
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Roberts, Elbert L.
 LEGAL REPRESENTATIVE: Bacon & Thomas
 NUMBER OF CLAIMS: 22
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulphoxide grouping.

IT 51087-29-7P 51087-32-2P


(prepn. of)

RN 51087-29-7 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 3 USPATFULL (Continued)



RN 51087-32-2 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:16:20 ON 17 NOV 1999)

FILE 'REGISTRY' ENTERED AT 15:16:31 ON 17 NOV 1999

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 94 S L1 FULL


FILE 'CAPLUS' ENTERED AT 15:19:32 ON 17 NOV 1999

L4 29 S L3

FILE 'USPATFULL' ENTERED AT 15:23:40 ON 17 NOV 1999

L5 3 S L3

L4 ANSWER 26 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



L4 ANSWER 27 OF 29 CAPLUS COPYRIGHT 1999 ACS


ACCESSION NUMBER: 1970:425761 CAPLUS
 DOCUMENT NUMBER: 73:25761
 TITLE: Antiinflammatory
 9.alpha.-Fluoro-11.beta.,17.alpha.,21-trihydroxy-16-hydroxymethyl-6-(dihydroxy)methyl-1,4-pregnadiene-3,20-dione
 INVENTOR(S): Krsek, George
 PATENT ASSIGNEE(S): Rachelle Laboratories, Inc.
 SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3494943	A	19700210	US 1967-694426	19671229

AB The title compd. is prepd. from 9.alpha.-fluoro-

3.alpha.,11.beta.,17.alpha.,21-tetrahydroxy-16-(hydroxymethyl)pregnan-20-one in 10 conventional steps, including a catalytic formylation and fermentation with *Corynebacterium* [Arthrobacter] simplex.
 IT 27406-07-1P 27406-09-3P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 27406-07-1 CAPLUS
 CN Pregnan-20-one,
 9-fluoro-3.alpha.,11.beta.,17-trihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-16-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-6,6-diacetate (8CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 27406-09-3 CAPLUS

L4 ANSWER 27 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

CN Pregnan-20-one, 6-(dihydroxymethyl)-2-fluoro-3.alpha.,11.beta.,17-trihydroxy-21-[(tetrahydro-2H-pyran-2-yl)oxy]-16-[[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-6,6-diacetate (8CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 28 OF 29 CAPLUS COPYRIGHT 1999 ACS


ACCESSION NUMBER: 1970:90745 CAPLUS
 DOCUMENT NUMBER: 72:90745
 TITLE: Antiinflammatory
 bicyclo[2.2.2]octane-1-carboxylate, and adamantylmethyl carbonate esters of the 4-pregnene series
 INVENTOR(S): Croos, Alexander D.; Fried, John H.
 PATENT ASSIGNEE(S): Syntex Corp.
 SOURCE: U.S., 12 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3484436	A	19691216	US 1967-665996	19670907

AB The title compds. show corticoid and antiinflammatory activity.
 Thus, a
 mixt. of 2.5 g pregn-4-ene-11.beta.,17.alpha.,21-triol-3,20-dione (I)
 in
 15 ml pyridine contg. 4.0 g bicyclo[2.2.2]octane-1-carbonyl chloride
 was
 heated at steam bath temp. 2 hr to yield 21-(bicyclo[2.2.2]oct-1-ylcarbonyloxy)pregn-4-ene-11.beta.,17.alpha.-diol-3,20-dione.
 Similarly
 prepd. were the other analogous title esters. Dihydropyran (2 ml) was
 added to a soln. of 1 g I in 150 ml C₆H₆, about 1 ml distd., 0.4 g
 p-MeC₆H₄SO₃H added, and the mixt. kept at room temp. 4 hr to yield
 21-(tetrahydropyran-2-yloxy)pregn-4-ene-11.beta.,17.alpha.-diol-3,20-dione
 (II); 200 ml II in 32 ml iso-PrOH and 25 mg NaBH₄ was stirred at room
 temp.
 15 hr to yield 21-(tetrahydropyran-2-yloxy)pregn-4-ene-
 3.beta.,11.beta.,17.alpha.-triol-20-one (III); III 3.beta.-
 (bicyclo[2.2.2]octane-1-carboxylate) (1 g) in 30 ml HOAc was treated
 with
 0.5 ml 2N HCl to yield
 3.beta.-(bicyclo[2.2.2]octane-1-carboxyloxy)pregn-4-ene-
 11.beta.,17.alpha.,21-triol-20-one. A mixt. of 2 g I, 4 mg
 p-MeC₆H₄SO₃H, and 800 ml C₆H₆ was treated with 1.5 ml
 bicyclo[2.2.2]oct-1-yltrimethoxymethane and a few drops pyridine to give 17.alpha.,21-
 [(methoxybicyclo[2.2.2]oct-1-yl)methylidenedioxy]pregn-4-ene-11.beta.-ol-
 3,20-dione, which (1 g) in 30 ml EtOH was treated with 0.5 ml 2N HCl to
 yield 17.alpha.-(bicyclo[2.2.2]octane-1-carboxyloxy)pregn-4-ene-
 11.beta.,21-diol-3,20-dione. Other similar compds. are mentioned.
 IT 26144-15-0P
 RI: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 26144-15-0 CAPLUS
 CN Pregn-4-en-20-one,
 3.beta.,11.beta.,17-trihydroxy-21-[(tetrahydro-2H-pyran-

L4 ANSWER 28 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
2-yloxy]- (8C1) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 29 OF 29 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1969:58144 CAPLUS
DOCUMENT NUMBER: 70:58144
TITLE: 9.alpha.-Difluoromethyl- and 9.alpha.-trifluoromethylpregnanes
INVENTOR(S): Fried, John H.
PATENT ASSIGNEE(S): Syntex Corp.
SOURCE: U.S., 15 pp.
CODEN: USXKAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3409610	A	19681105	US 1966-560864	19660627

AB 3.alpha.,17.alpha.,21-Trihydroxy-5.beta.-pregnane-11,20-dione 21-acetate (I g.), 1 g. KHCO₃, 10 ml. H₂O, and 90 ml. MeOH was kept under N 5 hrs. at room temp. to give 3.alpha.,17.alpha.,21-trihydroxy-5.beta.-pregnane-11,20-dione (I). I (5 g.) in 200 ml. CHCl₃ was mixed with 40 ml. 37% aq. HCHO and 5 ml. concd. HCl, and the mixt. stirred 48 hrs. at room temp. to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-hydroxy-5.beta.-pregnan-11-one (II). II (1 g.), 4 ml. C₅H₅N, and 2 ml. Ac₂O was kept 15 hrs. at room temp. to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-acetoxy-5.beta.-pregnan-11-one (III). Br in dioxane (1.2 molar equivs.) was added dropwise to 1 g. III in dioxane at 15.degree., a few drops anhyd. HBr in CHCl₃ added, and the mixt. kept 30 min. at room temp. to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-acetoxy-9.alpha.-bromo-5.beta.-pregnan-11-one (IV). Li (3 molar equivs.) was added slowly to 2 g. IV in 30 ml. anhyd. tetrahydrofuran (THF) and 50 ml. anhyd. liq. NH₃ at -35 to -40.degree., stirring continued 30 min., then 3 molar equivs. AcCl in tetrahydrofuran added, and the mixt. kept 30 min. to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.,11-diacetoxy-5.beta.-pregn-9(11)-ene (V). Na chlorodifluoroacetate (30 equivs.) in 30 ml. diglyme was added dropwise over 2 hrs. at reflux to 1 g. V in 8 ml. diglyme, and refluxing continued until the reaction was complete to give

L4 ANSWER 29 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.,11.beta.-diacetoxy-9.alpha.,11.alpha.-difluoromethylene-5.beta.-pregnane (VI). VI (1 g.) in 50 ml. MeOH was refluxed 3 hrs. with 0.2 g. KOH in 1 ml. H₂O to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-hydroxy-9.alpha.-difluoromethyl-5.beta.-pregnan-11-one (VII). VII (6 g.) in 120 ml. C₅H₅N was added to 6 g. CrO₃ in 20 ml. C₅H₅N, and the mixt. kept at room temp. 15 hrs. to give 17.alpha.,20:20,21-bis(methylenedioxy)-9.alpha.-difluoromethyl-5.beta.-pregnane-3,11-dione (VIII). A few drops 15% HBr in HOAc was added to 1 g. VIII in 17 ml. CHCl₃ and 20 ml. HOAc at -10.degree., then 0.46 g. Br in 12 ml. CHCl₃ added, followed by 2.5 g. NaOAc in 17 ml. H₂O to give the 4-bromo deriv. (IX). IX (1 g.) in 20 ml. HCONMe₂ contg. 0.5 g. LiCl was stirred under N 4 hrs. on a stream bath, cooled to 10.degree., and 11 ml. H₂O added to give 17.alpha.,20:20,21-bis(methylenedioxy)-9.alpha.-difluoromethylpregn-4-ene-3,11-dione (X). X (1 g.) in 100 ml. 80% HOAc was heated at 90.degree. under N 7 hrs. to give 9.alpha.-difluoromethyl-17.alpha.,21-dihydroxypregn-4-ene-3,11,20-trione. V (5 g.), 2.5 ml. anhyd. C₅H₅N, and 10 ml. F₃CCl was irradiated (high-pressure lamp) 72 hrs. at 4 cm. to give 17.alpha.,20:20,21-bis(methylenedioxy)-3.alpha.-acetoxy-9.alpha.-trifluoromethyl-5.beta.-pregnan-11-one. 9.alpha.-Trifluoromethyl-17.alpha.,21-dihydroxypregn-4-ene-3,11,20-trione (0.5 g.), 10 ml. dioxane, and 0.35 g. 2,3-dichloro-5,6-dicyano-1,4-benzoquinone was refluxed 10 hrs. to give 9.alpha.-trifluoromethyl-17.alpha.,21-dihydroxypregna-1,4-diene-3,11,20-trione. Prepd. similarly were a long series of analogs. No phys. properties were given.
IT 21365-47-9P
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
RN 21365-47-9 CAPLUS
CN Pregn-4-ene-11,20-dione, 17-hydroxy-3.beta.,21-bis[(tetrahydro-2H-pyran-2-yl)oxy]-9-(trifluoromethyl)- (8C1) (CA INDEX NAME)
Absolute stereochemistry.

L4 ANSWER 29 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




L7 ANSWER 62 OF 65 USPATFULL
 ACCESSION NUMBER: 75:16911 USPATFULL
 TITLE: Reduction of 3-keto-5 beta-H steroids to 3 beta-hydroxy-5beta-H steroids
 INVENTOR(S): Nickolson, Robert C., Ulrich Kerb, Germany, Federal Republic of
 Wiechert, Rudolf, Berlin, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin and Bergkamen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3875195	19750401
APPLICATION INFO.:	US 1973-416095	19731115 (5)


	NUMBER	DATE
PRIORITY INFORMATION:	DE 1972-2257132	19721118
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	French, Henry A.	
LEGAL REPRESENTATIVE:	Millen, Raptis & White	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIMS:	1	
LINE COUNT:	214	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB 3-KETO-5.beta.-H steroids are reduced to 3.beta.-hydroxy-5.beta.-H steroids with hydrogen under pressure and Raney nickel catalyst in a lower carboxylic acid as solvent.
 IT 601-03-6P 800-10-2P 10147-45-2P
 15734-50-6P 53604-15-2P 53604-17-4P
 (prepn. of)
 RN 601-03-6 USPATFULL
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 62 OF 65 USPATFULL (Continued)




RN 53604-15-2 USPATFULL
 CN Pregnan-20-one, 21-(acetyloxy)-, (3.beta.,5.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 53604-17-4 USPATFULL
 CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 62 OF 65 USPATFULL (Continued)
 RN 800-10-2 USPATFULL
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10147-45-2 USPATFULL
 CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 15734-50-6 USPATFULL
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.beta.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 62 OF 65 USPATFULL (Continued)

L7 ANSWER 63 OF 65 USPATFULL
 ACCESSION NUMBER: 75:11176 USPATFULL
 TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane series
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England
 Nevall, Christopher Earle, London, England
 Ayres, Barry Edward, Amersham, England
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3869451	19750304
APPLICATION INFO.:	US 1971-197915	19711111 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-53911	19701112
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIMS:	1	
LINE COUNT:	1677	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to steroids of the pregnane and 19-norpregnane series having anaesthetic properties and compositions containing them.
 More particularly the present invention relates to such steroids having a variety of substituents in the 2.beta.-position, a 3.alpha.-hydroxy group and a 5.alpha.-hydrogen atom and esters and 20-ketals thereof. At the 11-position of such steroids is preferably either two hydrogen atoms or an oxo group. The compounds according to the invention may conveniently be prepared by reaction of an appropriate 2.alpha.,3.alpha.-epoxy-pregnane or 19-norpregnane with a reagent which introduces the desired 2.beta.-substituent and various modifications of the compound produced are described to produce compounds within the scope of the invention. The present invention provides compositions containing certain steroids of the pregnane and 19-norpregnane series and such compositions generally may be administered intravenously to induce anaesthesia, the invention providing methods of inducing anaesthesia.
 IT 38689-90-6P (prepn. of)

L7 ANSWER 64 OF 65 USPATFULL
 ACCESSION NUMBER: 72:39193 USPATFULL
 TITLE: PROCESS FOR PREPARING 17.alpha.-HYDROXY-20-KETO AND 17.alpha.,21-DIHYDROXY-20-KETO PREGNANES AND DERIVATIVES AND INTERMEDIATES THEREOF
 INVENTOR(S): Crabbe, Pierre, Mexico City, Mexico
 Velarde, Esperanza, Mexico City, Mexico
 PATENT ASSIGNEE(S): Syntex Corporation, Panama, Panama

	NUMBER	DATE
PATENT INFORMATION:	US 3681410	19720801
APPLICATION INFO.:	US 1970-62201	19700807 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1969-854742, filed	


on 2 Sep 1969, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Gotts, Lewis
 ASSISTANT EXAMINER: Love, Ethel G.
 LEGAL REPRESENTATIVE: Merker, Evelyn K.
 NUMBER OF CLAIMS: 25
 LINE COUNT: 1282
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB New processes for preparing 17.alpha.-hydroxy-20-keto and 17.alpha.,21-dihydroxy-20-keto pregnanes and derivatives thereof, which compounds are useful as progestational and anti-inflammatory agents. The processes utilize the steps of converting a 17.alpha.-ethynyl-17.beta.-acetyloxy steroid to the corresponding 17-vinylidene steroid with zinc in an ethylene glycol ether and oxidizing the 17-vinylidene steroid to form the corresponding product pregnanes. The novel 17-vinylidene compounds are useful as intermediates as herein described and are also useful anti-androgenic agents.
 IT 35458-60-7P 35458-61-8P 36025-37-3P 36025-39-5P 36025-45-3P 36025-53-3P 36025-59-9P (prepn. of)

RN 35458-60-7 USPATFULL
 CN Pregnan-20-one, 3-(acetyloxy)-17,21-dihydroxy-, (3.beta.,5.alpha.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 63 OF 65 USPATFULL (Continued)
 RN 38689-90-6 USPATFULL
 CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-2-methoxy-, (2.beta.,3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 64 OF 65 USPATFULL (Continued)




RN 35458-61-8 USPATFULL
 CN Pregnan-20-one, 3-(acetyloxy)-21-[(3-chlorobenzoyl)oxy]-17-hydroxy-, (3.beta.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36025-37-3 USPATFULL
 CN Pregnan-20-one, 9-fluoro-3,11,17,21-tetrahydroxy-, (3.beta.,5.alpha.,11.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 64 OF 65 USPATFULL (Continued)


RN 36025-39-5 USPATFULL
 CN Pregnan-20-one, 3,21-bis(acetyloxy)-9-fluoro-11,17-dihydroxy-,
 (3.beta.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 36025-45-3 USPATFULL
 CN Pregnane-11,20-dione, 3-(acetyloxy)-17,21-dihydroxy-16-methyl-,
 (3.beta.,5.alpha.,16.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 36025-53-3 USPATFULL
 CN Pregnan-20-one, 9-fluoro-3,11,17,21-tetrahydroxy-6-methyl-,
 (3.beta.,5.alpha.,6.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 64 OF 65 USPATFULL (Continued)



RN 36025-59-9 USPATFULL
 CN Pregnan-20-one,
 21-[(3-chlorobenzoyloxy)-3,17-dihydroxy-6,16-dimethyl-,
 (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 65 OF 65 USPATFULL
 ACCESSION NUMBER: 72:39187 USPATFULL
 TITLE: PROCESS FOR THE PREPARATION OF 5-BROMO-6-FLUORO-
 STEROIDS
 INVENTOR(S): Wieske, Reinhold, Berlin, Germany, Federal
 Republic of
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin, Germany,
 Federal Republic of


	NUMBER	DATE
PATENT INFORMATION:	US 3681404	19720801
APPLICATION INFO.:	US 1970-23456	19700327 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1969-1916823	19690329
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	French, Henry A.	
LEGAL REPRESENTATIVE:	Millen, Raptes and White	
NUMBER OF CLAIMS:	6	
LINE COUNT:	242	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB 5-Bromo-6-fluoro steroids are produced by the bromine-fluorine addition to the double bond of a .DELTA.^{sup}.5 -unsaturated steroid using an N-bromoacylamide or N-bromoinide and aqueous hydrogen fluoride. A novel steroid produced by the process is 6.beta.-fluoro-5.alpha.-bromo-3.beta.,17.beta.-dihydroxy-androstane.

IT 1176-85-8P
 (prepn. of)
 RN 1176-85-8 USPATFULL
 CN Pregnan-20-one, 21-(acetyloxy)-5-bromo-6-fluoro-3-hydroxy-16-methyl-,
 (3.beta.,5.alpha.,6.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 09:00:07 ON 19 NOV 1999)

FILE 'REGISTRY' ENTERED AT 09:00:49 ON 19 NOV 1999

L1 STRUCTURE UPLOADED

L2 48 S L1

L3 1404 S L1 FULL

L4 1276 S L3 AND 1/NC

FILE 'CAPLUS' ENTERED AT 09:02:21 ON 19 NOV 1999

L5 52 S L4/THU

L6 7 S L5 NOT PY>=1995

FILE 'USPATFULL' ENTERED AT 09:03:29 ON 19 NOV 1999



L7 65 S L4

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1999:450892 CAPLUS
 DOCUMENT NUMBER: 131:102428
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk
 PATENT ASSIGNEE(S): J.; Lan, Nancy C.
 SOURCE: Cogenys, Inc., USA
 U.S. 28 pp.
 CODEN: USOXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5925630	A	19990720	US 1996-659192	19960606
CA 2223996	AA	19961219	CA 1996-2223996	19960606
CN 1190404	A	19980812	CN 1996-195360	19960606
			US 1995-467404	19950606


PRIORITY APPL. INFO.:
 OTHER SOURCE(S): MARPAT 131:102428
 AB Neuroactive steroids of formula I (R = H, NH₂, thio, sulfinyl, sulfonyl, halo, alkoxy, alkyl, alkenyl, alkynyl, etc.; R₁ = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, etc.; R₂ = H, alkoxy, keto, Me₂N; R₃ = alkoxy, alkenyloxy, alkynyloxy; R₄ = H, Me; R₅ = H, absent; R₆ = H, alkanoyl, etc.; R₇ = H, halo, OH, alkoxy, etc.; R₈ = H, halo; R₉ = H, halo, alkyl, alkoxy, arylalkoxy, amino; R₁₀ = H, halo, alkyl, OH, alkoxy, CN, etc.) are prepd. These derivs. are capable of acting at a recently identified site on the GABA receptor complex (GRC), thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.β-methoxy-5.β-androstan-3-one to give II. II protected 87.5% of mice injected with metrazol from convulsions.
 IT 186264-74-4P
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of neuroactive steroids of androstane and pregnane series)
 RN 186264-74-4 CAPLUS

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)





L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.β.,3.α.,5.α.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 162883-05-8P 186264-24-4P 186264-27-7P
 186264-34-6P 186264-35-7P 186264-36-8P
 186264-37-9P 186264-38-0P 186264-54-0P
 186264-61-9P 186264-63-1P 186264-79-9P
 186264-84-6P 186264-85-7P 186264-86-8P
 186264-87-9P 203719-57-7P 230958-75-5P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of neuroactive steroids of androstane and pregnane series)
 RN 162883-05-8 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-36-8 CAPLUS
 CN Pyridinium,
 4-[[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-
 methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-37-9 CAPLUS
 CN Pyridinium,
 4-[[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-
 methyl-, iodide (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-61-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-63-1 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-((6-quinolinyl)oxy)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

Absolute stereochemistry.




RN 186264-38-0 CAPLUS
 CN Pyridinium, 4-[[[(2.alpha.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-
 propoxy-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-54-0 CAPLUS

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-84-6 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-85-7 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-86-8 CAPLUS
 CN Quinolinium,
 6-[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 230958-75-5 CAPLUS
 CN Pyridinium, 4-[(2.beta.,3.beta.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


● I⁻

L4 ANSWER 1 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-87-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203719-57-7 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1998:112239 CAPLUS
 DOCUMENT NUMBER: 128:188632
 TITLE: Use of GABA agonists and NMDA receptor antagonists for the treatment of migraine headache
 INVENTOR(S): Lan, Nancy C.
 PATENT ASSIGNEE(S): Cocansys, Inc., USA; Lan, Nancy C.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: BIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9805337	A1	19980212	WO 1997-US13430	19970731
W:	AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RU, GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, HL, HR, NE, SN, TD, TG			
AP 9739672	A1	19980225	AU 1997-39672	19970731
PRIORITY APPLN. INFO.:			US 1996-22937	19960801
			WO 1997-US13430	19970731


AB Methods are disclosed for treating or preventing migraine headache by administering to an animal a GABA receptor agonist (e.g. a neuroactive steroid) and/or an NMDA receptor antagonist (e.g. a dihydroquinoline deriv.). Also disclosed are pharmaceutical compns. and kits for the treatment or prevention of migraine headache.

1st 162883-05-8 186264-24-4 186264-27-7
 186264-34-6 186264-35-7 186264-36-8
 186264-37-9 186264-54-0 186264-61-9
 186264-63-1 186264-74-4 186264-79-9
 186264-84-6 186264-85-7 186264-86-8
 186264-87-9 203716-90-9 203719-56-8
 203719-57-7 203785-79-9 203785-83-5
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (GABA agonists and NMDA receptor antagonists for migraine headache treatment)

RN 162883-05-8 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-24-4 CAPLUS
 CN Pregnan-20-one,
 3-hydroxy-3-((4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-27-7 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-34-6 CAPLUS
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-35-7 CAPLUS
 CN Pregnan-20-one,
 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-36-8 CAPLUS
 CN Pyridinium,
 4-[[[(3.alpha.,5.beta.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-
 methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

● I⁻

RN 186264-37-9 CAPLUS
 CN Pyridinium,
 4-[[[(3.alpha.,5.alpha.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-
 methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

● I⁻

RN 186264-54-0 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-61-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-63-1 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-74-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-84-6 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-85-7 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-86-8 CAPLUS
 CN Quinolinium,
 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-87-9 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 203716-90-9 CAPLUS
 CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 203719-56-6 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-,
 (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 203719-57-7 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)-
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




L4 ANSWER 2 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 203785-79-9 CAPLUS
 CN Pyridinium,
 4-[[[(2.beta.,5.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxy-19-norpregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203785-83-5 CAPLUS
 CN Pregnan-20-one, 21-(1H-benzimidazol-2-ylthio)-3-hydroxy-3-methyl-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS


ACCESSION NUMBER: 1997:113460 CAPLUS
 DOCUMENT NUMBER: 126:131695
 TITLE: Preparation of neuroactive steroids of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B.; Fick, David B.; Hogenkamp, Derk
 PATENT ASSIGNEE(S): J.; Lan, Nancy C.
 SOURCE: Cocensys, Inc., USA
 PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640043	A2	19961219	WO 1996-US10115	19960606
WO 9640043	A3	19970327		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, RW, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, CA 2223996 AA 19961219 CA 1996-2223996 19960606 AU 9661725 A1 19961230 AU 1996-61725 19960606 EP 837874 A2 19980429 EP 1996-919372 19960606 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1190404	A	19980812	CN 1996-195360	19960606
BR 9608592	A	19990629	BR 1996-8592	19960606
JP 11507643	T2	19990706	JP 1996-502210	19960606
NO 9705608	A	19980206	NO 1997-5608	19971204
FI 9704448	A	19971205	FI 1997-4448	19971205
PRIORITY APPLN. INFO.: US 1995-467404 19950606 WO 1996-US10115 19960606				

OTHER SOURCE(S): MARPAT 126:131695
 AB Comps. of formula I [R = H, NH2, thio, sulfinyl, sulfonyl, halogen, alkoxy, alkyl, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.; R2 = H, OH, alkoxy, alkanoyloxy, carbalkoxy, keto, amino; R3 = H, alkoxy, alkenyloxy, etc.; R4 = H, alkyl; R5 = H, absent; R6 = H, alkanoyl, aminocarbonyl, alkoxy carbonyl; R7 = H, halogen, OH, alkoxy, alkanoyloxy, carbalkoxy; R8 = H, halogen; R9 = H, halogen, alkyl, alkoxy, arylalkoxy, amino; R10 = H, halogen, OH, alkyl, etc.] are prepd. as neuroactive produgs, due to their ability to modulate the GABAA receptor-chloride ionophore complex. These derivs. are capable of acting at a recently

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. Thus, 2-methyl-1-buten-3-yne was added to 17.β-methoxy-5.β-androstan-3-one to give II. II (10 mg/kg IP) protected 87.5% of mice injected with metrazol from convulsions.
 IT 162883-05-8P 186264-27-7P 186264-74-4P
 RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neuroactive androstanes and pregnanes)
 RN 162883-05-8 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.β.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-27-7 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.α.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
 (3.α.,5.β.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-34-6 CAPLUS
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-(4-pyridinylthio)-, (3.α.,5.α.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-35-7 CAPLUS
 CN Pregnan-20-one, 3-[[4-(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-], (3.α.,5.β.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 186264-74-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-, (2.β.,3.α.,5.α.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 186264-24-4P 186264-34-6P 186264-35-7P
 186264-36-8P 186264-37-9P 186264-38-0P
 186264-54-0P 186264-61-9P 186264-63-1P
 186264-79-9P 186264-84-6P 186264-85-7P
 186264-86-8P 186264-87-9P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neuroactive androstanes and pregnanes)
 RN 186264-24-4 CAPLUS
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-(4-pyridinylthio)-, (3.α.,5.β.)-(9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-36-8 CAPLUS
 CN Pyridinium, 4-[[[(3.α.,5.β.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-37-9 CAPLUS
 CN Pyridinium, 4-[[[(3.α.,5.α.)-3-hydroxy-20-oxopregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)

● I⁻


RN 186264-38-0 CAPLUS
CN Pyridinium, 4-[[[(2.beta.,3.alpha.,5.alpha.)-3-hydroxy-20-oxo-2-propoxypregnan-21-yl]thio]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● I⁻


RN 186264-54-0 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI)

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-79-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-84-6 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 186264-61-9 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-63-1 CAPLUS
CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 29 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 186264-85-7 CAPLUS
CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-86-8 CAPLUS
CN Quinolinium, 6-[[[(3.alpha.,5.alpha.)-3-hydroxy-3-methyl-20-oxopregnan-21-yl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/321,882

Page 1

=> d ibib ab hitstr 1-7

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1995:298133 CAPLUS
 DOCUMENT NUMBER: 122:64421
 TITLE: Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
 INVENTOR(S): Clark, Abbot F.; Southren, Aaron L.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 4 pp. Cont. of U.S. Ser. No.399,349, abandoned.
 CODEN: USOXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5358943	A	19941025	US 1993-12181	19930202
PRIORITY APPLN. INFO.:			US 1987-139227	19871229
			US 1989-399349	19890828

AB Pharmaceutical compns. useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compns. are disclosed. The compns. contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compns. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical compn. contg. tetrahydrocortisol to a patient receiving such therapy. A formulation including tetrahydrocortisol and dexamethasone is presented.


IT 53-02-1D, Tetrahydrocortisol, mixts. with glucocorticoids
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids, and ophthalmic pharmaceuticals contg. combination of tetrahydrocortisol with corticosteroid)

RN 53-02-1 CAPLUS
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1994:646593 CAPLUS
 DOCUMENT NUMBER: 121:246593
 TITLE: Anticonvulsant activity of neurosteroids:
 correlation with .gamma.-aminobutyric acid-evoked chloride current potentiation
 AUTHOR(S): Kokate, Tushar G.; Svensson, Bjoern E.; Rogawski, Michael A.
 CORPORATE SOURCE: Neuronal Excitability Section, National Institute Neurological Diseases and Stroke, Bethesda, MD, USA
 SOURCE: J. Pharmacol. Exp. Ther. (1994), 270(3), 1223-9
 CODEN: JPETAB; ISSN: 0022-3565
 LANGUAGE: English
 AB Certain neurosteroids rapidly alter the excitability of neurons, in part by potentiating GABA-evoked chloride currents, and, like other GABA potentiating drugs, may have anticonvulsant activity. We compared the abilities of a series of isomeric metabolites of progesterone and deoxycorticosterone (3-hydroxy pregnane-20-ones and 3-hydroxy pregnane-21-of-20-ones) to enhance GABA-evoked chloride currents in cultured hippocampal neurons with their abilities to protect against pentylenetetrazole (PTZ)-induced seizures in mice. Metabolites with 3-hydroxy in the .alpha.-position and 5-H in the .alpha.- or .beta.-configuration were highly effective at potentiating GABA-evoked chloride current and also showed potent anticonvulsant activity in the PTZ seizure test. The corresponding metabolites with hydroxyl groups in the 3.beta.-position were considerably less potent in enhancing GABA responses and were inactive in the PTZ test. All of the neurosteroids failed to protect against tonic hindlimb extension in the maximal electroshock test. 5.alpha.-Pregnane-3.alpha.,11.beta.,21-triol-20-one, a corticosterone metabolite reported to block voltage-dependent Ca²⁺ channels, was inactive in either of the anticonvulsant tests. At higher doses, neurosteroids effective in the PTZ test also produced motor impairment. Relative motor toxicity was lower (higher protective index) for compds. with the 5.alpha.-configuration than for their corresponding 5.beta.-epimers. The anticonvulsant profile of the neurosteroids resembled that of the benzodiazepine clonazepam. Although the anticonvulsant steroids had greater in vitro potencies than clonazepam, they were less potent in vivo, and they had lower protective indexes. We conclude that certain naturally occurring neurosteroid isomers are highly effective anticonvulsants and this activity is correlated with their ability to potentiate GABA_A receptor responses. Although toxicity (sedation) may be an impediment to

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)




L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
 the clin. use of neurosteroids in seizure therapy, there is variation among analogs in the extent to which toxicity is produced at anticonvulsant doses.

IT 567-01-1, 3.beta.,21-Dihydroxy-5.alpha.-pregnan-20-one
 567-02-2, 3.alpha.,21-Dihydroxy-5.alpha.-pregnan-20-one
 567-03-3, 3.alpha.,21-Dihydroxy-5.beta.-pregnan-20-one
 600-63-5, 3.alpha.,11.beta.,21-Trihydroxy-5.alpha.-pregnan-20-one
 800-10-2, 3.beta.,21-Dihydroxy-5.beta.-pregnan-20-one
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anticonvulsant activity correlated with GABA-evoked chloride current potentiation in hippocampus)


RN 567-01-1 CAPLUS
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 567-02-2 CAPLUS
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 567-03-3 CAPLUS


L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 600-63-5 CAPLUS
 CN Pregnan-20-one, 3,11,21-trihydroxy-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 800-10-2 CAPLUS
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1994:621209 CAPLUS
 DOCUMENT NUMBER: 121:221209
 TITLE: Potentiation of cytotoxic cancer therapies by alone and with other anti-angiogenic agents
 AUTHOR(S): Teicher, Beverly A.; Holden, Sylvia A.; Ara, Gulshan; Alvarez Sotomayor, Enrique; Huang, Zhen Dong; Chen, Ying Nan; Brem, Harold
 CORPORATE SOURCE: Dana-Farber Cancer Institute, Boston, MA, 02115, USA
 SOURCE: Int. J. Cancer (1994), 57(6), 920-5
 CODEN: IJCNAA; ISSN: 0020-7136
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The ability of TNP-470, a synthetic analog of fumagillin which has been described as an anti-angiogenic agent, to potentiate cytotoxic cancer therapies was investigated in vivo in the murine FSaII fibrosarcoma and the Lewis lung carcinoma. TNP-470 was more toxic toward FSaII tumor cells from tumors treated in vivo than toward bone-marrow CFU-GM from the same animals. TNP-470 had a dose-modifying effect on the toxicity of cyclophosphamide toward FSaII tumor cells which amounted to an 8-fold increase in tumor-cell killing at a cyclophosphamide dose of 500 mg/kg. Treatment with TNP-470 and minocycline increased the permeability of the FSaII fibrosarcoma in vivo to the fluorescent dye Hoechst 33342 and increased the killing of both the bright and the dim tumor cells by cyclophosphamide. TNP-470, esp. in combination with minocycline, formed a highly effective modulator combination for treatment of the Lewis lung carcinoma with cytotoxic cancer therapies against primary and metastatic disease. The combination of TNP-470/minocycline and cyclophosphamide led to 40 to 50% long-term survivors in Lewis-lung-carcinoma-bearing animals. Our results indicate that the use of anti-angiogenic modulators in cancer therapy is a very promising area for further study.
 IT 53-02-1
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cytotoxic cancer therapies potentiation by TNP-470 alone and with other anti-angiogenic agents)
 RN 53-02-1 CAPLUS
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1994:595111 CAPLUS
 DOCUMENT NUMBER: 121:195111
 TITLE: .beta.-cyclodextrin
 tetradecasulfate/tetrahydrocortisol
 1.-. minocycline as modulators of cancer
 therapies in vitro and in vivo against primary and
 metastatic Lewis lung carcinoma
 AUTHOR(S): Teicher, Beverly A.; Sotomayor, Enrique Alvarez;
 Huang, Zhen Dong; Ara, Gulshan; Holden, Sylvia;
 Khaderkar, Vinod; Chen, Ying-Man
 CORPORATE SOURCE: Jt. Cent. Radiat. Ther., Dana-Farber Cancer Inst.,
 Boston, MA, 02115, USA
 SOURCE: Cancer Chemother. Pharmacol. (1993), 33(3), 229-38
 CODEN: CCFPDZ; ISSN: 0344-5704
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Tetrahydrocortisol, .beta.-cyclodextrin tetradecasulfate, and
 minocycline used alone or in combination are not very cytotoxic toward EMT-6 mouse
 mammary tumor cells growing in monolayer. Tetrahydrocortisol (100
 .mu.M, 24 h) and .beta.-cyclodextrin tetradecasulfate (100 .mu.M, 24 h)
 protected EMT-6 cells from the cytotoxicity of CDDP, melphalan, 4-
 hydroperoxycyclophosphamide, BCNU, and X-rays under various
 conditions of oxygenation and pH. Minocycline (100 .mu.M, 24 h) either had no
 effect upon or was additive with the antitumor alkylating agents or X-rays in
 cytotoxic activity toward the EMT-6 cells in culture. The
 combination of the three modulators either had no effect upon or was to a small
 degree protective against the cytotoxicity of the antitumor alkylating
 agents or X-rays. The Lewis lung carcinoma was chosen for primary tumor
 growth-delay studies and tumor lung-metastases studies.
 Tetrahydrocortisol and .beta.-cyclodextrin tetradecasulfate were
 given in a 1:1 molar ratio by continuous infusion over 14 days, and
 minocycline was given i.p. over 14 days, from day 4 to day 18 post tumor implantation.
 The combination of tetrahydrocortisol/.beta.-cyclodextrin
 tetradecasulfate diminished the tumor growth delay induced by CDDP and melphalan and
 produced modest increases in the tumor growth delay produced by
 cyclophosphamide and radiation. Minocycline co-treatment increased
 the tumor growth delay produced by CDDP, melphalan, radiation, bleomycin,
 and,

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
 esp. cyclophosphamide, where 4 of 12 animals receiving minocycline (14
 times, 5 mg/kg, days 4-18) and cyclophosphamide (3 times, 150 mg/kg,
 days 7, 9, 11) were long-term survivors. The 3 modulators given in
 combination produced further increases in tumor growth delay with all
 of the cytotoxic therapies, and 5 of 12 of the animals treated with the
 3-modulator combination and cyclophosphamide were long-term survivors.
 Although neither tetrahydrocortisol/.beta.-cyclodextrin
 tetradecasulfate, minocycline, nor the three modulator combination impacted the no. of
 lung metastases, there was a decrease in the no. of large lung metastases.
 Treatment with the cytotoxic therapies alone reduced the no. of lung
 metastases. Addn. of the modulators to treatment with the cytotoxic
 therapies resulted in a further redn. in the no. of lung metastases.
 These results indicate that agents that inhibit the breakdown of the
 extracellular matrix can be useful addns. to the treatment of solid
 tumors.
 IT 53-02-1, Tetrahydrocortisol
 RI: BAC (Biological activity or effector, except adverse); THU
 (therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.-cyclodextrin tetradecasulfate/tetrahydrocortisol .+-.
 minocycline as modulators of cancer therapies in vitro and in vivo
 against primary and metastatic Lewis lung carcinoma)
 RN 53-02-1 CAPLUS
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)-
 (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1986:39720 CAPLUS
 DOCUMENT NUMBER: 104:39720
 TITLE: Pharmaceutical compositions containing unilamellar
 liposomes
 INVENTOR(S): Muntwyler, Rene; Hauser, Helmut
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 65 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 152379	A2	19850821	EP 1985-810050	19850211
EP 152379	A3	19861029		
ES 540372	A1	19860601	ES 1985-540372	19850213
CA 1246446	A1	19881213	CA 1985-474204	19850213
DK 8500685	A	19850816	DK 1985-685	19850214
AU 8538753	A1	19850822	AU 1985-38753	19850214
AU 588798	B2	19890928		
ZA 850111	A	19850925	ZA 1985-1111	19850214
JP 60190710	A2	19850928	JP 1985-26616	19850215
			CH 1984-736	19840215


PRIORITY APPLN. INFO.:
 AB Aq. pharmaceutical dispersions made of unilamellar liposomes contg. an
 amphipathic drug and a phospholipid are given. The amphipathic drugs
 are quaternary ammonium compds., compds. convertible into quaternary
 ammonium derivs. by salt formation, .alpha.-amino acids, phosphonic acid
 esters.
 etc. Thus, 50 mg soybean lecithin was added to 20.33 mg
 1-isopropylamino-3-(2-pyrrol-1-ylphenoxy)propan-2-ol-HCl
 (99740-06-4) in 30 mL MeOH-CHCl3 (1:1) in a vial. The vial was rotated, and the film
 which formed was treated with 1.5 mL H2O to give a dispersion of
 unilamellar liposomes.
 IT 14107-37-0
 RI: THU (therapeutic use); BIOL (Biological study); USES (Uses)
 (unilamellar liposome pharmaceutical compns. contg.)
 RN 14107-37-0 CAPLUS
 CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA
 INDEX NAME)
 Absolute stereochemistry.

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1976:441191 CAPLUS
 DOCUMENT NUMBER: 85:41191
 TITLE: Structure-activity relationships in steroidal anesthetics
 AUTHOR(S): Phillipps, G. H.
 CORPORATE SOURCE: Scot.
 SOURCE: Mol. Mech. Gen. Anaesth., Glaxo Symp. (1974),
 Meeting Date 1973, 32-47. Editor(s): Halsey, M. J.,
 Millar, Ronald Alexander, Sutton, J. A. Churchill-
 Livingstone: London, Engl.
 CODEN: 32QIAP
 CONFERENCE
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB The essential nature of an oxygen atom in the 3-position of hydroxysteroids and of the importance of the exact manner in which it projects from the A ring for anesthetic potency was studied in mice. Improved potency and decreased toxicity compared with alphaxalone [23930-19-0] was achieved with a no. of water sol. compds. related to the pregnane-20-ones (I). These compds. gave instantaneous anesthesia and did not show untoward effects.
 IT 567-02-2 14107-37-0 23930-37-2
 38392-87-9 38601-29-5 51086-93-2
 51086-95-4 51087-15-1
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anesthetic activity of)
 RN 567-02-2 CAPLUS
 CN Pregnane-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 14107-37-0 CAPLUS
 CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
 INDEX NAME

Absolute stereochemistry.



RN 23930-37-2 CAPLUS
 CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-87-9 CAPLUS
 CN Glycine, N,N-diethyl-, (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 38601-29-5 CAPLUS
 CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-93-2 CAPLUS
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 51086-95-4 CAPLUS
 CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-15-1 CAPLUS
 CN Pregnane-11,20-dione, 3-hydroxy-21-[[[2-(4-morpholinyl)ethoxy]thiomethyl]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1975:558163 CAPLUS
 DOCUMENT NUMBER: 83:158163
 TITLE: Structure-activity relations in steroidal
 anesthetics
 AUTHOR(S): Philipps, G. H.
 CORPORATE SOURCE: Org. Chem. Dep., Glaxo Res. Ltd.,
 Greenford/Middlesex,
 SOURCE: Engl.
 J. Steroid Biochem. (1975), 6(5), 607-13
 CODEN: JSTBBK
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The introduction of double bonds and substituents into Alphaxalone
 [23930-19-0] modify its anesthetic activity, as detd. in mice, and
 these modifications are discussed with particular ref. to the conformation
 of the A-ring. A variety of side chains may be present at the
 17.beta.-position. Some water-sol. steroids which show instantaneous
 induction of anesthesia are described.
 IT 567-02-2 14107-37-0 23930-37-2
 38601-29-5 51086-93-2 51086-95-4
 51087-15-1 56857-38-6
 RL: BAC (Biological activity or effector, except adverse); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anesthetic activity of)
 RN 567-02-2 CAPLUS
 CN Pregnane-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 14107-37-0 CAPLUS
 CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)




RN 23930-37-2 CAPLUS
 CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-29-5 CAPLUS
 CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-93-2 CAPLUS


L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51086-95-4 CAPLUS
 CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-15-1 CAPLUS
 CN Pregnane-11,20-dione,
 3-hydroxy-21-[[2-(4-morpholinyl)ethoxy]thiomethyl
]thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1999 ACS (Continued)



RN 56857-38-6 CAPLUS
CN Pregnenolone-21-((1-pyrrolidinylacetyl)oxy)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib ab hitstr 1-65

L7 ANSWER 1 OF 65 USPATFULL
 ACCESSION NUMBER: 1999:99389 USPATFULL
 TITLE: Formulations and methods for providing prolonged local anesthesia
 INVENTOR(S): Chasin, Mark, Manalapan, NJ, United States
 Sackler, Richard, Greenwich, CT, United States
 Burch, Ronald M., Wilton, CT, United States
 Goldenheim, Paul, Wilton, CT, United States
 Tigner, Joseph, New Milford, CT, United States
 PATENT ASSIGNEE(S): Euro-Celtique, S.A., Luxembourg, Luxembourg
 (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5942241	19990824
	WO 9641616	19961227
APPLICATION INFO.:	US 1997-793861	19970616 (8)
	WO 1996-US10439	19960607
	19970616	PCT 371 date
	19970616	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1995-60000105	19950609
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Levy, Neil S.	
LEGAL REPRESENTATIVE:	Davidson, Davidson & Kappel, LLC	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1918	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

IT 547-77-3, Allotetrahydrocortisone
 (formulations and methods for providing prolonged local anesthesia)

RN 547-77-3 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 65 USPATFULL (Continued)



L7 ANSWER 2 OF 65 USPATFULL
 ACCESSION NUMBER: 1999:96496 USPATFULL
 TITLE: Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
 INVENTOR(S): Xia, Haiji, Foothill Ranch, CA, United States
 Hogenkamp, Derk, Carlsbad, CA, United States
 CoCensys, Inc., Irvine, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5939545	19990817
APPLICATION INFO.:	US 1997-887229	19970702 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-389820, filed on 14 Feb 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-346927, filed on 23 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-196919, filed on 14 Feb 1994, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose G.	
ASSISTANT EXAMINER:	Badio, Barbara	
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	3557	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Methods, compositions, and compounds for modulating the GABA subunit A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.

IT 162882-76-0P 162882-80-0P 162882-89-5P
 162882-90-8P 162882-92-0P 162882-98-6P
 162883-05-8P 162883-10-3P 162883-28-5P
 162883-38-7P 162883-85-4P
 (pregn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)

RN 162882-76-0 USPATFULL
 CN 19-Norpregnan-20-one, 3,21-dihydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)




RN 162882-80-6 USPATFULL
 CN Pregnane-20-one, 3,21-dihydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162882-89-5 USPATFULL
 CN Pregnane-20-one, 21-(acetyloxy)-3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 2 OF 65 USPATFULL (Continued)

RN 162882-90-8 USPATFULL

CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-ethynyl-3-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162882-92-0 USPATFULL

CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162882-98-6 USPATFULL

CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-28-5 USPATFULL

CN Pregnan-20-one, 3-ethynyl-3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162883-38-7 USPATFULL

CN Pregnan-20-one, 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-(trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-05-8 USPATFULL

CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162883-10-5 USPATFULL

CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(methylsulfonyl)oxy]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 65 USPATFULL (Continued)



RN 162883-85-4 USPATFULL

CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-methoxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 567-03-3 2402-24-6 95611-83-5

117899-40-8 140346-37-6 162882-67-9

162883-26-3


(prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as sedatives and hypnotics)

RN 567-03-3 USPATFULL


CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)




RN 2402-24-6 USPATFULL
 CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.beta.)- (9CI)
 (CA INDEX NAME)
 Absolute stereochemistry.




RN 96611-83-5 USPATFULL
 CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)




RN 117899-40-8 USPATFULL
 CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 148346-37-6 USPATFULL
 CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)




RN 162882-67-9 USPATFULL
 CN Pregnan-20-one, 21-(3-carboxy-1-oxopropoxy)-3-hydroxy-3-methyl-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 162883-26-3 USPATFULL
 CN 19-Norpregnan-20-one, 3-hydroxy-21-methoxy-3-(trifluoromethyl)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)




IT 162883-49-0
 (prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as
 sedatives and hypnotics)
 RN 162883-49-0 USPATFULL
 CN Pregnan-20-one, 3,21-dihydroxy-3-methyl-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)
 Absolute stereochemistry.




IT 162883-34-3P 162883-41-2P
 (prepn. and formulation of 3.alpha.-hydroxypregnanes and analogs as
 sedatives and hypnotics)
 RN 162883-34-3 USPATFULL
 CN Pregnan-20-one,
 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-methyl-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 2 OF 65 USPATFULL (Continued)




RN 162883-41-2 USPATFULL
 CN 19-Norpregnan-20-one,
 21-[[bis(phenylmethoxy)phosphinyl]oxy]-3-hydroxy-3-
 (trifluoromethyl)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 3 OF 65 USPATFULL (Continued)

Absolute stereochemistry.




RN 186264-40-4 USPATFULL
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(3-hydroxypropyl)thio]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-51-7 USPATFULL
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(3-hydroxypropyl)sulfinyl]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 65 USPATFULL

1999:81822 USPATFULL
 TITLE: Neuroactive steroids of the androstane and pregnane series
 INVENTOR(S): Upasani, Ravindra B., Foothill Ranch, CA, United States
 Fick, David B., Mission Viejo, CA, United States
 Hogenkamp, Derk J., Carlsbad, CA, United States
 Lan, Nancy C., South Pasadena, CA, United States
 CoCensys, Inc., Irvine, CA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):

	NUMBER	DATE
PATENT INFORMATION:	US 5925630	19990720
APPLICATION INFO.:	US 1996-659192	19960606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-467404, filed	

DOCUMENT TYPE: on 6 Jun 1995
 Utility
 PRIMARY EXAMINER: Dees, Jose' G.
 ASSISTANT EXAMINER: Badio, Barbara
 LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 3047


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).
 IT 186264-39-1P 186264-40-4P 186264-51-7P
 186264-62-0P 186264-74-4P 186264-76-6P
 (pregn. of neuroactive steroids of androstane and pregnane series)
 RN 186264-39-1 USPATFULL
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(2-hydroxyethyl)thio]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 65 USPATFULL (Continued)


RN 186264-62-0 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-(4-nitrophenoxy)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186264-74-4 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-2-propoxy-21-(4-pyridinylthio)-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-76-6 USPATFULL
 CN Pregnan-20-one,
 21-[(4-fluorophenyl)sulfonyl]-3-hydroxy-3-(methoxymethyl)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 3 OF 65 USPATFULL (Continued)



IT 567-02-2P, 3.alpha.,21-Dihydroxy-5.alpha.-pregnan-20-one
 567-03-3P 162883-05-8P 186264-24-4P
 186264-27-7P 186264-31-3P 186264-33-5P
 186264-34-6P 186264-35-7P 186264-41-5P
 186264-42-6P 186264-52-8P 186264-53-9P
 186264-54-0P 186264-61-9P 186264-63-1P
 186264-64-2P 186264-65-3P 186264-66-4P
 186264-67-5P 186264-70-9P 186264-81-3P
 186264-84-6P 186264-85-7P 186264-87-9P
 203719-57-7P


(prepn. of neuroactive steroids of androstane and pregnane series)
 RN 567-02-2 USPATFULL
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 567-03-3 USPATFULL
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-27-7 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-[(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186264-31-3 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 3 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



RN 162883-05-8 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-[(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-24-4 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-(4-hydroxy-1-butynyl)-21-[(4-pyridinylthio)-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-33-5 USPATFULL
 CN Pregnan-20-one, 21-[(4-fluorophenylthio)-3-hydroxy-3-(methoxymethyl)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-34-6 USPATFULL
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(4-pyridinylthio)-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-35-7 USPATFULL
 CN Pregnan-20-one,
 3-[(4-acetylphenyl)ethynyl]-3-hydroxy-21-(4-pyridinylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-41-5 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-[(3-hydroxypropyl)thio]-2-propoxy-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-53-9 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-[(3-hydroxypropyl)sulfonyl]-2-propoxy-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-54-0 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-(3-pyridinyloxy)-, (3.alpha.,5.beta.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-42-6 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-[(2-hydroxyethyl)thio]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-52-8 USPATFULL
 CN Pregnan-20-one, 3-ethynyl-3-hydroxy-21-[(3-hydroxypropyl)sulfonyl]-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-61-9 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinyloxy)-, (3.alpha.,5.beta.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-63-1 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-methyl-21-[(6-quinolinyl)oxy]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-64-2 USPATFULL
 CN Pregnan-20-one, 21-[[4-(dimethylamino)phenoxy]-3-hydroxy-3-methyl-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-65-3 USPATFULL
 CN Pregnan-20-one, 21-[[4-(dimethylamino)phenylthio]-3-hydroxy-3-(methoxymethyl)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-66-4 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-nitrophenyl)sulfonyl]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-67-5 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-[(4-(1-pyrrolidinyl)phenyl)sulfonyl]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-79-9 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-3-(methoxymethyl)-21-(4-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-81-3 USPATFULL
 CN Pregnan-20-one, 21-[(4-aminophenylthio)-3-hydroxy-3-(methoxymethyl)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)



RN 186264-84-6 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-(1H-imidazol-2-ylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186264-85-7 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-(4-pyridinylsulfinyl)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)




RN 186264-87-9 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-[(1-oxido-3-pyridinyl)oxy]-,
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 203719-57-7 USPATFULL
CN Pregnan-20-one, 3-hydroxy-21-(2-pyridinylthio)-, (3.alpha.,5.beta.)-
(9CI)
(CA INDEX NAME)
Absolute stereochemistry.

L7 ANSWER 3 OF 65 USPATFULL (Continued)




L7	ANSWER 4 OF 65	USPATFULL
ACCESSION NUMBER:	1999:24638	USPATFULL
TITLE:	Compositions and methods for modulating growth of a tissue in a mammal	
INVENTOR(S):	Herrmann, Howard C., Bryn Mawr, PA, United States Barnathan, Elliot, Haverhill, MA, United States Weisz, Paul B, State College, PA, United States	
PATENT ASSIGNEE(S):	The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)	

	NUMBER	DATE
PATENT INFORMATION:	US 5874419	19990223
APPLICATION INFO.:	US 1977-905612	19970804 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-345011, filed on 23 Nov	
	1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned, said Ser. Ser. No. -900592 which is a continuation-in-part of	

```


L7 ANSWER 4 OF 65 USPATFULL (Continued)
IT 53-05-4
      (prepn. of cyclodextrin conjugates with drugs to improve water
sol.)
CN 53-05-4 USPATFULL
PN Pregnen-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI)
(CA
INDEX NAME)

```




L7 ANSWER 5 OF 65 USPTFULL
 ACCESSION NUMBER: 1998:157488 USPTFULL
 TITLE: Oligosaccharide-containing 14 aminosteroid compounds
 INVENTOR(S): and novel diastereoselective aminosteroid process chemistry
 Dybas, Paul Michael, Port Crane, NY, United States
 Johnson, Roland Norman, Norwich, NY, United States
 Muth, Randy Stuart, Poolville, NY, United States
 Liu, Song, Norwich, NY, United States
 Portlock, David Edward, Norwich, NY, United States
 PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5849889 19981215
 APPLICATION INFO.: US 1997-802491 19970220 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-406833, filed on 20 Mar 1995, now abandoned which is a continuation of Ser. No. US 1993-126459, filed on 24 Sep 1993, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Knode, Marian C.
 ASSISTANT EXAMINER: Lee, Howard C.
 LEGAL REPRESENTATIVE: McMahon, Mary Pat; Winter, William J.; Clark, Karen F.
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2245
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to new 14-aminosteroids, pharmaceutical compositions containing the new compounds and methods of treatment for humans or other mammals afflicted with congestive heart failure.
 IT 26520-64-9P (prepn. of oligosaccharide-contg. 14-aminosteroid cardiovascular and inotropic agents and diastereoselective aminosteroid process chem.)
 RN 26520-64-9 USPTFULL
 CN Pregnan-20-one, 3-[(10-3,4-di-O-acetyl-2,6-dideoxy-.beta.-D-ribohexopyranosyl-(1.fvdarv.4)-O-3-O-acetyl-2,6-dideoxy-.beta.-D-ribohexopyranosyl-(1.fvdarv.4)-3-O-acetyl-2,6-dideoxy-.beta.-D-ribohexopyranosyl)oxy]-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L7 ANSWER 5 OF 65 USPTFULL (Continued)



L7 ANSWER 6 OF 65 USPTFULL
 ACCESSION NUMBER: 1998:101671 USPTFULL
 TITLE: Cytoskeletal active agents for glaucoma therapy
 INVENTOR(S): Kaufman, Paul L., Madison, WI, United States
 Geiger, Benjamin, Rehovot, Israel
 Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5798380 19980825
 APPLICATION INFO.: US 1996-604568 19960221 (8)
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Fay, Zohreh
 LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
 NUMBER OF CLAIMS: 4
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 29 Drawing Figure(s); 15 Drawing Page(s)
 LINE COUNT: 2552
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
 IT 53-02-1 (glaucoma treatment with compds. causing perturbation of cell adhesions in trabecular meshwork)
 RN 53-02-1 USPTFULL
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L7 ANSWER 7 OF 65 USPTFULL
 ACCESSION NUMBER: 1998:72617 USPTFULL
 TITLE: Prevention and treatment of ocular neovascularization using angiostatic steroids
 INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States (U.S. corporation)
 NUMBER DATE
 PATENT INFORMATION: US 5770592 19980623
 APPLICATION INFO.: US 1997-895184 19970716 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-342524, filed on 21 Nov 1994, now patented, Pat. No. US 5679666 And Ser. No. US 1991-796169, filed on 22 Nov 1991, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Fay, Zohreh
 LEGAL REPRESENTATIVE: Yeager, Sally
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 316
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.
 IT 68-60-0, Tetrahydrocortexolone (glaucoma treatment with)
 RN 68-60-0 USPTFULL
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.



L7 ANSWER 8 OF 65 USPATFULL

ACCESSION NUMBER: 1998:64714 USPATFULL
 TITLE: Methods of using steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
 PATENT ASSIGNEE(S): Board of Regents the University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5762918	19980609
	WO 9318793	19930930
APPLICATION INFO.:	US 1994-307745	19941205 (8)
	WO 1993-US2619	19930322
		19941205 PCT 371 date
		19941205 PCT 102(e) date

RELATED APPL. INFO.: Continuation-in-part of Ser. No. US 1992-856018, filed

on 23 Mar 1992, now patented, Pat. No. US 5474765
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Page, Thurman K.
 LEGAL REPRESENTATIVE: Arnold, White & Durkee
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 15 Drawing Figure(s); 14 Drawing Page(s)
 LINE COUNT: 2568

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention discloses new targeted conjugates for the delivery of a compound, and particularly, a steroid, to vascular endothelial cells.

The conjugates comprise two components, preferably linked by a selectively-hydrolyzable bond, such as an acid-labile bond or enzyme-sensitive bond. The first component, a polyanionic polymer, and

preferably, a polysulphated polymer such as a heparin-derivative, specifically directs the conjugate to vascular endothelial cells.


The second component is a selected agent, such as a steroid, which exerts a specific effect on the target cell following its release. In particular, the present invention provides novel conjugated angiogenesis inhibitors, for use in the treatment of pathogenic conditions including cancer, arthritis, and diabetic blindness. An inhibitor comprising a heparin derivative and the anti-angiogenic steroid, cortisol, is herein shown to be markedly acid-labile, to suppress DNA synthesis and cell migration in human umbilical vein endothelial cells, to retard or abolish (depending on the route of injection) the vascularization of sponges in

L7 ANSWER 8 OF 65 USPATFULL (Continued)

vivo and to retard lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin plus cortisol were significantly less effective in all cases.


IT 53-02-1DP, Tetrahydrocortisol, heparin conjugate
 53-05-4DP, Tetrahydrocortisone, heparin conjugate
 68-42-8DP, Tetrahydrocorticosterone, heparin conjugate
 68-60-0DP, Tetrahydro S, heparin conjugate
 (prepn. of steroid-heparin conjugates as angiogenesis inhibitors)
 RN 53-02-1 USPATFULL
 CN Pregnane-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)-(9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 8 OF 65 USPATFULL (Continued)


RN 68-42-8 USPATFULL
 CN Pregnane-20-one, 3,11,21-trihydroxy-, (3.alpha.,5.beta.,11.beta.)-(9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 68-60-0 USPATFULL
 CN Pregnane-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 65 USPATFULL

ACCESSION NUMBER: 1998:61630 USPATFULL
 TITLE: Cyclodextrin compounds and methods of making and use
 INVENTOR(S): thereof, Joulie, Madeleine M., Philadelphia, PA, United States
 PATENT ASSIGNEE(S): Weisz, Paul B., State College, PA, United States
 The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 5760015	19980602
APPLICATION INFO.:	US 1995-416107	19950403 (8)
RELATED APPL. INFO.:	Continuation-in-part of Ser. No. US 1994-345011, filed	
	on 23 Nov 1994, now patented, Pat. No. US 5658894	
which	is a continuation of Ser. No. US 1992-900592,	
filed on	18 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-480407,	
filed	on 15 Feb 1990, now patented, Pat. No. US 5183809	
And a	continuation of Ser. No. US 1991-790592, filed on	
12	Nov 1991, now abandoned which is a continuation of	
Ser.	No. US 1991-691168, filed on 24 Apr 1991, now	
abandoned	which is a continuation-in-part of Ser. No. US 1989-434659, filed on 9 Nov 1989, now patented,	
Pat.	No. US 5019562 which is a continuation of Ser. No.	
US	1989-295638, filed on 10 Jan 1989, now abandoned	
which	is a continuation-in-part of Ser. No. US	
1988-145407,	filed on 19 Jan 1988, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fonda, Kathleen K.	
LEGAL REPRESENTATIVE:	Paritich Schwarze Jacobs & Nadel, P.C	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1401	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides polyanionic, substituted CDs having cellular growth modulating activity. The invention further provides CDs having anionic groups on one side of the CD molecule. Therapeutic methods for using, as well as methods of making the CD compounds of the invention, are also disclosed herein.

L7 ANSWER 9 OF 65 USPATFULL (Continued)
 IT 53-05-4
 (prepn. of cyclodextrin conjugates with drugs to improve water
 soly.)
 RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI)
 (CA

INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 65 USPATFULL
 ACCESSION NUMBER: 1998:7175 USPATFULL
 TITLE: Oligosaccharide-containing 14-aminosteroid
 compounds
 and novel diastereoselective aminosteroid process
 chemistry
 Dybas, Paul Michael, Port Crane, NY, United States
 Johnson, Roland Norman, Norwich, NY, United States
 Muth, Randy Stuart, Poolville, NY, United States
 Liu, Song, Norwich, NY, United States
 The Procter & Gamble Company, Cincinnati, OH,
 States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5710259	19980120
APPLICATION INFO.:	US 1995-459911	19950602 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-406833,	filed on 20
Mar	1995, now abandoned which is a continuation of	
Ser. No.	US 1993-126459, filed on 24 Sep 1993, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Right, John	
ASSISTANT EXAMINER:	Lee, Howard C.	
LEGAL REPRESENTATIVE:	McMahon, Mary P.; Clark, Karen F.; Rasser, Jacobus C.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2072	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention relates to oligosaccharide-containing
 14-aminosteroid compounds and the pharmaceutically-acceptable acid
 salts
 or esters thereof of the general formula: ##STR1## wherein a)
 R.sub.1 is

(i) COOR.sub.5, where

alkyl R.sub.5 is hydrogen, a 1-6 carbon lower alkyl; a 1-6 carbon lower
 substituted by an amino group; an arylalkyl or heteroarylalkyl or a
 carbocyclic ring, or

(ii) CHR.sub.6 OH, where

R.sub.6 is a hydrogen atom or 1-6 carbon lower alkyl group, or

carbon (iii) COR'', where R'' is hydrogen; 1-6 carbon lower alkyl; 1-6
 lower alkyl substituted amino; amino or dialkylamino; and

L7 ANSWER 10 OF 65 USPATFULL (Continued)
 b) R.sub.2 is --NR.sub.7 R.sub.8, where
 R.sub.7 and R.sub.8, which may be the same or different, are
 hydrogen atoms or a 1-6 carbon lower alkyl; and
 c) R.sub.3 is an oligosaccharide sugar residue; and
 d) R.sub.4 is

(i) OH, or

(ii) H, or

(iii) OR.sub.13, where

arylalkyl R.sub.13 is a monosaccharide sugar residue; acetoxy; benzyloxy;
 or heteroarylalkyl; and

e) Z is

(i) --CH--, where

a and b are single bonds, or

(ii) .dbd.C, where

either a or b is a double bond.

The present invention also relates to a process for introducing an
 amino group at the 14-position on a steroid nucleus wherein said amino
 group is diastereoselectively introduced onto the 14-position of the
 steroid nucleus via an iodoisocyanate addition comprising the steps of:

a) adding the iodoisocyanate to the 14-15 position double bond on
 the steroid nucleus; and


b) dehalogenation; and

c) isocyanate conversion to the amine moiety on the 14-position of
 the steroid nucleus.

IT 26520-64-9P
 (prepn. of oligosaccharide-contg. 14-aminosteroid cardiovascular
 and inotropic agents and diastereoselective aminosteroid process chem.)
 RN 26520-64-9 USPATFULL
 CN Pregnane-20-one, 3-[(O-3,4-di-O-acetyl-2,6-dideoxy-.beta.-D-ribo-
 hexopyranosyl-(1.fvdarv.4)-O-3-O-acetyl-2,6-dideoxy-.beta.-D-ribo-
 hexopyranosyl-(1.fvdarv.4)-3-O-acetyl-2,6-dideoxy-.beta.-D-ribo-
 hexopyranosyl)oxy]-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)-
 (9CI)

L7 ANSWER 10 OF 65 USPATFULL (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 11 OF 65 USPATFULL
 ACCESSION NUMBER: 97:118036 USPATFULL
 TITLE: Angiostatic steroids and methods and compositions for
 controlling ocular hypertension
 INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
 Conrow, Raymond E., Fort Worth, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
 States
 (U.S. corporation)


NUMBER	DATE
US 5698545	19971216
US 1996-643387	19960506 (8)

PATENT INFORMATION:
 APPLICATION INFO.:
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-349342, filed on 2 Dec 1994, now abandoned which is a continuation of Ser. No. US 1992-941485, filed on 8 Sep 1992, now patented, Pat. No. US 5371078 which is a continuation-in-part of Ser. No. US 1990-559123, filed on 27 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-419226, filed on 10 Oct 1989, now abandoned which is a continuation of Ser. No. US 1988-264918, filed on 31 Oct 1988, now patented, Pat. No. US 4876250
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Prior, Kimberly J.
 LEGAL REPRESENTATIVE: Yeager, Sally
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 LINE COUNT: 695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed. In addition, the combination of the compounds with glucocorticoids for the prevention of elevated IOP during the treatment of inflammation is disclosed.
 IT 68-60-0, Tetrahydrocortexolone (glaucoma treatment with)
 RN 68-60-0 USPATFULL
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX

L7 ANSWER 11 OF 65 USPATFULL (Continued)
 NAME)

Absolute stereochemistry.



L7 ANSWER 12 OF 65 USPATFULL
 ACCESSION NUMBER: 97:99410 USPATFULL
 TITLE: Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
 INVENTOR(S): Ashton, Paul, Boston, MA, United States
 Smith, Thomas J., Weston, MA, United States
 Glavinov, Peter G., Doylestown, PA, United States
 Conklin, Jr., John D., Lexington, KY, United States
 Crooks, Peter A., Lexington, KY, United States
 Riggs, Robert M., Birmingham, AL, United States
 Cynkowski, Tadeusz, Lexington, KY, United States
 Cynkowska, Grazyna, Lexington, KY, United States
 PATENT ASSIGNEE(S): University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

NUMBER	DATE
US 5681964	19971028
US 1994-318160	19941005 (8)

PATENT INFORMATION:
 APPLICATION INFO.:
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-162388, filed on 7 Dec 1993, now abandoned which is a continuation of Ser. No. US 1993-16179, filed on 11 Feb 1993, now abandoned which is a continuation of Ser. No. US 1990-601644, filed on 23 Oct 1990, now abandoned


DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Killos, Paul J.
 LEGAL REPRESENTATIVE: Lowe, Price, LeBlanc & Becker
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
 LINE COUNT: 1180

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Prodrugs containing an active drug molecule linked to a polyethylene glycol group, and a method of use thereof are described. Exemplary soluble ester prodrugs contain naproxen, triamcinolone acetonide, gancyclovir, taxol, cyclosporin, dideoxyinosine, trihydroxy steroids, and flurbiprofen molecules linked to polyethylene glycol (PEG) groups. Pharmaceutical compositions containing these prodrugs, and a method of using these esters for treating disease states or symptoms are also described.

IT 68-60-0 (prepn. of permeable, non-irritating prodrugs of nonsteroidal and steroidal agents)
 RN 68-60-0 USPATFULL
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX

NAME)
 Absolute stereochemistry.


L7 ANSWER 12 OF 65 USPATFULL (Continued)




IT 198209-75-5P 198209-77-7P 198209-79-9P
 198209-81-3P 198209-83-5P 198209-85-7P
 (prepn. of permeable, non-irritating prodrugs of nonsteroidal and steroidal agents)
 RN 198209-75-5 USPATFULL
 CN Pregnan-20-one, 3,21-bis[(10,10-dimethyl-1-oxo-9,9-diphenyl-2,5,8-trioxa-9-silaundec-1-yl)oxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX

NAME)
 Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 198209-77-7 USPATFULL
 CN Pregnan-20-one, 3-[(10,10-dimethyl-1-oxo-9,9-diphenyl-2,5,8-trioxa-9-silaundec-1-yl)oxy]-17,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 12 OF 65 USPATFULL (Continued)


Absolute stereochemistry.



RN 198209-79-9 USPATFULL

CN Pregnan-20-one, 21-[(10,10-dimethyl-1-oxo-9,9-diphenyl-2,5,8-trioxo-9-silaundec-1-yl)oxy]-3,17-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198209-81-3 USPATFULL


CN Pregnan-20-one, 3,21-bis[(16,16-dimethyl-1-oxo-15,15-diphenyl-2,5,8,11,14-pentaoxa-15-silaheptadec-1-yl)oxy]-17-hydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



RN 198209-85-7 USPATFULL


CN Pregnan-20-one, 21-[(16,16-dimethyl-1-oxo-15,15-diphenyl-2,5,8,11,14-pentaoxa-15-silaheptadec-1-yl)oxy]-3,17-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 12 OF 65 USPATFULL (Continued)


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 198209-83-5 USPATFULL

CN Pregnan-20-one, 3-[(16,16-dimethyl-1-oxo-15,15-diphenyl-2,5,8,11,14-pentaoxa-15-silaheptadec-1-yl)oxy]-17,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A



PAGE 1-B



IT 198209-87-9P 198209-89-1P 198209-91-5P


198209-93-7P 198209-95-9P 198209-97-1P
(prepn. of permeable, non-irritating prodrugs of nonsteroidal and steroidal agents)

RN 198209-87-9 USPATFULL

CN Pregnan-20-one, 17-hydroxy-3,21-bis[[[2-(2-hydroxyethoxy)ethoxy]carbonyl]oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 12 OF 65 USPATFULL (Continued)


PAGE 1-B



RN 198209-89-1 USPATFULL

CN Pregnan-20-one,
17,21-dihydroxy-3-[[[2-(2-hydroxyethoxy)ethoxy]carbonyl]oxy]-
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 198209-91-5 USPATFULL

CN Pregnan-20-one,
3,17-hydroxy-21-[[[2-(2-hydroxyethoxy)ethoxy]carbonyl]oxy]-
(3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 12 OF 65 USPATFULL (Continued)


CN Pregnan-20-one, 17,21-dihydroxy-3-[(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-1-yl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 198209-97-1 USPATFULL

CN Pregnan-20-one,
3,17-hydroxy-21-[(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-1-yl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 12 OF 65 USPATFULL (Continued)

RN 198209-93-7 USPATFULL


CN Pregnan-20-one, 17-hydroxy-3,21-bis[(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-1-yl)oxy]-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C



RN 198209-95-9 USPATFULL

L7 ANSWER 12 OF 65 USPATFULL (Continued)

PAGE 1-A




PAGE 1-B



L7 ANSWER 13 OF 65 USPATFULL
 ACCESSION NUMBER: 97:96861 USPATFULL
 TITLE: Prevention and treatment of ocular neovascularization
 INVENTOR(S): by treatment with angiostatic steroids
 Clark, Abbot F., Arlington, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
 States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5679666	19971021
APPLICATION INFO.:	US 1994-342524	19941121 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-796169, filed on 22 Nov 1991, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fay, Zohreh	
LEGAL REPRESENTATIVE:	Yeager, Sally	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	348	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.		
IT 68-60-0, Tetrahydrocortaxolone (glaucoma treatment with)		
RN 68-60-0 USPATFULL		
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)		

Absolute stereochemistry.




L7 ANSWER 13 OF 65 USPATFULL (Continued)

L7 ANSWER 14 OF 65 USPATFULL
 ACCESSION NUMBER: 97:41865 USPATFULL
 TITLE: Method, compositions, and compounds for modulating brain excitability
 INVENTOR(S): Gee, Kelvin W., Irvine, CA, United States
 Bolger, Michael B., Los Alamitos, CA, United States
 Lan, Nancy C., South Pasadena, CA, United States
 PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 35517	19970520
APPLICATION INFO.:	US 5120723	19920609 (Original)
	US 1992-980377	19921123 (7)
	US 1990-521724	19900510 (Original)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned	
DOCUMENT TYPE:	Reissue	
PRIMARY EXAMINER:	Tsang, Cecilia	
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1072	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionpore (GBR) complex.		
IT 567-02-2 (anticonvulsant and anxiolytic)		
RN 567-02-2 USPATFULL		
CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)		

Absolute stereochemistry.

L7 ANSWER 14 OF 65 USPATFULL (Continued)



L7 ANSWER 15 OF 65 USPATFULL
 ACCESSION NUMBER: 97:3830 USPATFULL
 TITLE: Substituted 2.beta.-morpholino-androstane derivatives
 INVENTOR(S): Campbell, Alexander C., Falkirk, Scotland
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Arnhem, Netherlands (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5593983	19970114
APPLICATION INFO.:	US 1994-347974	19941201 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1993-309663	19931202
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Grumbling, Matthew V.	
LEGAL REPRESENTATIVE:	Gornley, Mary E.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1.2	
LINE COUNT:	1442	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is related to substituted

2.beta.-morpholino-androstane derivatives, bonded at their 2.beta.-position to the nitrogen of a group

of formula I ##STR1## wherein R represents one to four substituents, each one independently selected from (1-4C) alkyl, phenyl and benzyl, or two at the same carbon atom being together --(CH.sub.2).sub.n -- wherein

n is 2-6; and Y is O or S, or a pharmaceutically acceptable salt thereof. These steroids are very potent intravenous anaesthetics.


The compounds have fast onset times and ideal 'sleep duration' vs. 'recovery to full coordination' profiles.

IT 167947-21-9P
 (prepn. of 2.beta.-morpholinoandrostanes as anesthetics)

RN 167947-21-9 USPATFULL
 CN Pregnane-20-one, 2-(2,2-dimethyl-4-morpholinyl)-3,21-dihydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L7 ANSWER 15 OF 65 USPATFULL (Continued)



IT 167946-99-8P 167947-00-4P 167947-17-3P
 167947-23-1P 167947-78-6P 167947-79-7P
 (prepn. of 2.beta.-morpholinoandrostanes as anesthetics)
 RN 167946-99-8 USPATFULL
 CN Pregnane-11,20-dione,
 21-(acetylthio)-2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 167947-00-4 USPATFULL
 CN Pregnane-11,20-dione, 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L7 ANSWER 15 OF 65 USPATFULL (Continued)




RN 167947-17-3 USPATFULL
 CN Pregnane-11,20-dione, 2-(2,2-dimethyl-4-morpholinyl)-3,21-dihydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167947-23-1 USPATFULL
 CN Pregnane-20-one,
 21-(acetylthio)-2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



L7 ANSWER 15 OF 65 USPATFULL (Continued)


RN 167947-78-6 USPATFULL
 CN Pregnane-20-one,
 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-21-thiocyanato-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 167947-79-7 USPATFULL
 CN Pregnane-11,20-dione, 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-21-thiocyanato-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



IT 167947-07-1P 167947-08-2P 167947-22-0P
 (prepn. of 2.beta.-morpholinoandrostanes as anesthetics)
 RN 167947-07-1 USPATFULL
 CN Pregnane-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L7 ANSWER 15 OF 65 USPATFULL (Continued)



RN 167947-08-2 USPATFULL
 CN Pregnan-11,20-dione,
 21-(acetyloxy)-3-[(4-methylphenyl)sulfonyloxy]-,
 (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 167947-22-0 USPATFULL
 CN Pregnan-20-one, 2-(2,2-dimethyl-4-morpholinyl)-3-hydroxy-21-
 [(methylsulfonyl)oxy]-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 15 OF 65 USPATFULL (Continued)




L7 ANSWER 16 OF 65 USPATFULL

ACCESSION NUMBER: 97:1455 USPATFULL
 TITLE: Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
 INVENTOR(S): Bolger, Michael B., Los Alamitos, CA, United States
 Gee, Kelvin W., Irvine, CA, United States
 Lan, Nancy C., South Pasadena, CA, United States
 Purdy, Robert H., La Jolla, CA, United States
 Mirsadeghi, Seid, Rolling Hills, CA, United States
 Tahir, Syed Hasan, Edmonton, Canada
 Belelli, Delia, Kingsbarns by St. Andrews, Scotland
 PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5591733	19970107
APPLICATION INFO.:	US 1993-101497	19930802 (8)
DISCLAIMER DATE:	20100803	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-745216, filed on 13 Aug 1991, now patented, Pat. No. US 5232917 which is a continuation-in-part of Ser. No. US 1990-521724, filed on 10 May 1990, now patented, Pat. No. US 5120723 which is a continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Tsang, Cecilia	
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox P.L.L.C.	
NUMBER OF CLAIMS:	129	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5060	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.	
IT	567-02-2 (anticonvulsant and anxiolytic)	
RN	567-02-2 USPATFULL	
CN	Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.

L7 ANSWER 16 OF 65 USPATFULL (Continued)



L7 ANSWER 17 OF 65 USPATFULL
 ACCESSION NUMBER: 96:77773 USPATFULL
 TITLE: Regulating neuropeptide hormone secretion
 INVENTOR(S): Jackson, Meyer B., 3568 Tallyho La., Madison, WI,
 United States 53705

NUMBER	DATE
US 5550120	19960827
US 1995-415741	19950403 (8)

PATENT INFORMATION: US 5550120 19960827
 APPLICATION INFO.: US 1995-415741 19950403 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-109683, filed on
 20 Aug 1993, now abandoned

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Naff, David M.
 ASSISTANT EXAMINER: Lankford, L. Blaine
 LEGAL REPRESENTATIVE: Gulbrandsen, Carl E. Stroud, Stroud, Willink,
 Thompson & Howard


NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 10 Drawing Figure(s); 4 Drawing Page(s)
 LINE COUNT: 565
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are described for regulating neuropeptide secretion to
 alleviate premature labor, hypertension, fluid imbalance, and risk of heart
 disease: using neuroactive steroids targeted for a newly-identified
 site of action in the nerve terminals of neurosecretory neurons. The
 steroids 17 betaestradiol and dehydroepiandrosterone increase the release of
 neuropeptide hormones such as oxytocin and vasopressin. Pregnenolone
 derivatives decrease the release of the same hormones.

IT 14107-37-0, 3.alpha.,21-dihydroxy-5.alpha.-pregnane-11,20-dione
 (pharmacol. of vasopressin and oxytocin secretion-inhibiting
 steroids)
 RN 14107-37-0 USPATFULL
 CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 17 OF 65 USPATFULL (Continued)



L7 ANSWER 18 OF 65 USPATFULL
 ACCESSION NUMBER: 96:43650 USPATFULL
 TITLE: Method for treating Kaposi's sarcoma and blocking
 or inhibiting vascular permeability
 INVENTOR(S): Nakamura, Shuji, Pasadena, CA, United States
 Gallo, Robert C., Bethesda, MD, United States
 Osada, Yasuaki, Tokyo, Japan
 Sakurada, Shinsaku, Tokyo, Japan
 Tanaka, Noriko G., Tokyo, Japan
 Salahuddin, Syed Z., Pasadena, CA, United States
 PATENT ASSIGNEE(S): The United States of America as represented by the
 Secretary of the Department of Health and Human
 Services, Washington, DC, United States (U.S.
 government)
 Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan
 (non-U.S. corporation)

NUMBER	DATE
US 5518999	19960521
US 1994-336612	19941109 (8)

PATENT INFORMATION: US 5518999 19960521
 APPLICATION INFO.: US 1994-336612 19941109 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1991-810420, filed on
 20 Dec 1991, now abandoned


DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Schain, Howard E.
 LEGAL REPRESENTATIVE: Townsend and Townsend and Crew
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 22 Drawing Figure(s); 19 Drawing Page(s)
 LINE COUNT: 759
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a method for arresting or
 inhibiting the growth of cells in Kaposi's Sarcoma lesions and a
 method for arresting or inhibiting the growth of the Kaposi's Sarcoma
 lesions, said methods comprising contacting the cells in the lesions with an
 effective amount of SP-PG, a naturally occurring sulfated
 polysaccharide-peptidoglycan produced by a specific species of the
 bacterium Arthrobacter, AT-25. The invention is also directed to
 blocking or inhibiting the activity of cellular vascular
 permeability factor(s), which comprises contacting vascular cells with an
 effective amount of SP-PG. In one embodiment, there is provided a method for
 blocking or inhibiting increased vascular permeability (and
 resulting edema) in diseases and disorders in which the increased vascular
 permeability contributes to the pathology, for example, in Kaposi's
 Sarcoma, tumorigenesis, inflammation, diabetic retinopathy, etc.
 Increased effectiveness is obtained when SP-PG is combined with
 cortisone or a cortisone derivative, such as hydrocortisone or
 tetrahydrocortisone.

IT 53-05-4, Tetrahydrocortisone
 (cellular vascular permeability factor in vascular cells inhibition

L7 ANSWER 18 OF 65 USPATFULL (Continued)
 with) with sulfated polysaccharide-peptidoglycan SP-PG in combination
 RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 65 USPATFULL
 ACCESSION NUMBER: 95:110215 USPATFULL
 TITLE: Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
 PATENT ASSIGNEE(S): UT SV Medical CTR at Dallas, Dallas, TX, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5474765	19951212
APPLICATION INFO.:	US 1992-856018	19920323 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kishore, Gollamudi	
ASSISTANT EXAMINER:	Kulkosky, Peter F.	
LEGAL REPRESENTATIVE:	Arnold, White & Durkee	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	2175	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention discloses new targeted conjugates for the delivery of a

compound, and particularly, a steroid, to vascular endothelial cells.

The conjugates comprise two components, preferably linked by a selectively-hydrolyzable bond, such as an acid-labile bond or enzyme-sensitive bond. The first component, a polyanionic polymer,

and preferably, a polysulphated polymer such as a heparin-derivative, specifically directs the conjugate to vascular endothelial cells.

The second component is a selected agent, such as a steroid, which

exerts a specific effect on the target cell following its release. In

particular, the present invention provides novel conjugated angiogenesis

inhibitors, for use in the treatment of pathogenic conditions including cancer, arthritis, and diabetic blindness. An inhibitor comprising a heparin derivative and the anti-angiogenic steroid, cortisol, is herein


shown to be markedly acid-labile, to suppress DNA synthesis and cell

migration in human umbilical vein endothelial cells, to retard or abolish

(depending on the route of injection) the vascularization of sponges in vivo


and to retard lung tumor growth in mice by 65%. No adverse effects of the conjugate were detected, and equivalent treatments with a mixture of heparin plus cortisol were significantly less effective in all cases.

L7 ANSWER 19 OF 65 USPATFULL (Continued)




L7 ANSWER 19 OF 65 USPATFULL (Continued)
 IT 53-02-1D, Tetrahydrocortisol, conjugates with anionic polymers
 53-05-4D, Tetrahydrocortisone, conjugates with anionic polymers
 68-42-8D, Tetrahydrocorticosterone, conjugates with anionic polymers
 (for targeting to vascular endothelium)
 RN 53-02-1 USPATFULL
 CN Pregnane-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 68-42-8 USPATFULL
 CN Pregnane-20-one, 3,11,21-trihydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 20 OF 65 USPATFULL
 ACCESSION NUMBER: 95:71350 USPATFULL
 TITLE: Methods and compositions for providing analgesia and enhanced anesthesia
 INVENTOR(S): Bukusoglu, Cuneyt, 125 Old Mill Rd., Shrewsbury, MA,
 United States 01545
 Thalhammer, Johann G., 398 Central St., Framingham, MA,
 United States 01701
 Krieger, Neil R., 23 Lila Rd., Jamaica Plain, MA, United States 02130

	NUMBER	DATE
PATENT INFORMATION:	US 5439900	19950808
APPLICATION INFO.:	US 1993-23793	19930225 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Dees, Jose G.	
ASSISTANT EXAMINER:	Conrad, III, Joseph M.	
LEGAL REPRESENTATIVE:	Bromberg & Sunstein	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	697	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel method for preparing a subject for surgery by administering to

said subject a composition which contains at least one steroid, an alcohol and a vehicle which is distinct from said alcohol. It has

been discovered that there is a synergistic effect between the steroid


and the alcohol which increases the anesthetic effect and the analgesic effect and shortens recovery times.

IT 567-03-3 800-10-2 (steroid and alc. combinations for providing analgesia and enhanced anesthesia for surgery)

RN 567-03-3 USPATFULL
 CN Pregnane-20-one, 3,21-dihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 20 OF 65 USPATFULL (Continued)



RN 800-10-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-, (3.beta.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 21 OF 65 USPATFULL


ACCESSION NUMBER: 95:64955 USPATFULL
TITLE: Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
INVENTOR(S): Collins, Delwood C., Lexington, KY, United States
Gagliardi, Antonio, Lexington, KY, United States
Bhattacharyya, Anjan, Lexington, KY, United States
PATENT ASSIGNEE(S): The University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

NUMBER	DATE
US 5434185	19950718
US 1993-61477	19930517 (8)

PATENT INFORMATION: US 5434185 19950718
APPLICATION INFO.: US 1993-61477 19930517 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Weddington, K.
LEGAL REPRESENTATIVE: Lowe, Price, LeBlanc & Becker
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 776

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aurintricarboxylic acid has potent anti-angiogenic activity and may be used for new therapeutic approaches for diseases of neovascularization including the treatment of solid tumors, diabetic retinopathy and arthritis, among others.
IT 53-02-1, Tetrahydrocortisol 68-60-0, Tetrahydrocortexolone (aurintricarboxylic acid and analogs with anti-angiogenic activity)
RN 53-02-1 USPATFULL
CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-60-0 USPATFULL

L7 ANSWER 21 OF 65 USPATFULL (Continued)
CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 22 OF 65 USPATFULL

ACCESSION NUMBER: 95:43238 USPATFULL
TITLE: 21-chloro-pregnane derivative
INVENTOR(S): Campbell, Alexander C., Falkirk, Scotland
PATENT ASSIGNEE(S): Akzo N.V., Arnhem, Netherlands (non-U.S. corporation)


NUMBER	DATE
US 5416079	19950516
US 1993-96327	19930722 (8)

NUMBER	DATE
EP 1992-306697	19920722

PATENT INFORMATION: EP 1992-306697 19920722
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rizzo, Nicholas
LEGAL REPRESENTATIVE: Blackstone, William M.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 3
LINE COUNT: 158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is related to a 21-chloro-pregnane derivative of the formula ##STR1## or pharmaceutically acceptable salts thereof. The compound has intravenous anaesthetic activity, short onset time and high potency.
IT 156685-97-1P (prepn. and hydrolysis of, in prepn. of anesthetic)

RN 156685-97-1 USPATFULL
CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



IT 156685-98-2P 156685-99-3P (prepn. of, as anesthetic intermediate)
RN 156685-98-2 USPATFULL
CN Pregnan-20-one, 3,21-dihydroxy-2-(4-morpholinyl)-, (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L7 ANSWER 22 OF 65 USPATFULL (Continued)




RN 156685-99-3 USPATFULL
 CN Pregnan-20-one, 3-hydroxy-21-[(methylsulfonyl)oxy]-2-(4-morpholinyl)-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 23 OF 65 USPATFULL (Continued)
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 23 OF 65 USPATFULL
 ACCESSION NUMBER: 95:34174 USPATFULL
 TITLE: Ophthalmic composition
 INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Ft. Worth, TX, United States
 States
 (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION:	US 5407926 19950418
APPLICATION INFO.:	US 1992-966118 19921023 (7)
DISCLAIMER DATE:	20070731
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1990-555692, filed on 23 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-399351, filed on 28 Aug 1989, now patented, Pat. No. US 4945089 which is a continuation of Ser. No. US 1987-139222, filed on 29 Dec 1987, now abandoned And Ser. No. US 1989-419226, filed on 10 Oct 1989, now abandoned which is a continuation of Ser. No. US 1988-264918, filed on 31 Oct 1988, now patented, Pat. No. US 4876250
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Fay, Zohreh
LEGAL REPRESENTATIVE:	Cheng, Julie J. L.; Brown, Gregg C.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIMS:	1
LINE COUNT:	477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and an angiostatic steroid. The angiostatic steroid substantially prevents any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent anti-inflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure.
 IT 68-60-0, Tetrahydrocortexolone
 (glaucoma treatment with)
 RN 68-60-0 USPATFULL


L7 ANSWER 24 OF 65 USPATFULL
 ACCESSION NUMBER: 95:34082 USPATFULL
 TITLE: Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
 INVENTOR(S): Dubler, Robert E., Gurnee, IL, United States
 Frintner, Mary P., Elk Grove, IL, United States
 Grote, Jonathan, Grayslake, IL, United States
 Hadley, Gregg A., St. Louis, MO, United States
 Hawkins, David J., Vernon Hills, IL, United States
 Hopkins, Hal D., Chicago, IL, United States
 Nam, Daniel S., Lake Elsinore, CA, United States
 Ungemach, Frank S., Lake Villa, IL, United States
 Wray, Larry K., Highland Park, IL, United States
 Abbott Laboratories, Abbott Park, IL, United States
 States
 (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION:	US 5407834 19950418
APPLICATION INFO.:	US 1992-831762 19920427 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-529988, filed on 29 May 1990, now patented, Pat. No. US 5155212 which is a continuation-in-part of Ser. No. US 1986-866193, filed on 21 May 1986, now abandoned
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Kim, Kay K. A.
LEGAL REPRESENTATIVE:	Pope, Lawrence S.
NUMBER OF CLAIMS:	12
EXEMPLARY CLAIMS:	1
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT:	1662

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.
 IT 53-05-4, Tetrahydrocortisone
 (phencyclidine fluorescence polarization immunoassay crossreactivity to)
 RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI)
 (CA

L7 ANSWER 24 OF 65 USPATFULL (Continued)
INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 25 OF 65 USPATFULL
ACCESSION NUMBER: 95:15936 USPATFULL
TITLE: Process for the production of
4-pregnene-3,20-dione and
its derivatives using mycobacterium NRRL B-3805
INVENTOR(S): Weber, Alfred, Berlin, Germany, Federal Republic of
Kennecke, Mario, Berlin, Germany, Federal Republic
of
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin, Germany,
Federal
Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5391484	19950221
	WO 9203571	19920305
APPLICATION INFO.:	US 1992-861807	19920618 (7)
	WO 1991-DE620	19910730
		19920618 PCT 371 date
		19920618 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1990-4026464	19900818
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Naff, David M.	
ASSISTANT EXAMINER:	Lankford, L. Blaine	
LEGAL REPRESENTATIVE:	Millen, White, Zelano & Branigan	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	207	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the production of 4-pregnene-3,20-dione and its derivatives of general formula I ##STR1## in which R.sub.1 means a hydrogen atom, a fluorine atom or a methyl group,

R.sub.2 represents a hydrogen atom or a hydroxy group, and

R.sub.3 and R.sub.4 together symbolize a carbon-carbon bond or

R.sub.3 represents a hydrogen atom, a hydroxy group or an alkanoyloxy group with up to 6 carbon atoms and

R.sub.4 means a hydrogen atom or a methyl group, is described, which is characterized in that a pregnane derivative of general formula II ##STR2## in which R.sub.1, R.sub.3 and R.sub.4 have the above-mentioned meaning, symbolizes a single bond or a double bond,

R.sub.5 represents a hydrogen atom, a hydroxy group or an alkanoyloxy

L7 ANSWER 25 OF 65 USPATFULL (Continued)
group with at most 6 carbon atoms and

R.sub.6 means a hydrogen atom or an alkanoyl group with at most 6 carbon atoms, is fermented with a bacterial culture of species Mycobacterium spec. NRRL B-3805.


IT 10147-45-2 (pregnenediones manuf. from, with Mycobacterium)

RN 10147-45-2 USPATFULL

CN Pregnan-20-one, 21-(acetyloxy)-3-hydroxy-, (3.beta.,5.beta.)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 26 OF 65 USPATFULL
ACCESSION NUMBER: 94:106777 USPATFULL
TITLE: Angiostatic steroids and methods and compositions for
controlling ocular hypertension
INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
Conrow, Raymond E., Fort Worth, TX, United States
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United
States
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5371078	19941206
APPLICATION INFO.:	US 1992-941485	19920908 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-559123, filed on 27 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-419226, filed on 10 Oct 1989, now abandoned which is a continuation of Ser. No. US 1988-264918, filed on 31 Oct 1988, now patented, Pat. No. US 4876250	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Kestler, Kimberly J.
LEGAL REPRESENTATIVE: Yeager, Sally
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1

LINE COUNT: 744
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids

and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open

angle glaucoma, are disclosed. In addition, the combination of the

compounds with glucocorticoids for the prevention of elevated IOP during the treatment of inflammation is disclosed.

IT 53-02-1, Tetrahydrocortisol


(prepn. of angiostatic steroids for controlling ocular hypertension)

RN 53-02-1 USPATFULL

CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 65 USPATFULL (Continued)




IT 149916-71-2P 150213-49-3P

(prepn. of angiostatic steroids for controlling ocular hypertension)

RN 149916-71-2 USPATFULL

CN Pregnan-20-one, 21-[[[(1,1-dimethylethyl)diphenylsilyloxy]-3,11,17-trihydroxy-, (3.alpha.,5.beta.,11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 150213-49-3 USPATFULL

CN Pregnan-20-one,

21-[[[(1,1-dimethylethyl)diphenylsilyloxy]-11,17-dihydroxy-3-(1H-imidazol-1-ylthiomethoxy)-, (3.alpha.,5.beta.,11.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 26 OF 65 USPATFULL (Continued)



L7 ANSWER 27 OF 65 USPATFULL

ACCESSION NUMBER: 94:102232 USPATFULL

TITLE: Modulation of receptor-mediated ion transport

INVENTOR(S): Farb, David H., Cambridge, MA, United States

PATENT ASSIGNEE(S): Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5366968	19941122
APPLICATION INFO.:	US 1991-7068	19930121 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-758129, filed on 12 Sep 1991, now patented, Pat. No. US 5212167	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Cantins, Marianne M.
 ASSISTANT EXAMINER: Jordan, Kimberly R.
 LEGAL REPRESENTATIVE: Hamilton, Brook, Smith & Reynolds
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 379
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The subject application discloses methods for modulating
 NMDA-mediated ion transport, and inhibiting non-NMDA glutamate-induced ion transport, in neuronal cells. The methods involve contacting a neuronal cell with an effective amount of the neurosteroid pregnenolone sulfate, or pharmacologically effective derivatives thereof.

IT 148000-91-3
 (for central nervous system disorder treatment, methylaspartate receptor in relation to)

RN 148000-91-3 USPATFULL

CN Pregnane-11,20-dione, 3,21-dihydroxy-, mono(hydrogen sulfate), (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

CM 1


CRN 14107-37-0

CMF C21 H32 O4

CODES 4:3A,5A.PREGN

Absolute stereochemistry.

L7 ANSWER 27 OF 65 USPATFULL (Continued)



CM 2

CRN 7664-93-9

CMF H2 O4 S




L7 ANSWER 28 OF 65 USPATFULL
 ACCESSION NUMBER: 94:93322 USPATFULL
 TITLE: Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
 INVENTOR(S): Clark, Abbot F., 5708 Stage Line Dr., Arlington, TX,
 United States 76017
 Southren, Aaron L., 107 Grandview Ave., Monsey, NY,
 United States 10952

NUMBER	DATE
US 5358943	19941025
US 1993-12181	19930202 (8)
Continuation of Ser. No. US 1989-399349, filed on 28 Aug 1989, now abandoned which is a continuation of Ser. No. US 1987-139227, filed on 29 Dec 1987, now abandoned	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Fay, Zohreh
 LEGAL REPRESENTATIVE: Arno, James A.; Brown, Gregg C.
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 LINE COUNT: 341
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortisol to a patient receiving such therapy.
 IT 53-02-1D, Tetrahydrocortisol, mixts. with glucocorticoids (tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids, and ophthalmic pharmaceuticals contg. combination of tetrahydrocortisol with corticosteroid)
 RN 53-02-1 USPATFULL

L7 ANSWER 28 OF 65 USPATFULL (Continued)
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)-(9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L7 ANSWER 29 OF 65 USPATFULL
 ACCESSION NUMBER: 94:49295 USPATFULL
 TITLE: Method for making 3.alpha.-hydroxy, 3.beta.-substituted-pregnanes
 INVENTOR(S): Tahir, Hasan, Pasadena, CA, United States
 Bolger, Michael, Los Alamitos, CA, United States
 Buswell, Richard, Santa Rosa, CA, United States
 Gabriel, Richard, Woburn, MA, United States
 Stearns, Jay, Santa Rosa, CA, United States
 Cocanays Inc., Irvine, CA, United States (U.S. corporation)
 PATENT ASSIGNEE(S):

NUMBER	DATE
US 5319115	19940607
US 1992-846193	19920304 (7)
Continuation-in-part of Ser. No. US 1991-745216, filed on 13 Aug 1991, now patented, Pat. No. US 5232917	
which is a continuation-in-part of Ser. No. US 1990-521724, filed on 10 May 1990, now patented, Pat. No. US 5120723	
which is a continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned	
which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now abandoned	

 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Tsang, Cecilia
 LEGAL REPRESENTATIVE: Lyon & Lyon
 NUMBER OF CLAIMS: 16
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 349
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3.alpha.-hydroxy, 3.beta.-substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereoselectively into a 3(R)-pregnan-3-spiro-2' oxirane-20-one intermediate. This intermediate can then be converted regioselectively by a second set of reactions to the 3.alpha.-hydroxy, 3.beta.-substituted-20-one form, which can be further modified at the 20-keto position.
 Through this method, each ketone group is independently treated. By modifying the ketones one at a time, one can obtain the desired stereo-specificity at each site.
 IT 567-02-2 (anticonvulsant and anxiolytic)
 RN 567-02-2 USPATFULL
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX

L7 ANSWER 29 OF 65 USPATFULL (Continued)
 NAME)
 Absolute stereochemistry.




L7 ANSWER 30 OF 65 USPATFULL
 ACCESSION NUMBER: 93:61162 USPATFULL
 TITLE: Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
 INVENTOR(S): Bolger, Michael, Los Alamitos, CA, United States
 Gee, Kelvin V., Hacienda Heights, CA, United States
 Lan, Nancy C., S. Pasadena, CA, United States
 Belelli, Delia, Rowland Heights, CA, United States
 Micsadeghi, Seid, Sherman Oaks, CA, United States
 Purdy, Robert, San Antonio, TX, United States
 PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

NUMBER	DATE
US 5232917	19930803
US 1991-745216	19910813 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1990-521724, filed on 10 May 1990, now patented, Pat. No. US 5120723 which is a continuation-in-part of Ser. No. US 1989-379047, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, on 25 Aug 1987, now abandoned

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Tsang, Cecilia
 LEGAL REPRESENTATIVE: Lyon & Lyon
 NUMBER OF CLAIMS: 119
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 17 Drawing Figure(s); 14 Drawing Page(s)
 LINE COUNT: 3795
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.
 IT 567-02-2 (anticonvulsant and anxiolytic)
 RN 567-02-2 USPATFULL
 CN Pregnane-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 30 OF 65 USPATFULL (Continued)




L7 ANSWER 31 OF 65 USPATFULL
 ACCESSION NUMBER: 93:50500 USPATFULL
 TITLE: Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
 INVENTOR(S): Ungemach, Frank S., Lake Villa, IL, United States
 Nam, Daniel S., Chicago, IL, United States
 PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

NUMBER	DATE
US 5221629	19930622
US 1990-537669	19900614 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1986-066193, filed on 21 May 1986, now abandoned

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Cooperley, Mary E.
 LEGAL REPRESENTATIVE: Breininger, Thomas M.
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 28 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 899
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.
 IT 53-05-4, Tetrahydrocortisone (phencyclidine fluorescence polarization immunoassay crossreactivity to)
 RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 31 OF 65 USPATFULL (Continued)



L7 ANSWER 32 OF 65 USPATFULL
 ACCESSION NUMBER: 93:39991 USPATFULL
 TITLE: Modulation of receptor-mediated ion transport
 INVENTOR(S): Farb, David H., Cambridge, MA, United States
 PATENT ASSIGNEE(S): Trustees of Boston University, Boston, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5212167	19930518
APPLICATION INFO.:	US 1991-758129	19910912 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Waddell, Frederick E.	
ASSISTANT EXAMINER:	Jordan, Kimberly	
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	438	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The subject application discloses methods for modulating NMDA-mediated ion transport, and inhibiting non-NMDA glutamate-induced ion transport, in neuronal cells. The methods involve contacting a neuronal cell with an effective amount of the neurosteroid pregnenolone sulfate, or pharmacologically effective derivatives thereof.


IT 148000-91-3 (for central nervous system disorder treatment, methylaspartate receptor in relation to)
 RN 148000-91-3 USPATFULL
 CN Pregnane-11,20-dione, 3,21-dihydroxy-, mono(hydrogen sulfate), (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

CM 1

CRN 14107-37-0
 CMF C21 H32 O4
 CDES 4:3A,5A.PREGN

Absolute stereochemistry.

L7 ANSWER 32 OF 65 USPATFULL (Continued)



CM 2

CRN 7664-93-9
 CMF H2 O4 S



L7 ANSWER 33 OF 65 USPATFULL
 ACCESSION NUMBER: 93:39986 USPATFULL
 TITLE: Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
 INVENTOR(S): Hissel, Paul J. T., Arlington, TX, United States
 Lang, John C., Arlington, TX, United States
 Jani, Rajni, Fort Worth, TX, United States
 Alcon Laboratories, Inc., United States (U.S. corporation)
 PATENT ASSIGNEE(S):


	NUMBER	DATE
PATENT INFORMATION:	US 5212162	19930518
APPLICATION INFO.:	US 1992-857673	19920325 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-676146, filed on 27 Mar 1991, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Wityshyn, Michael G.	
ASSISTANT EXAMINER:	Leary, Louise N.	
LEGAL REPRESENTATIVE:	Cheng, Julie J. L.; Yeager, Sally S.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	463	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Ophthalmic compositions comprising combinations of gelling polysaccharides and finely-divided drug carrier substrates which become relatively more viscous on contact with the eye are disclosed. These ophthalmic compositions are both comfortable and long-lasting
 Ophthalmic compositions further comprising a pharmaceutically active drug are also disclosed, as are methods of use.

IT 53-02-1, Tetrahydrocortisol (ophthalmic formulation of, controlled-release)
 RN 53-02-1 USPATFULL
 CN Pregnane-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 33 OF 65 USPATFULL (Continued)



L7 ANSWER 34 OF 65 USPATFULL
 ACCESSION NUMBER: 93:35677 USPATFULL
 TITLE: Method, compositions, and compounds for modulating brain excitability
 INVENTOR(S): Gee, Kelvin W., Hacienda Heights, CA, United States
 Bolger, Michael B., Los Alamitos, CA, United States
 Brinton, Roberta E., New York, NY, United States
 Burke, Deborah J., Hacienda Heights, CA, United States
 States
 McEwen, Bruce S., Englewood, NJ, United States
 PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5208227	19930504
APPLICATION INFO.:	US 1991-655275	19910213 (7)
DISCLAIMER DATE:	20090609	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-379047, filed on 13	


Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362, filed on 25 Aug 1987, now

abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Tsang, Cecilia
 LEGAL REPRESENTATIVE: Lyon & Lyon
 NUMBER OF CLAIMS: 12
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 966
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionophore (GBR) complex.

IT 567-02-2 (anticonvulsant and anxiolytic)
 RN 567-02-2 USPATFULL
 CN Pregnan-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 34 OF 65 USPATFULL (Continued)



L7 ANSWER 35 OF 65 USPATFULL
 ACCESSION NUMBER: 93:6166 USPATFULL
 TITLE: Device for assembling superposed, glued web-like layers
 INVENTOR(S): Schoch, Gregor, Morges, Switzerland
 PATENT ASSIGNEE(S): Bobst SA, Switzerland (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5181330	19930126
APPLICATION INFO.:	US 1991-790592	19911108 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1990-3617	19901114


DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Bennet, Henry A.
 ASSISTANT EXAMINER: Gromada, Denise L. F.
 LEGAL REPRESENTATIVE: Hill, Steadman & Simpson
 NUMBER OF CLAIMS: 9
 EXEMPLARY CLAIM: 6
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 470
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A device, which assembles web-like workpieces consisting of superimposed glued layers to form a web of corrugated board material, includes three sections with a first section having a single heating plate and an upper blowing case, a second section including upper and lower transverse nozzles, as well as upper and lower suction chambers and a third section including the extension of the upper and lower suction chambers. The device includes a conveying arrangement which has an upper continuous mesh belt passing through the first, second and third sections, and a lower belt passing only through the second and third sections.

IT 53-05-4 (prepn. of cyclodextrin conjugates with drugs to improve water soly.)
 RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, -3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 35 OF 65 USPATFULL (Continued)




L7 ANSWER 36 OF 65 USPATFULL
 ACCESSION NUMBER: 92:84969 USPATFULL
 TITLE: Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
 INVENTOR(S): Dubler, Robert E., Gurnee, IL, United States
 Frintner, Mary P., Elk Grove, IL, United States
 Grote, Jonathan, Grayslake, IL, United States
 Hadley, Gregg A., St. Louis, MO, United States
 Hawksworth, David J., Vernon Hills, IL, United States
 States
 Hopkins, Hal D., Chicago, IL, United States
 Nam, Daniel S., Lake Elsinore, CA, United States
 Ungemach, Frank S., Lake Villa, IL, United States
 Wray, Larry K., Highland Park, IL, United States
 PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5155212	19921013
APPLICATION INFO.:	US 1990-529988	19900529 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1986-866193, filed	

DOCUMENT TYPE: on 21 May 1986, now abandoned
 Utility
 PRIMARY EXAMINER: Nucker, Christine
 ASSISTANT EXAMINER: Kim, Kay K.
 LEGAL REPRESENTATIVE: Breininger, Thomas M.
 NUMBER OF CLAIMS: 3
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 32 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 1511
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.
 IT 53-05-4, Tetrahydrocortisone (phencyclidine fluorescence polarization immunoassay crossreactivity to)
 RN 53-05-4 USPATFULL

L7 ANSWER 36 OF 65 USPATFULL (Continued)
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 37 OF 65 USPATFULL
 ACCESSION NUMBER: 92:47049 USPATFULL
 TITLE: Method, compositions, and compounds for modulating brain excitability
 INVENTOR(S): Gee, Kelvin W., Hacienda Heights, CA, United States
 Bolter, Michael B., Los Alamitos, CA, United States
 PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5120723	19920609
APPLICATION INFO.:	US 1990-521724	19900510 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-379047, filed	

on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1987-89362,


filed on 25 Aug 1987, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Shen, Cecilia
 LEGAL REPRESENTATIVE: Lyon & Lyon
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
 LINE COUNT: 911
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionpore (GABA) complex.

IT 567-02-2 (anticongulsant and anxiolytic)

RN 567-02-2 USPATFULL
 CN Pregnane-20-one, 3,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 37 OF 65 USPATFULL (Continued)

L7 ANSWER 39 OF 65 USPATFULL
 ACCESSION NUMBER: 91:18943 USPATFULL
 TITLE: Tetrahydrocortisol in glaucoma therapy
 INVENTOR(S): Southren, Aaron L., Valhalla, NY, United States
 Weinstein, Bernard I., Valhalla, NY, United States
 Gordon, Gary G., Valhalla, NY, United States
 PATENT ASSIGNEE(S): New York Medical College, Valhalla, NY, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4997826	19910305
APPLICATION INFO.:	US 1989-396072	19890821 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1986-864610, filed on 19 May	

1986, now patented, Pat. No. US 4863912
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Friedman, Stanley J.
 ASSISTANT EXAMINER: Fay, Zohreh A.
 LEGAL REPRESENTATIVE: Zarley, McKee, Thome, Voorhees & Sease
 NUMBER OF CLAIMS: 7
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Page(s)
 LINE COUNT: 225
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.
 IT 53-02-1, Tetrahydrocortisol
 (ophthalmic preps. contg., for glaucoma treatment)
 RN 53-02-1 USPATFULL
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 39 OF 65 USPATFULL
 ACCESSION NUMBER: 90:93264 USPATFULL
 TITLE: DELTA..sup.9(11) -angiotatic steroids
 INVENTOR(S): Aristoff, Paul A., Portage, MI, United States
 Skulnick, Harvey I., Kalamazoo, MI, United States
 Wierenga, Wendell, Kalamazoo, MI, United States
 PATENT ASSIGNEE(S): The Upjohn Company, Kalamazoo, MI, United States
 (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 4975537	19901204
APPLICATION INFO.:	US 1989-351977	19890515 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1987-87228, filed	

on 19 Jun 1987, now abandoned which is a continuation-in-part of Ser. No. US 1985-790564, filed
 on 23 Oct 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-811866, filed
 on 20 Dec 1985, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Ward, Edward C.
 NUMBER OF CLAIMS: 7
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1654
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Disclosed are .DELTA..sup.9(11) -steroids of the formula ##STR1## which


have been found to be angiotatic and therefore are useful in the control of embryogenesis, inflammatory conditions, tumor growth as well as other abnormalities.

IT 111245-66-0P 133361-46-3P
 (formation of, in prepn. of antiangiogenesis agents)
 RN 111245-66-0 USPATFULL
 CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 133361-46-3 USPATFULL
 CN Pregn-9(11)-en-20-one, 17-(acetyloxy)-6-fluoro-3,21-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 111245-64-8P 111245-65-9P 111245-67-1P
 111245-70-6P 111245-71-7P 133442-74-7P
 (prepn. and reaction of, in prepn. of antiangiogenesis agents)
 RN 111245-64-8 USPATFULL
 CN Pregn-9(11)-en-20-one, 21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)

RN 111245-65-9 USPATFULL
 CN Pregn-9(11)-en-20-one, 21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 111245-67-1 USPATFULL
 CN Pregn-9(11)-en-20-one, 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-, (3.beta.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 111245-70-6 USPATFULL
 CN Pregn-9(11)-en-20-one,
 21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,
 (3.alpha.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 111245-71-7 USPATFULL
 CN Pregn-9(11)-en-20-one,
 21-(acetyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,
 (3.alpha.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 133442-74-7 USPATFULL
 CN Pregn-9(11)-en-20-one,
 21-(benzoyloxy)-6-fluoro-3,17-dihydroxy-16-methyl-,
 (5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 111245-58-0P 111320-97-9P
 (prepn. of, as antiangiogenesis agent)
 RN 111245-58-0 USPATFULL
 CN Pregn-9(11)-en-20-one, 6-fluoro-3,17,21-trihydroxy-16-methyl-,
 (3.alpha.,5.beta.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 39 OF 65 USPATFULL (Continued)



RN 111320-97-9 USPATFULL
 CN Pregn-9(11)-en-20-one, 6-fluoro-3,17,21-trihydroxy-16-methyl-,
 (3.alpha.,5.alpha.,6.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 40 OF 65 USPATFULL

ACCESSION NUMBER: 90:59474 USPATFULL
 TITLE: Use of tetrahydrocortexolone to prevent elevations
 in
 intraocular pressure caused by corticosteroids
 Clark, Abbot F., Arlington, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United
 States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4945089	19900731
APPLICATION INFO.:	US 1989-399351	19890828 (7)
RELATED APPLM. INFO.:	Continuation of Ser. No. US 1987-139222, filed on 29	

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Robinson, Douglas W.
 ASSISTANT EXAMINER: Fay, Zohreh A.
 LEGAL REPRESENTATIVE: Arno, James A.; Brown, Gregg C.
 NUMBER OF CLAIMS: 10
 EXEMPLARY CLAIM: 1
 LINE COUNT: 311

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortexolone. The tetrahydrocortexolone serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortexolone to a patient receiving such therapy.

IT 68-60-0, Tetrahydrocortexolone
 (ophthalmic compn. contg. glucocorticoid and, for intraocular pressure elevation prevention)

RN 68-60-0 USPATFULL
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 40 OF 65 USPATFULL (Continued)




L7 ANSWER 41 OF 65 USPATFULL
 ACCESSION NUMBER: 89:87537 USPATFULL
 TITLE: Methods for controlling ocular hypertension with angiotatic steroids
 INVENTOR(S): Clark, Abbot F., Arlington, TX, United States
 PATENT ASSIGNEE(S): Alcon Laboratories, Inc., Fort Worth, TX, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4876250	19891024
APPLICATION INFO.:	US 1988-264918	19881031 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Robinson, Douglas W.	
ASSISTANT EXAMINER:	Lipovsky, Joseph A.	
LEGAL REPRESENTATIVE:	Arno, James; Brown, Gregg; Stewart, Sally	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	419	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Angiotatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical composition of the angiotatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed.
 IT 68-60-0, Tetrahydrocortexolone (glaucoma treatment with)
 RN 68-60-0 USPATFULL
 CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 41 OF 65 USPATFULL (Continued)

L7 ANSWER 42 OF 65 USPATFULL
 ACCESSION NUMBER: 89:74172 USPATFULL
 TITLE: Use of tetrahydrocortisol in glaucoma therapy
 INVENTOR(S): Southren, Aaron L., Valhalla, NY, United States
 Weinstein, Bernard I., Valhalla, NY, United States
 Gordon, Gary G., Valhalla, NY, United States
 New York Medical College, Valhalla, NY, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4863912	19890905
APPLICATION INFO.:	US 1986-864610	19860519 (6)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Robinson, Douglas W.	
ASSISTANT EXAMINER:	Lipovsky, Joseph A.	
LEGAL REPRESENTATIVE:	Zarley, McKee, Thomte, Voorhees & Sease	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	237	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.
 IT 53-02-1, Tetrahydrocortisol (ophthalmic preps. contg., for glaucoma treatment)
 RN 53-02-1 USPATFULL
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 43 OF 65 USPATFULL
 ACCESSION NUMBER: 89:27895 USPATFULL
 TITLE: Method and composition for arresting angiogenesis and
 capillary, cell or membrane leakage
 INVENTOR(S): Gillespie, Larrian, Brentwood, CA, United States
 PATENT ASSIGNEE(S): Angiogenics, Ltd., San Francisco, CA, United States (U.S. corporation)

NUMBER	DATE
US 4820693	19890411
US 1987-20859	19870302 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-865981, filed

on 22 May 1986, now abandoned which is a continuation-in-part of Ser. No. US 1986-848288, filed

on 4 Apr 1986, now abandoned

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Rollins, John W.
 LEGAL REPRESENTATIVE: Sandler & Greenblum
 NUMBER OF CLAIMS: 53
 EXEMPLARY CLAIM: 1
 LINE COUNT: 698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition and method for arresting angiogenesis, and cell, capillary or membrane leakage comprising a pharmaceutically effective amount of angiostatic steroid and pentosan polysulfate, or a salt thereof, having the formula: ##STR1## wherein X is at least one member selected from the group consisting of H and --SO.sub.3 Y, and Y is at least one member selected from the group consisting of H and a pharmaceutically acceptable cation.

IT 68-60-0, Tetrahydro S (pharmaceuticals contg. pentosan polysulfate and, for arresting angiogenesis and capillary, cell or membrane leakage)

RN 68-60-0 USPATFULL


CN Pregnan-20-one, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA

INDEX

NAME)

Absolute stereochemistry.

L7 ANSWER 43 OF 65 USPATFULL (Continued)



L7 ANSWER 44 OF 65 USPATFULL
 ACCESSION NUMBER: 88:72350 USPATFULL
 TITLE: Production of primary or secondary alcohol derivatives
 of phospholipids by the enzymatic technique
 INVENTOR(S): Kokusho, Yoshitaka, Kunitachi, Japan
 Kato, Shigeaki, Hino, Japan
 Machida, Haruo, Hino, Japan
 PATENT ASSIGNEE(S): Meito Sangyo Kabushiki Kaisha, Aichi, Japan (non-U.S. corporation)

NUMBER	DATE
US 4783402	19881108
US 1984-598697	19840410 (6)

NUMBER	DATE
JP 1983-63304	19830411
JP 1983-63305	19830411

DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Hazel, Blondel
 LEGAL REPRESENTATIVE: Sherman & Shalloway
 NUMBER OF CLAIMS: 5
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for producing a primary or secondary alcohol derivative of a phospholipid which comprises reacting the phospholipid with a primary or secondary alcohol in the presence of phospholipase DM.

IT 53-02-1 53-05-4 (phosphatidic acid alc. deriv. manuf. from lecithin and, enzymic)



RN 53-02-1 USPATFULL

CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.beta.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 44 OF 65 USPATFULL (Continued)
 INDEX NAME)

Absolute stereochemistry.



RN 53-05-4 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)- (9CI) (CA


L7 ANSWER 45 OF 65 USPATFULL
 ACCESSION NUMBER: 88:55514 USPATFULL
 TITLE: Antidigoxin antibodies
 INVENTOR(S): Lingwood, Clifford A., Toronto, Canada
 PATENT ASSIGNEE(S): HSC Research Development Corporation, Toronto, Canada
 (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4767720	19880830
APPLICATION INFO.:	US 1985-774370	19850910 (6)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Marantz, Sidney	
ASSISTANT EXAMINER:	Wagner, Richard	
LEGAL REPRESENTATIVE:	Banner, Birch, McKie & Beckett	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	620	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A digoxin derivative/immunogenic protein conjugate is disclosed which has the carbohydrate moiety of digoxin intact. Antibodies raised against this conjugate show minimal cross-reactivity to digoxin metabolites enabling the use as an antibody in the diagnostic analysis for digoxin when measured in the presence of its metabolites found in serum isolated from a human.

IT 99286-16-5
 (NMR spectrum of)
 RN 99286-16-5 USPATFULL
 CN Pregnan-20-one,
 3-[(0-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-
 O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-2,6-dideoxy-.
 .beta.-D-ribo-hexopyranosyl)oxy]-12,14,21-trihydroxy-,
 (3.beta.,5.beta.,12.beta.,14.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 45 OF 65 USPATFULL (Continued)



IT 99286-15-4DP, immunogenic protein conjugates
 (prepn. of and antibodies to, for digoxin immunoassay)
 RN 99286-15-4 USPATFULL
 CN Pregnan-20-one,
 3-[(0-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-
 O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-2,6-dideoxy-.
 .beta.-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-21-[(oxoacetyl)oxy]-,
 (3.beta.,5.beta.,12.beta.,14.beta.)- (9CI) (CA INDEX NAME)




L7 ANSWER 45 OF 65 USPATFULL (Continued)

PAGE 1-B

—CHO

IT 99286-15-4P
 (prepn. of, for digoxin immunoassay)
 RN 99286-15-4 USPATFULL
 CN Pregnan-20-one,
 3-[(0-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-
 O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-2,6-dideoxy-.
 .beta.-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-21-[(oxoacetyl)oxy]-,
 (3.beta.,5.beta.,12.beta.,14.beta.)- (9CI) (CA INDEX NAME)



PAGE 1-B

—CHO

L7 ANSWER 46 OF 65 USPATFULL
 ACCESSION NUMBER: 83:27696 USPATFULL
 TITLE: Adrenosteriod composition and method for the treatment of shock by infusional therapy
 INVENTOR(S): Fussi, Fernando F., Fribourg, Switzerland
 PATENT ASSIGNEE(S): Hepar Industries, Franklin, OH, United States (U.S. corporation)


	NUMBER	DATE
PATENT INFORMATION:	US 4391803	19830705
APPLICATION INFO.:	US 1982-375749	19820506 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-365867, filed	

DOCUMENT TYPE: on 5 Apr 1982, now abandoned
 Utility
 PRIMARY EXAMINER: Roberts, Elbert L.
 LEGAL REPRESENTATIVE: Cushman, Darby & Cushman
 NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 LINE COUNT: 286

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Septic shock and other forms of shock are effectively treated using a blend of 18 different adrenosteroids in their physiologic ratios based upon an animal cortex extract as a model. The blend preferably administered by infusion to a person suffering from shock. The blend is more effect and at a lower dosage level than hydrocortisone base or water-soluble derivatives of hydrocortisone.

IT 302-91-0 516-16-5 516-45-0 516-47-2
 566-02-9
 (infusions of corticosteroid mixts. contg., for septic and traumatic shock treatment)
 RN 302-91-0 USPATFULL
 CN Pregnan-20-one, 3,11,17,21-tetrahydroxy-,
 (3.alpha.,5.alpha.,11.beta.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 46 OF 65 USPATFULL (Continued)


RN 516-16-5 USPATFULL
 CN Pregnane-20-one, 3,11,21-trihydroxy-, (3.beta.,5.alpha.,11.beta.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 516-45-0 USPATFULL
 CN Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.beta.,5.alpha.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 516-47-2 USPATFULL
 CN Pregnane-20-one, 3,17,21-trihydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 47 OF 65 USPATFULL
 ACCESSION NUMBER: 82:36452 USPATFULL
 TITLE: Immunochemical assay reagent for the determination of
 INVENTOR(S): haptens, and assay method therewith
 Sakakibara, Kyoichi, Tokyo, Japan
 Manita, Hideaki, Sagami, Japan
 Gondo, Masaaki, Kawasaki, Japan
 Yamashita, Haruo, Kunitachi, Japan
 PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Tokyo, Japan
 (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4341758	19820727
APPLICATION INFO:	US 1979-83938	19791011 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1978-125710	19781014
	JP 1978-125711	19781014
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fagelson, Anna P.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1,2,3	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	2279	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel immunochemical assay reagents comprising combinations of (A) a carboxyl-containing water-soluble mono-olefinic polymeric compound combined with a hapten or its chemically modified product, or a hapten-supported latex resulting from the chemical linking of the hapten-bound polymeric compound to a polymeric latex, with (B) a hapten


antibody, or a hapten antibody-supported carrier; and a method for immunochemically determining haptens by using the aforesaid reagent. This reagent is very stable and can be stored for an extended

period of time without degradation. It enables transition from an agglutination inhibited pattern to an agglutinated pattern to be discerned clearly and rapidly with high sensitivity.

IT 26312-90-SDP, albumin complexes 75088-42-SDP, reduced, reaction products with polyacrylic acid 75088-42-SP (prepn. of)


RN 26312-90-3 USPATFULL
 CN .beta.-D-Glucopyranosiduronic acid, (3.alpha.,5.beta.,11.beta.)-11,17,21-trihydroxy-20-oxopregnan-3-yl (9CI) (CA INDEX NAME)

L7 ANSWER 46 OF 65 USPATFULL (Continued)




RN 566-02-9 USPATFULL
 CN Pregnane-11,20-dione, 3,21-dihydroxy-, (3.beta.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 47 OF 65 USPATFULL (Continued)



RN 75088-42-5 USPATFULL
 CN L-Lysine, N6-[(phenylmethoxy)carbonyl]-N2-[1-O-

[(3.alpha.,5.beta.,11.beta.)-11,17,21-trihydroxypregnan-3-yl]-.beta.-D-glucopyranuronoyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-CH2-OH

RN 75088-42-5 USPATFULL
 CN L-Lysine, N6-[(phenylmethoxy)carbonyl]-N2-[1-O-

[(3.alpha.,5.beta.,11.beta.)-11,17,21-trihydroxypregnan-3-yl]-.beta.-D-glucopyranuronoyl]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 47 OF 65 USPATFULL (Continued)

—CH₂—OH

L7 ANSWER 48 OF 65 USPATFULL

ACCESSION NUMBER: 81:44727 USPATFULL
 TITLE: Chemical process for fluorinating a tertiary carbon atom in the steroid nucleus
 INVENTOR(S): Barton, Derek H. R., London, England
 Hesse, Robert H., Cambridge, MA, United States
 Research Institute for Medicine and Chemistry, Inc.,
 Cambridge, MA, United States (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION:	US 4284558 19810818
APPLICATION INFO.:	US 1977-775879 19770309 (5)
DISCLAIMER DATE:	19940719
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1975-581293, filed on 27 May 1975, now patented, Pat. No. US 4036864, issued on 19 Jul 1977

NUMBER	DATE
PRIORITY INFORMATION:	GB 1974-24734 19740604
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Bacon & Thomas
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
LINE COUNT:	1297
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB Saturated organic compounds containing a hydrogen atom bound to a tertiary carbon atom may be electrophilically fluorinated by reaction with an electrophilic fluorinating agent such as molecular fluorine or trifluoromethyl hypofluorite under conditions whereby the formation of free fluorine radicals is suppressed, e.g. by the presence of a free radical inhibitor such as oxygen or nitrobenzene, the reactants being substantially homogeneously dispersed in a liquid medium, e.g. a solvent medium such as fluorotrichloromethane or chloroform/fluorotrichloromethane, so that the said hydrogen atom is electrophilically replaced by a fluorine atom. The fluorination is highly selective and, in the case of complex substrates such as saturated steroids which contain a number of tertiary C—H bonds, may be substantially completely confined to replacement of the hydrogen atom at the tertiary carbon atom which has	

L7 ANSWER 48 OF 65 USPATFULL (Continued)

the highest electron density about the C—H bond. The electron density and thus the direction of the fluorination may be controlled by appropriate selection of substituent groupings in the substrate molecule.

Novel 14.alpha.-fluorosteroids are also disclosed, including compounds having valuable androgenic or progestational activity and useful synthetic intermediates.


IT 58652-60-1

(fluorination of)

RN 58652-60-1 USPATFULL

CN Pregnan-20-one, 3,21-bis(acetyloxy)-16-methyl-17-(nitrooxy)-, (3.beta.,5.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 49 OF 65 USPATFULL

ACCESSION NUMBER: 81:10709 USPATFULL
 TITLE: Steroid conversion method and products produced thereby
 INVENTOR(S): Breslow, Ronald C. D., Englewood, NJ, United States
 Corcoran, Richard J., Maywood, NJ, United States
 Snider, Barry B., Princeton, NJ, United States
 Research Corporation, New York, NY, United States (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION:	US 4252719 19810224
APPLICATION INFO.:	US 1978-934314 19780817 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1977-786060, filed on 8 Apr 1977, now abandoned which is a continuation of Ser. No. US 1975-621163, filed on 9 Oct 1975, now abandoned
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Cooper, Dunham, Clark, Griffin & Moran
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1,21
NUMBER OF DRAWINGS:	31 Drawing Page(s)
LINE COUNT:	964

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for the removal of selected tertiary hydrogen atoms from 5.alpha.-steroids of the cholestane, androstane and pregnane series by chlorination of 5.alpha.-steroids esterified with selected iodoaryl substituted esterifying agents which direct a chlorine atom from the chlorinating agent into reactive proximity to the hydrogen atom to be removed.


IT 77546-98-6P

(prepn. of)

RN 77546-98-6 USPATFULL

CN Pregn-9(11)-en-20-one, 3-(acetyloxy)-17,21-dihydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 49 OF 65 USPATFULL (Continued)

L7 ANSWER 50 OF 65 USPATFULL
 ACCESSION NUMBER: 80:12729 USPATFULL
 TITLE: Chemical compounds
 INVENTOR(S): Philipps, Gordon H., Wembley, England
 May, Peter J., North Harrow, England
 Ayres, Barry E., Ickenham, England
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England
 (non-U.S. corporation)

NUMBER	DATE
US 4192871	19800311
APPLICATION INFO.: US 1978-907915	19780522 (5)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1976-752513, filed on 20 Dec 1976, now abandoned	


NUMBER	DATE
PRIORITY INFORMATION: GB 1976-357	19760106
DOCUMENT TYPE: Utility	
PRIMARY EXAMINER: Roberts, Elbert L.	
LEGAL REPRESENTATIVE: Bacon & Thomas	
NUMBER OF CLAIMS: 23	
EXEMPLARY CLAIM: 1,16,21	
LINE COUNT: 2797	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB Pregnanes and androstanes are described which essentially possess a 3.alpha.-hydroxy group, a 5.alpha.-hydrogen atom or a 4.5- or 5,6-double bond, a 17.alpha.-hydrogen atom and an 11.beta.-aminoester group.	
Other optional substituents or double bonds may be present. The compounds have anaesthetic activity.	
IT 64510-35-6 (hydrolysis of)	
RN 64510-35-6 USPATFULL	
CN Glycine, N,N-dipropyl-, (3.alpha.,5.alpha.,11.beta.)-21-(acetyloxy)-3-hydroxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)	
Absolute stereochemistry.	

L7 ANSWER 50 OF 65 USPATFULL (Continued)



IT 64510-35-6P 64510-36-7P 64510-56-1P
 64565-05-5P 64565-95-3P
 (prepn. of)
 RN 64510-35-6 USPATFULL
 CN Glycine, N,N-dipropyl-, (3.alpha.,5.alpha.,11.beta.)-21-(acetyloxy)-3-hydroxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 64510-36-7 USPATFULL
 CN Glycine, N,N-dipropyl-, (3.alpha.,5.alpha.,11.beta.)-3,21-dihydroxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 50 OF 65 USPATFULL (Continued)




RN 64510-56-1 USPATFULL
 CN Pregnan-20-one, 3,11-dihydroxy-21-methoxy-, (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 64565-05-5 USPATFULL
 CN Glycine, N,N-diethyl-, (3.alpha.,5.alpha.,11.beta.)-3-hydroxy-21-methoxy-20-oxopregnan-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 50 OF 65 USPATFULL (Continued)

RN 64565-95-3 USPATFULL
 CN Pregnan-20-one, 11-[(chloroacetyl)oxy]-3-hydroxy-21-methoxy-,
 (3.alpha.,5.alpha.,11.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 51 OF 65 USPATFULL
 ACCESSION NUMBER: 77:37370 USPATFULL
 TITLE: Chemical process
 INVENTOR(S): Barton, Derek Harold Richard, London, England
 Hesse, Robert Henry, Cambridge, MA, United States
 RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC.,
 Cambridge, MA, United States (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION:	US 4036864 19770719
APPLICATION INFO.:	US 1975-581283 19750527 (5)
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Bacon & Thomas
NUMBER OF CLAIMS:	25
EXEMPLARY CLAIM:	1,22
LINE COUNT:	1426

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Saturated organic compounds containing a hydrogen atom bound to a tertiary carbon atom may be electrophilically fluorinated by reaction with an electrophilic fluorinating agent such as molecular fluorine or trifluoromethyl hypofluorite under conditions whereby the formation of free fluorine radicals is suppressed, e.g. by the presence of a free radical inhibitor such as oxygen or nitrobenzene, the reactants being substantially homogeneously dispersed in a liquid medium, e.g. a solvent medium such as fluorotrichloromethane or chloroform/fluorotrichloromethane, so that the said hydrogen atom is electrophilically replaced by a fluorine atom. The fluorination is highly selective and, in the case of complex substrates such as saturated steroids which contain a number of tertiary C-H bonds, may be substantially completely confined to replacement of the hydrogen atom at the tertiary carbon atom which has the highest electron density about the C-H bond. The electron density and thus the direction of the fluorination may be controlled by appropriate selection of substituent groupings in the substrate molecule.


Novel 14.alpha.-fluorosteroids are also disclosed, including compounds having valuable androgenic or progestational activity and useful synthetic intermediates.

IT 58652-60-1

L7 ANSWER 51 OF 65 USPATFULL (Continued)

(fluorination of)
 RN 58652-60-1 USPATFULL
 CN Pregnan-20-one, 3,21-bis(acetyloxy)-16-methyl-17-(nitrooxy)-,
 (3.beta.,5.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 61841-77-8P

(prepn. of)

RN 61841-77-8 USPATFULL

CN Pregnan-20-one, 3,21-bis(acetyloxy)-9-fluoro-16-methyl-17-(nitrooxy)-,
 (3.beta.,5.alpha.,16.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 52 OF 65 USPATFULL

ACCESSION NUMBER: 77:11539 USPATFULL
 TITLE: 22-Cyano-24-norcholanes
 INVENTOR(S): Abraham, Nedumparambil A., Dollard des Ormeaux,
 Canada
 Lefebvre, Yvon, Pierrefonds, Canada
 PATENT ASSIGNEE(S): American Home Products Corporation, New York, NY,
 United States (U.S. corporation)

NUMBER	DATE
PATENT INFORMATION:	US 4011212 19770308
APPLICATION INFO.:	US 1975-641128 19751215 (5)
RELATED APPL. INFO.:	Division of Ser. No. US 1974-469269, filed on 13 May 1974, now patented, Pat. No. US 3944541
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Roberts, Elbert L.
LEGAL REPRESENTATIVE:	Venetianer, Stephen
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
LINE COUNT:	359

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed herein the 3.beta.,14-dihydroxy-, 3.beta.,5,14-trihydroxy-, 3.beta.,12.beta.,14-trihydroxy- and 3.beta.,14,16.beta.-trihydroxy-21,23-epoxy-23-methoxy-24-nor-5.beta.,14.beta.-chola-20,22-diene-22-carbonitriles, as well as their corresponding 3-acetates, 3-propionates and 3-butyrate and their 3-digitosides and 3.beta.-cyanoaroyl-glucosides as encountered in naturally-occurring starting materials. The compounds possess useful cardiotonic activity. Also included are the corresponding 22-cyano-5.beta.-card-20(22)-enolides, useful as intermediates in the preparation of the compounds of this invention and also as cardiotonic agents.

IT 24533-02-6P 59445-44-2P


(prepn. and cyclocondensation of, with ethyl cyanoacetate)

RN 24533-02-6 USPATFULL

CN Pregnan-20-one, 3-(acetyloxy)-14,21-dihydroxy-,
 (3.beta.,5.beta.,14.beta.)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 52 OF 65 USPATFULL (Continued)



RN 59445-44-2 USPATFULL

CN Pregnan-20-one,

3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-
O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarv.4)-2,6-dideoxy-
.beta.-D-ribo-hexopyranosyl)oxy]-14,21-dihydroxy-,
(3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)



IT 42516-41-6P

(prepn. and selective hydrolysis of)

RN 42516-41-6 USPATFULL

CN Pregnan-20-one, 3-(acetyloxy)-14-hydroxy-21-[(oxoacetyl)oxy]-,
(3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL

ACCESSION NUMBER: 76:39285 USPATFULL

TITLE:

20.beta.,21-Epoxy-3.alpha.-hydroxy-5.alpha.-pregnanes

and

derivatives thereof

INVENTOR(S):

Phillipps, Gordon Hanley, Wembley, England

Newall, Christopher Earle, London, England

PATENT ASSIGNEE(S):

Glaxo Laboratories Limited, Greenford, England
(non-U.S. corporation)

NUMBER	DATE
US 3969345	19760713
US 1975-551315	19750220 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1971-208961, filed on 16 Dec
Dec	1971, now patented, Pat. No. US 3882151

NUMBER	DATE
GB 1970-60065	19701217

PRIORITY INFORMATION:

DOCUMENT TYPE:

PRIMARY EXAMINER: Roberts, Elbert L.

LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides 3.alpha.-oxygenated pregnane 21-ethers

possessing

a hydroxy group in the 3.alpha.-position; a hydrogen atom or a

methyl

group at the 10-position; a hydrogen atom in the

17.alpha.-position; a

keto group in the 20-position; and an etherified hydroxyl group in

the

21-position.

IT 32354-01-1P 38601-17-1P 38601-29-5P

38601-30-8P 38601-31-9P 38601-32-0P

38601-33-1P 38601-34-2P 38601-35-3P

38601-36-4P 38601-37-5P 38601-38-6P

38601-39-7P 38601-40-0P 38601-41-1P

38601-43-3P 38601-44-4P 38601-45-5P

38601-46-6P 38601-47-7P 38601-48-8P

38746-02-0P

(prepn. of)

RN 32354-01-1 USPATFULL


CN Pregnane-11,20-dione, 21-hydroxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-

(9CI)


(CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 52 OF 65 USPATFULL (Continued)



L7 ANSWER 53 OF 65 USPATFULL (Continued)




RN 38601-17-1 USPATFULL

CN Pregnane-11,20-dione, 21-methoxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 38601-29-5 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)-
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 53 OF 65 USPATFULL (Continued)


RN 38601-30-8 USPATFULL
 CN Pregnane-11,20-dione, 21-ethoxy-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-31-9 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-propoxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-32-0 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-(1-methylethoxy)-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-33-1 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-methoxyethoxy)-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-34-2 USPATFULL
 CN Pregnane-11,20-dione, 21-(4-aminophenoxy)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)




RN 38601-35-3 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-16-methyl-, (3.alpha.,5.alpha.,16.alpha.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-36-4 USPATFULL
 CN Pregnane-20-one, 3-hydroxy-21-methoxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 53 OF 65 USPATFULL (Continued)


RN 38601-37-5 USPATFULL
 CN Pregnane-11,20-dione, 3-(acetyloxy)-21-methoxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 38601-38-6 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-2,21-dimethoxy-, (2.beta.,3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-39-7 USPATFULL
 CN Pregnane-11,20-dione, 21-(2-chloroethoxy)-3-(nitrooxy)-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-40-0 USPATFULL
CN Pregnan-11,20-dione, 3-hydroxy-21-(2-(4-morpholinyl)ethoxy)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-41-1 USPATFULL
CN Pregnan-11,20-dione,
3-hydroxy-21-(2-(4-methyl-1-piperazinyl)ethoxy)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-43-3 USPATFULL
CN Propanenitrile,
3-[[[3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-44-4 USPATFULL
CN Propanoic acid,
3-[[[3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-45-5 USPATFULL
CN Pregnan-11,20-dione, 21-(2-chloroethoxy)-3-hydroxy-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-46-6 USPATFULL
CN Pregnan-11,20-dione, 21-(3-chloropropoxy)-3-hydroxy-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38601-47-7 USPATFULL
CN Pregnan-11,20-dione, 3-hydroxy-21-(phenylmethoxy)-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38601-48-8 USPATFULL
CN Pregnan-11,20-dione, 21-(cyclopentylthio)-3-hydroxy-,
(3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 53 OF 65 USPATFULL (Continued)



RN 38746-02-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-methoxy-, (3.alpha.,5.beta.)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 54 OF 65 USPATFULL

ACCESSION NUMBER: 76:29138 USPATFULL
TITLE: Anaesthetic steroids of the pregnane and 19-norpregnane

series having a sulfur-containing group at the 21-position

INVENTOR(S): Philipps, Gordon Hanley, Wembley, England
Lawrence, Robin, Stoke Poges, England
Newall, Christopher Earle, London, England
Wright, Michael, Stoke Poges, England

PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England
(non-U.S. corporation)

NUMBER	DATE
US 3959260	19760525
APPLICATION INFO.: US 1974-488989	19740716 (5)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1973-356097, filed on 1 May	1973, now Defensive Publication No.

NUMBER	DATE
PRIORITY INFORMATION: GB 1972-21145	19720505
DOCUMENT TYPE: Utility	
PRIMARY EXAMINER: Roberts, Elbert L.	
LEGAL REPRESENTATIVE: Bacon & Thomas	
NUMBER OF CLAIMS: 22	
EXEMPLARY CLAIM: 1	
LINE COUNT: 1493	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroid anaesthetics of the pregnane and 19-norpregnane series are described, the compounds possessing a 3.alpha.-hydroxy group, a 17.alpha.-hydrogen atom, a 20-oxo group and at the 21-position the residue of a sulphur nucleophile or a sulphone or sulphoxide grouping.


IT 51086-87-4P 51086-88-5P 51086-89-6P
51086-90-9P 51086-91-0P 51086-92-1P
51086-93-2P 51086-94-3P 51086-95-4P
51086-96-5P 51086-97-6P 51086-98-7P
51086-99-8P 51087-00-4P 51087-09-3P
51087-10-6P 51087-11-7P 51087-12-8P
51087-13-9P 51087-14-0P 51087-15-1P
51087-17-3P 51087-18-4P 51087-19-5P
51087-20-6P 51087-21-9P 51087-23-1P
51087-25-3P 51087-28-6P 51087-29-7P
51087-30-0P 51087-31-1P 51087-32-2P
51087-33-3P 51087-34-4P 51087-35-5P
51087-36-6P 51087-37-7P 51087-38-8P
51087-39-9P 51087-51-5P 51087-52-6P

(prepn. of)

RN 51086-87-4 USPATFULL
CN Pregnane-11,20-dione, 21-[(benzoylthio)-3-hydroxy-, (3.alpha.,5.alpha.)-]


L7 ANSWER 54 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



RN 51086-88-5 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-iodobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-89-6 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-nitrobenzoyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-90-9 USPATFULL
CN Pregnane-11,20-dione, 21-[(2-ethoxycarbonyl)benzoylthio]-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-91-0 USPATFULL
CN Pregnane-11,20-dione, 3-hydroxy-21-[(2-pyridinylcarbonyl)thio]-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-92-1 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(3-pyridinylcarbonyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-93-2 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-94-3 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(1-piperidinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-95-4 USPATFULL
 CN Pregnone-11,20-dione, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-96-5 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(1-oxobutyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-97-6 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(1-oxopentyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51086-98-7 USPATFULL
 CN Pregnan-20-one, 21-(acetylthio)-3-hydroxy-, (3.alpha.,5.alpha.)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 51086-99-8 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(2-methylthio)benzoyl]thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-00-4 USPATFULL
 CN Pregnone-11,20-dione,
 3-hydroxy-21-[[2-(4-morpholinyl)-1-oxopentyl]thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-09-3 USPATFULL
 CN Pregnone-11,20-dione, 21-(ethylthio)-3-hydroxy-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-10-6 USPATFULL
 CN Pregnone-11,20-dione, 21-(ethylsulfonyl)-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-11-7 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(1-methylethyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)




RN 51087-12-8 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(phenylmethyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-13-9 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-thiocyanato-, (3.alpha.,5.alpha.)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51087-14-0 USPATFULL

L7 ANSWER 54 OF 65 USPATFULL (Continued)


CN Pregnone-11,20-dione, 3-hydroxy-21-[[2-(4-morpholinyl)ethyl]thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51087-15-1 USPATFULL
 CN Pregnone-11,20-dione,
 3-hydroxy-21-[[2-(4-morpholinyl)ethoxy]thio]thiomethyl
 thio-, (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-17-3 USPATFULL
 CN Pregnone-11,20-dione, 3-hydroxy-21-[(4-morpholinylthio)thiomethyl]thio-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-18-4 USPATFULL
 CN Pregnane-11,20-dione, 21-((ethylsulfinyl)-3-hydroxy-,
 [3.alpha.,5.alpha.,21(R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-19-5 USPATFULL
 CN Pregnane-11,20-dione, 21-((ethylsulfinyl)-3-hydroxy-,
 [3.alpha.,5.alpha.,21(S)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-20-8 USPATFULL
 CN Pregnane-11,20-dione, 2-ethoxy-3-hydroxy-21-mercapto-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-21-9 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-thiomorpholinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-23-1 USPATFULL
 CN Pregnane-11,20-dione, 21-[(butylthio)thiomethylthio]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-25-3 USPATFULL
 CN Pregnane-11,20-dione,
 21-[(3,6-dihydro-1(2H)-pyridinyl)acetylthio]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-28-6 USPATFULL
 CN Pregnane-11,20-dione, 21-[(3-chloro-1-oxopropyl)thio]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-29-7 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-30-0 USPATFULL
 CN Pregnan-11,20-dione,
 3-hydroxy-21-[[3-(4-morpholinyl)-1-oxopropyl]thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-31-1 USPATFULL
 CN Pregnan-11,20-dione,
 3-hydroxy-21-[[4-(4-morpholinyl)-1-oxobutyl]thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-34-4 USPATFULL
 CN Pregnan-11,20-dione, 21-(acetylthio)-3-hydroxy-2-methoxy-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-35-5 USPATFULL
 CN Pregnan-20-one, 21-(acetylthio)-3-hydroxy-2-methoxy-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-32-2 USPATFULL
 CN Pregnan-11,20-dione, 3-hydroxy-21-(2-pyridinylthio)-,
 (3.alpha.,5.beta.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-33-3 USPATFULL
 CN Pregnan-11,20-dione,
 3-hydroxy-2-methyl-21-[(4-morpholinylacetyl)thio]-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-36-6 USPATFULL
 CN Pregnan-11,20-dione,
 3-hydroxy-3-methyl-21-[(4-morpholinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51087-37-7 USPATFULL
 CN 19-Norpregnan-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-38-8 USPATFULL
 CN Pregnane-11,20-dione,
 2-ethoxy-3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 51087-39-9 USPATFULL
 CN Pregn-1-ene-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)thio]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 54 OF 65 USPATFULL (Continued)




L7 ANSWER 54 OF 65 USPATFULL (Continued)



RN 51087-51-5 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-mercapto-, (3.alpha.,5.alpha.)-
 (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



RN 51087-52-6 USPATFULL
 CN Pregnane-11,20-dione, 21-[(4-chloro-1-oxobutyl)thio]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 55 OF 65 USPATFULL

ACCESSION NUMBER: 76:21864 USPATFULL
 TITLE: Anaesthetic composition containing a steroid of the
 5.alpha.-pregnane series and method of using same
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England
 Newall, Christopher Earle, Acton, England
 Ayres, Barry Edward, Amersham, England
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, England
 (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3952031	19760420
APPLICATION INFO.:	US 1974-532612	19741213 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1971-197915, filed on 11 Nov	
	1971, now patented, Pat. No. US 3869451	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-53911	19701112
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1788	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This invention relates to steroids of the pregnane and 19-norpregnane series having anaesthetic properties and compositions containing them.
 More particularly the present invention relates to such steroids having a variety of substituents in the 2.beta.-position, a 3.alpha.-hydroxy group and a 5.alpha.-hydrogen atom and esters and 20-ketals thereof. At the 11-position of such steroids is preferably either two hydrogen atoms or an oxo group. The compounds according to the invention may conveniently be prepared by reaction of an appropriate 2.alpha.,3.alpha.-epoxy-pregnane or 19-norpregnane with a reagent which introduces the desired 2.beta.-substituent and various modifications of the compound produced are described to produce compounds within the scope of the invention. The present invention provides compositions containing certain steroids of the pregnane and 19-norpregnane series and such compositions generally may be administered intravenously to induce anaesthesia, the invention providing methods of inducing anaesthesia.

IT 38689-90-6P


(prepn. of)

RN 38689-90-6 USPATFULL

CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-2-methoxy-,

L7 ANSWER 55 OF 65 USPATFULL (Continued)
(2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 56 OF 65 USPATFULL
ACCESSION NUMBER: 76:14331 USPATFULL
TITLE: 22-Cyano-24-norcholanes
INVENTOR(S): Abraham, Nedumparambil A., Dollard des Ormeaux, Canada
PATENT ASSIGNEE(S): Lefebvre, Yvon, Pierrefonds, Canada
American Home Products Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3944541	19760316
APPLICATION INFO.:	US 1974-469269	19740513 (5)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Brown, Johnnie R.	
ASSISTANT EXAMINER:	Owens, Cary B.	
LEGAL REPRESENTATIVE:	Floyd, John P.	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
LINE COUNT:	345	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed herein the 3.beta., 14-dihydroxy-, 3.beta., 5, 14-trihydroxy-, 3.beta., 12.beta., 14-trihydroxy- and 3.beta., 14, 16.beta.-

trihydroxy-21,23-epoxy-23-methoxy-24-nor-5.beta., 14.beta.-chola-20,22-diene-22-carbonitriles, as well as their corresponding 3-acetates, 3-propionates and 3-butyrate and their 3-digitosides and 3.beta.-cyamarosyl-glucosides as encountered in naturally-occurring starting materials. The compounds possess useful cardiotonic activity.

Also included are the corresponding 22-cyano-5.beta.-card-20(22)-enolides, useful as intermediates in the preparation of the compounds of

this invention and also as cardiotonic agents.

IT 3945-61-OP 59445-44-2P


(prepn. and condensation of, with ethyl cyanoacetate)

RN 3946-61-0 USPATFULL

CN Pregnan-20-one, 3,14,21-trihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 56 OF 65 USPATFULL (Continued)





RN 59445-44-2 USPATFULL

CN Pregnan-20-one,

3-[(O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy]-14,21-dihydroxy-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 56 OF 65 USPATFULL (Continued)



IT 59445-40-6P

(prepn. and hydrolysis of)

RN 59445-48-6 USPATFULL

CN Pregnan-20-one, 3,14-dihydroxy-21-[(oxoacetyl)oxy]-, (3.beta.,5.beta.,14.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 57 OF 65 USPATFULL
 ACCESSION NUMBER: 76:8956 USPATFULL
 TITLE: 15.alpha.,-Sulfonyloxy-12.beta.-hydroxypregnanes
 and
 process for the preparation thereof
 INVENTOR(S): Lehmann, Hans-Gunter, Berlin, Germany, Federal
 Republic
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Berlin & Bergkamen,
 Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3939187	19760217
APPLICATION INFO.:	US 1974-485062	19740702 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1973-2334559	19730704
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Millen, Raptis & White	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	238	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB 15.alpha.-Sulfonyl-12.beta.-hydroxypregnanes of the formula ##SPC1##

Wherein Ac is lower-acyl and R is alkyl, cycloalkyl, aralkyl or
 aryl,
 which are useful as intermediates for the production of
 digoxigenin, are
 produced by the selective sulfonic acid esterification of the
 corresponding 12.beta., 15.alpha.-dihydroxy steroid.

IT 55534-62-8P
 (prepn. and dehydrosulfonation of)
 RN 55534-62-8 USPATFULL
 CN Pregnan-20-one, 3,12,21-tris(acetyloxy)-15-[(2,4,6-
 trimethylphenyl)sulfonyloxy]-,
 (3.beta.,5.beta.,12.beta.,15.alpha.)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 57 OF 65 USPATFULL (Continued)



L7 ANSWER 58 OF 65 USPATFULL
 ACCESSION NUMBER: 75:71659 USPATFULL
 TITLE: Process for the manufacture of steroid epoxides
 INVENTOR(S): Kaufmann, Heinz, Fullingsdorf, Switzerland
 Wettstein, Albert, Riehen, Switzerland
 PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Ardsley, NY, United States
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3929769	19751230
APPLICATION INFO.:	US 1974-451261	19740314 (5)
RELATED APPL. INFO.:	Continuation of Ser. No. US 1973-360230, filed on 14 May 1973, now abandoned	


	NUMBER	DATE
PRIORITY INFORMATION:	CH 1972-7479	19720519
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Kolodny, Joseph G.; Maitner, John J.; Groeger, Theodore	

NUMBER OF CLAIMS: 11
 EXEMPLARY CLAIM: 1
 LINE COUNT: 526
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention is directed to a process for the manufacture of
 5.alpha.,6.alpha.-oxido-steroids starting from corresponding
 5.alpha.,6.beta.-dihydroxy steroids. The starting steroids are
 treated
 with a fluorinated amine of the formula ##EQU1## wherein X.sub.1 is
 chlorine or fluorine, X.sub.2 is chlorine, fluorine or
 trifluoromethyl
 and R and R' are alkyl groups or together with the nitrogen atom
 form a heterocyclic radical. There are preferably used compounds in which
 R and R' are lower alkyl groups, such as for instance N- (2-chloro-1,1,2-
 trifluoroethyl)-diethylamine, and the reaction is performed in an
 inert
 solvent e.g. ethylene chloride, at room temperature or elevated
 temperature, if desired, in the presence of another organic nitrogen
 base. The compounds of the process are intermediates for the
 preparation
 of therapeutically useful 6-fluoro-steroids, such as
 6-fluoro-corticoids. In particular, the epoxides can be further
 reacted
 with the same fluorinated amine used in their preparation to give
 the
 6.beta.,5.alpha.-fluorohydrins.

IT 51467-16-4
 (dehydration of, with (chlorotrifluoroethyl)diethylamine)
 RN 51467-16-4 USPATFULL
 CN Pregnan-20-one, 3,21-bis(acetyloxy)-5,6,17-trihydroxy-,
 (3.beta.,5.alpha.,6.beta.)- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 65 USPATFULL (Continued)

Absolute stereochemistry.



L7 ANSWER 59 OF 65 USPATFULL
 ACCESSION NUMBER: 75:59665 USPATFULL
 TITLE: Steroidal anaesthetic composition for intravenous injection
 INVENTOR(S): Pearce, Derek Roger, Bracknell, England
 Davis, Benjamin, Chalfont St. Peter, England
 Pearce, Derek Roger, Bracknell, England
 Connor, Paul, Chalfont St. Giles, England
 Glaxo Laboratories Limited, Greenford, England
 (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3917830	19751104
APPLICATION INFO.:	US 1972-263133	19720615 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1971-208924, filed	
	on 16 Dec 1971, now abandoned	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60067	19701217
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Rose, Shep K.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	566	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for use by injection as an anaesthetic comprising 3.alpha.-hydroxy 5.alpha.-pregnane - 11,20 dione in solution in an inert organic liquid medium. The composition may be in the form of a solution which also contains water, a non-aqueous solution or an emulsion or microemulsion. The emulsions and microemulsions are preferably of the oil-in-water type.

Water-miscible substances which may be used as or in the liquid medium include polyhydroxy alcohols and water-soluble esters and amides.

Other substances which may be used as the liquid medium include oils, long chain alcohols and esters, and fatty acid esters.


IT 23930-37-2 (pharmaceutical solubilizer, for hydroxypregnanedione)

RN 23930-37-2 USPATFULL

CN Pregnane-11,20-dione, 21-(acetyloxy)-3-hydroxy-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 59 OF 65 USPATFULL (Continued)



L7 ANSWER 60 OF 65 USPATFULL
 ACCESSION NUMBER: 75:25277 USPATFULL
 TITLE: Novel 3.alpha.-hydroxysteroids of the 5.alpha.-pregnane series
 INVENTOR(S): Philipps, Gordon Hanley, Wembley, England
 Newall, Christopher Earle, Acton, England
 Cook, Martin Christopher, Chalfont St. Peter, England
 PATENT ASSIGNEE(S): Glaxo Laboratories Limited, Greenford, Middlesex, England (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 3883569	19750513
APPLICATION INFO.:	US 1971-208985	19711216 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1970-60066	19701217
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Roberts, Elbert L.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	845	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Steroids of the 5.alpha.-pregnane series possessing a 3.alpha.-hydroxy group, a 10-hydrogen atom or methyl group, an 11-oxo group, a 17.alpha.-hydrogen atom, a 20-oxo group, and a group of the formula -XR at the 21-position wherein -XR represents --OCOR, --OCOOR, --COOSR or --OCONHR and R represents (a) a solubilising group containing a basic nitrogen atom, (b) a nitrobenzyl group (c) a lower alkyl group (when X is not --OCO-- or (d) a halogenoalkyl group.

The steroids possess anaesthetic properties.

IT 32226-14-5P 32354-01-1P 38392-70-0P

38392-71-1P 38392-72-2P 38392-75-5P

38392-76-6P 38392-77-7P 38392-78-8P

38392-79-9P 38392-80-2P 38392-81-3P

38392-82-4P 38392-83-7P 38392-87-9P

38392-88-0P 38392-89-1P 38392-90-4P

38392-91-5P 38392-92-6P 38392-93-7P


(prepn. of)

RN 32226-14-5 USPATFULL

CN Pregnane-11,20-dione, 21-(acetyloxy)-3-(nitrooxy)-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 32354-01-1 USPATFULL

CN Pregnane-11,20-dione, 21-hydroxy-3-(nitrooxy)-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 38392-70-0 USPATFULL

CN Pregnane-11,20-dione, 3-hydroxy-21-[[4-(nitrophenyl)acetyl]oxy]-, (3.alpha.,5.alpha.)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-71-1 USPATFULL
 CN Pregnane-11,20-dione, 21-[(4-aminophenyl)acetyl]oxy]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-72-2 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(3-pyridinylcarbonyl)oxy]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-75-5 USPATFULL
 CN Pregnane-11,20-dione, 21-[(chloroacetyl)oxy]-3-(nitrooxy)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-76-6 USPATFULL
 CN Pregnane-11,20-dione, 21-[(chloroacetyl)oxy]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-77-7 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(iodoacetyl)oxy]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-78-8 USPATFULL
 CN Glycine, N,N-dimethyl-,
 (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-
 21-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-79-9 USPATFULL
 CN Pregnane-11,20-dione, 3-hydroxy-21-[(4-morpholinylacetyl)oxy]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-80-2 USPATFULL
 CN Pregnane-11,20-dione,
 3-hydroxy-21-[(4-methyl-1-piperazinyl)acetyl]oxy]-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-81-3 USPATFULL
 CN Pregnane-11,20-dione, 21-[(ethoxycarbonyl)oxy]-3-(nitroxy)-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-82-4 USPATFULL
 CN Pregnane-11,20-dione, 21-[(ethoxycarbonyl)oxy]-3-hydroxy-,
 (3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-85-7 USPATFULL
 CN Glycine, N-[(phenylmethoxy)carbonyl]-,
 (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-87-9 USPATFULL
 CN Glycine, N,N-diethyl-,
 (3.alpha.,5.alpha.)-3-hydroxy-11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-88-0 USPATFULL
 CN Glycine, N,N-diethyl-,
 (2.beta.,3.alpha.,5.alpha.)-3-hydroxy-2-methoxy-
 11,20-dioxopregnan-21-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 38392-89-1 USPATFULL
 CN Pregnane-11,20-dione, 21-(acetyloxy)-2-methoxy-3-(nitroxy)-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 60 OF 65 USPATFULL (Continued)



RN 38392-90-4 USPATFULL
 CN Pregnane-11,20-dione, 21-hydroxy-2-methoxy-3-(nitroxy)-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38392-91-5 USPATFULL
 CN Pregnane-11,20-dione, 21-[(chloroacetyl)oxy]-2-methoxy-3-(nitroxy)-,
 (2.beta.,3.alpha.,5.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

